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Introduction
General introduction
Palliative care
Palliative care is defined by the world health organisation (WHO) as: ”an approach that 
improves the quality of life of patients and their families facing the problem associated 
with life-threatening illness, through the prevention and relief of suffering by means of 
early identification and impeccable assessment and treatment of pain and other problems, 
physical, psychosocial and spiritual” [1]. Palliative care is generally initiated in the case of 
terminal illness when cure is no longer possible and life expectancy is limited. There is 
however not always a clearly defined moment when palliative care replaces curative care. 
Instead this shift from cure to care is a gradual transition, described by the model of Lynn 
and Adamson (figure 1) [2]. This gradual transition makes it difficult to calculate prevalence 
numbers for patients in need of palliative care. The WHO estimates that worldwide, a total of 
40 million people are in need of palliative care each year. Because of differences in medical 
care standards and disease prevalence, the number of patients in need of palliative care will 
differ between countries. For the Netherlands, an estimation is made on the basis of the 
total number of deaths each year. In 80% of these cases, the death of the patient did not 
come unexpectedly and it was therefore assumed that in these cases death was preceded 
by some form of palliative care [3]. Based on these data a total of 108.500 patients, annually, 
will receive palliative care in the Netherlands. This number will most likely increase in the 
upcoming years, due to the ageing population. As reflected by the WHO definition, the main 
goal of palliative care is symptom management. Since symptoms can be both physical, 
psychosocial and spiritual, symptom management is best performed in a multidisciplinary 
setting and consists of both pharmacological and non-pharmacological interventions.
Curative Care
Palliative Care 
Hospice Care
Family 
Bereavement 
Progression of disease over time 
Palliative care
Death 
 
 
 
 
 
 
Figure 1. Trajectory Model adapted from Lynn et al [2]. 
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symptom management
Palliative care patients can suffer from a variety of symptoms depending on their terminal 
illness as well as co-morbidities. In terminally ill cancer patients, which is the majority of the 
terminally ill population, patients suffer from an average of 12 symptoms in the last year of 
life [4]. Of these symptoms the five most common symptoms are fatigue (74%), pain (71%), 
lack of energy (69%), weakness (60%) and appetite loss (53%) [5]. They can have a severe 
impact on the quality of life and their burden will increase with decreasing life expectancy 
[6]. Relieving distress in these patients can be done either by treating the underlying cause 
or trigger, by symptomatic treatment (both with and without medication) and/or with sup-
portive care. There are however circumstances in which symptoms cannot be adequately 
controlled with these measures alone. In the case of such refractory symptoms, palliative 
sedation can be initiated as an option of last resort. 
By applying palliative sedation, a patient’s consciousness is decreased, thereby taking 
away the perception of the symptoms. Palliative sedation is applied proportionally, guided 
by the symptoms of the patients without striving for deep coma, or shortening life. It is 
generally only used for limited amount of time as 47% of the patient die within 24 hours 
after sedation is started and another 47% within 1 to 7 days [7, 8]. In a hospice setting 
this form of symptom management is regularly applied, with an average of 46% (range 
22 – 67%) of the terminally ill patients being sedated for refractory symptoms at the end of 
life [9-13]. The most common causes for palliative sedation are delirium or restlessness in the 
terminal phase (57%), dyspnoea (23%), pain (17%) and vomiting (4%) [7]. 
Pharmacology 
Pharmacological therapy plays an important role in symptom management, both in general 
symptom management as well as in palliative sedation. An overview of the pharmacological 
therapy in this population is given by the International Association for Hospice and Palliative 
Care (IAHPC) who provided a list of 33 essential medicines for palliative care [14]. As this list 
is an international consensus, not all drugs mentioned here are used in the Dutch palliative 
care setting. Looking specifically at the Dutch hospice setting the top 3 of most commonly 
used drugs at the end of life were morphine, midazolam and haloperidol [15]. Morphine is 
an analgesic of the opioid class. It is an antagonist of the µ-opioid receptor in the central 
nervous system and is used in palliative care to treat pain and dyspnoea. It was the most 
commonly used drug in the final days of life with over 80% of the terminally ill patients 
receiving it. Midazolam is a sedative of the benzodiazepine class and has a prominent role in 
the national guideline for palliative sedation and is being prescribed in approximately 50% 
of the terminally ill patients. Finally, haloperidol is a typical antipsychotic and the drug of 
choice according to the guidelines to treat (terminal) delirium. With delirium occurring in 85 
to 90% of the terminally ill patients in the last hours or days before death it is also commonly 
subscribed. The fact that it is less commonly used than morphine or midazolam is due to the 
11
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fact that delirium in its agitated form only occurs in around 20% of the cases and in 22-50% 
of all cases delirious symptoms go unnoticed.  
Despite the fact that these drugs are frequently used and have a prominent place in 
(inter)national guidelines, there are very few high quality clinical trials on their safety and ef-
ficacy in terminally ill patients. The efficacy and safety of palliative sedation has been studied 
by Morita et al in 2005 [16]. This study showed that if full symptom control was reached this 
took between 1 and 48 hours. It also showed that in 17% of the patient’s symptom relief 
remained inadequate and that 49% of the patients awoke at least once from a deeply seda-
tive state. In addition, this study also revealed that in 22% of the cases patients’ experienced 
serious adverse events, such as aspiration, paradoxical reactions and respiratory suppres-
sion. This is of clinical concern as it causes severe distress for both the patients themselves 
as well as their loved ones. 
Such a variability in response may be explained by several different factors. First of all, the 
fact that patients suffer from multiple symptoms and co-morbidities may lead to polyphar-
macy which increases the possibility of relevant drug-drug interactions [17-19]. In addition, 
pathophysiological changes and co-morbidities, like renal and hepatic impairment, are 
also likely to cause variability between and within patients by affecting the way the body 
processes these drugs (pharmacokinetics). In fact, such pharmacokinetic changes as well 
as pharmacodynamic ones have been shown before in elderly and critically ill patients [20-
25]. Terminally ill patients do show some similarities with these populations however the 
terminally ill population is also a very heterogeneous so there will likely be large variability 
both between patients as well as within a single patient as their disease progresses. Unfor-
tunately, most current guidelines lack individualised dosing recommendations. Instead dos-
ing is often guided by clinical effect. These empirical dose adjustments however take time 
and this is disadvantageous in the case of severe symptoms and limited life expectancy. We 
therefore need to expand our knowledge on pharmacokinetics and pharmacodynamics 
in terminally ill patients, and aim to develop individualised dosing regimens that will help 
improve the care for these patients in their final months of life. 
the aims of this thesis are
1.  To give an overview of how the pharmacokinetic processes in terminally ill patients dif-
fer from the average population, and how this may affect drug exposure 
2.   To gain insight in the drugs used in palliative care and the relevance of drug-drug inter-
actions in this population
3. To evaluate the pharmacokinetics and the inter-individual variability of morphine and its 
metabolites in terminally ill patients. 
12
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4.  To evaluate the pharmacokinetics and the inter-individual variability of midazolam and 
its metabolites in terminally ill patients.
5.  To investigate the effect of midazolam plasma concentrations on depth of sedation. 
6.  To evaluate the pharmacokinetics of haloperidol in terminally ill patients.
13
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aBstract
introduction
A variety of medications are used for symptom control in palliative care, such as morphine, 
midazolam and haloperidol. The pharmacokinetics of these drugs may be altered in these 
patients as a result of physiological changes that occur at the end stage of life. 
areas covered
This review gives an overview of how the pharmacokinetics in terminally ill patients may 
differ from the average population and discusses the effect of terminal illness on each of 
the four pharmacokinetic processes absorption, distribution, metabolism, and elimination. 
Specific considerations are also given for three commonly prescribed drugs in palliative 
care: morphine, midazolam and haloperidol).
expert opinion 
The pharmacokinetics of drugs in terminally ill patients can be complex and limited evi-
dence exists on guided drug use in this population. To improve the quality of life of these 
patients, more knowledge and more pharmacokinetic/pharmacodynamics studies in 
terminally ill patients are needed to develop individualised dosing guidelines. Until then 
knowledge of pharmacokinetics and the physiological changes that occur in the final days 
of life can provide a base for dosing adjustments that will improve the quality of life of 
terminally ill patients. As the interaction of drugs with the physiology of dying is complex, 
pharmacological treatment is probably best assessed in a multi-disciplinary setting and the 
advice of a pharmacist, or clinical pharmacologist, is highly recommended.
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introduction
In palliative care, when curation is no longer possible, the goal is to maintain or improve the 
quality of life. To achieve this, a variety of medications, such as morphine, midazolam, and 
haloperidol, are used for symptom control.[1] Changes in the pharmacokinetics of these 
drugs may cause increased or decreased drug blood concentrations, which can result in 
altered efficacy or increased risk of adverse drug reactions. To optimize the use of these 
drugs, an understanding of pharmacokinetics in this specific patient population is therefore 
essential.
Pharmacokinetic (Pk) parameters (e.g. drug clearance and volume of distribution) are 
subject to interpatient variability and may be altered in the palliative population, as patients 
with cancer are known to differ from healthy volunteers with regards to, for example, age, 
body weight, and plasma protein levels.[2] In addition, several physiological changes (e.g. 
decreased fluid intake, a catabolic state, inflammation, and cachexia) occur at the end of life, 
which can also influence pharmacokinetics.[3–5]
So far there is limited knowledge on how these changes affect the different drugs used 
in palliative care, in particular in the terminal phase, i.e. the last days before death in which 
a patient is bedridden, semi-comatose, and are no longer able to take oral medication. 
The aim of this review is to give an overview of how the pharmacokinetics in terminally ill 
patient differ from the average population, and how changes in the palliative, and especially 
the terminal phase, can affect drug exposure (Figure 1). We will discuss the effect of terminal 
illness on each of the four pharmacokinetic processes: absorption, distribution, metabolism, 
and elimination (ADME) and give some considerations for three drugs commonly prescribed 
in the terminal phase (i.e. morphine, midazolam, and haloperidol). [6] 
Figure 1. Physiological changes that can influence pharmacokinetics in the terminally ill adult patient.
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aBsorPtion
Terminally ill patients frequently suffer from gastro intestinal (GI) problems, such as consti-
pation, nausea, vomiting, and diarrhoea. In the case of orally administered drugs, which are 
used in the palliative care setting when patients are still able to take oral medication, these 
symptoms can influence both the rate of absorption and bioavailability of a drug. Changes 
in the absorption rate will affect time-to-peak concentrations (Tmax), whereas changes in 
bioavailability will affect the initial peak concentration (Cmax) and total exposure, expressed 
as area under the curve (AUC). If and to what extent a drug is influenced by physiological 
changes will depend on the physicochemical properties of the drug and the pharmaceuti-
cal formulation (e.g. drug solubility and extended release formulations). An overview of the 
factors influencing absorption is given in Table 1. For this review, we will focus on the most 
commonly used routes of administration in palliative care, which are oral administration in 
the palliative phase and subcutaneous and transdermal administration in the terminal phase. 
Table 1. Physiological changes affecting drug absorption
Physiological change in 
palliative care
Potential pharmacokinetic change Consequence Example drugs
Decreased GI motility Increase in Tmax Drug concentration is unaffected yet the 
effect may be delayed 
Morphine and 
tramadol
Increase in F and AUC of sustained release 
formulations and drugs with enterohepatic 
cycling 
Increase in drug concentration and effect Oxycontin ® and 
lorazepam
Vomiting or administration 
via tube 
Possible decrease in F and AUC depending 
on the moment of vomiting or declamping 
the tube 
Possible decrease in drug concentration 
and effect
All oral drugs
Delayed gastric emptying Increase in Tmax Drug concentration is unaffected yet the 
effect may be delayed
Morphine and 
tramadol
Increase in AUC for drugs in which 
dissolution is the rate limiting step
Increase in drug concentration and effect Oral haloperidol 
Diarrhoea Increase in AUC of drugs with low F Increase in drug concentration and effect  Domperidon
Decrease in AUC of drugs with normal to 
high F
Decrease in drug concentration and effect  Haloperidol
Small intestine resections Decrease in F and AUC Decrease in drug concentration and effect Morphine and 
tramadol
Alterations in gut wall 
function due to cachexia
Decrease in  F and AUC Decrease in drug concentration and effect Morphine and 
tramadol
Decreased hepatic function 
or liver blood flow
Decrease in first-pass effect, resulting in 
increased AUC
Increase in drug concentration and effect Morphine
Decreased tissue perfusion Decrease in Tmax and possibly  F 
of subcutaneously or transdermal 
administered drugs
Decrease in drug concentration and the 
effect may be delayed
Fentanyl patches 
and subcutaneous 
midazolam 
Decreased subcutaneous 
fat
Increased Tmax of subcutaneously or 
transdermal administered drugs
Drug concentration is unaffected yet the 
effect may be accelerated 
Fentanyl patches 
and subcutaneous 
midazolam
Abbreviations: Tmax = time to peak concentration, AUC = area under the curve (i.e. total exposure to the drug), 
F = bioavailability
21
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oral administration 
The absorption of orally administered drugs is complex as a drug has to dissolve in the 
stomach, pass through either the stomach or gut wall, and pass the liver via the portal vein 
before they reach the systemic circulation. Whether the transportation of the dissolved drug 
into the bloodstream occurs in the stomach or gut is dependent on the drug’s physico-
chemical properties. Drugs that are weakly acidic are best absorbed within the acid environ-
ment of the stomach. Though most drugs are weak bases (e.g. morphine, haloperidol, and 
midazolam) and are therefore absorbed in the alkaline environment of the small intestine. 
GI symptoms
Absorption of oral drugs can be altered in terminally ill (cancer) patients as this population 
often suffers from GI symptoms, such as constipation, vomiting, diarrhoea, or a delayed 
gastric emptying due to cachexia. Constipation (i.e. decreases GI motility) occurs in around 
50% of the terminal cancer patients and can be a result of dehydration, hypercalcaemia, a 
bedridden state, and medication use (e.g. opiates). [7, 8] Decreased GI motility can result in a 
reduced absorption rate as it takes longer for the drug to reach the site of absorption. [9–11] 
In the case of a sustained release formulation or drugs with an enterohepatic circulation, 
decreased GI motility can increase the absorption as there is more contact time with the GI 
mucosa. 
Constipation can also cause nausea and vomiting. Vomiting can evidently decrease the 
bioavailability of oral medication. The same applies for unclamping the tube if medication 
is administered via this tube. To what extend the bioavailability is decreased will depend on 
the time between ingestion and vomiting or releasing the clamp of the tube. The time it 
takes for a drug to pass from the stomach to the intestine can range from 1 h, for healthy 
persons up to 4 h, for patients with delayed gastric emptying. As delayed gastric empty-
ing is relevant in this patient population, it has to be taken into account that vomiting or 
unclamping the tube even several hours after intake of medication the bioavailability can 
be decreased. 
Delayed gastric emptying by itself can also result in a decreased absorption rate for 
drugs that are absorbed through the small intestine. [11,12] In the case of a drug for which 
formulation dissolution in the stomach is the rate-limiting step in absorption, a decrease in 
gastric emptying time may increase the overall extent of absorption and, hence, systemic 
drug exposure. 
Diarrhoea can also influence the bioavailability of oral drugs. It can cause a decrease in 
bioavailability due to increased elimination from the gastro intestinal tract. On the other 
hand, if the intestinal mucosa is damaged (for instance in the case of an inflammatory pro-
cess) it can also lead to increased bioavailability. These concepts cause drugs with low bio-
availability generally have increased absorption in patients with diarrhoea while drugs with 
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good intestinal absorption are more affected by the increased GI motility and, therefore, will 
have lower absorption. [13] 
Furthermore, patients with a gastrointestinal malignancy may have some of their small 
intestine resected. Small intestine resections involving the loss of more than 100 cm of 
ileum frequently lead to malabsorption, which could also decrease drug absorption.[14] 
Absorption might also be decreased by alterations in gut wall function, which is caused by 
body wasting or cachexia, or decreased splanchnic perfusion. [13, 15] 
First-pass metabolism
After absorption from the GI tract, the bioavailability of drugs may be altered in terminal 
patients due to changes in hepatic function or liver blood flow, which can occur in the case 
of hepatic cirrhosis or congestive heart failure. A decrease in hepatic blood flow can result 
in increased bioavailability of drugs with a high first-pass metabolism, as was shown for 
hydromorphone. [16] 
subcutaneous/transdermal administration
Other common routes to administer drugs in palliative care are transdermal or by subcuta-
neous injection or infusion. These routes are advantageous in the case of GI problems as this 
route also bypasses the portal vein, first-pass metabolism does not occur. Factors that may 
influence absorption of subcutaneous or transdermal medication, however, are tissue blood 
perfusion and amount of subcutaneous fat. In terminally ill patients, reduced tissue blood 
perfusion, which can occur as a result of dehydration or old age, can result in a decrease 
in absorption rate or bioavailability after subcutaneous or transdermal administration. [9, 
17, 18] Alternatively a decrease in subcutaneous fat mass, which is also commonly seen in 
terminally ill patients, can in theory lead to increased absorption rate and possibly higher 
peak concentrations. [19]
clinical considerations
For clinical practice, we recommend that in the palliative phase GI problems should be 
closely monitored, and that medication and doses should be reassessed if changes in GI 
motility occur. As the effect of alterations in GI motility will differ per drug, depending on 
their chemical properties, this needs to be evaluated on a case by case basis. This assess-
ment is preferably performed in a multi-disciplinary setting and the advice of a pharmacist, 
or clinical pharmacologist, is recommended. In the presence of a nasogastric tube that 
decompresses the gut in case of an intestinal obstruction, the administration of drugs 
through the oral route, or via the tube, is not rational. In the terminal phase, switching to 
subcutaneous administration, if possible, is preferred not only for the prescribing physician 
but also for patient’s comfort. In the case of subcutaneous or transdermal drug administra-
tion, changes will occur more gradually and monitoring of the clinical effect will probably 
23
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suffice. If therapy is switched from oral to subcutaneous administration, one should correct 
for a difference in bioavailability, in addition, it is advisable to look for signs of diminished 
tissue perfusion (cool extremities, cyanosis, oedema, and diminished or absent peripheral 
pulses) as this could result in a decreases absorption. Finally, in patients with an intestinal 
obstruction either anatomical or functional administering drugs via a tube followed by 1 or 
2 h of clamping the tube will not likely lead to drug absorption, as most drugs are absorbed 
in the small intestine and in the case of delayed gastric emptying the drug may not have 
passed from the stomach yet. Therefore, in the case of intestinal obstruction drug adminis-
tration via the subcutaneous route is preferred. 
distriBution
The volume of distribution (Vd) of a drug is dependent on its chemical properties (e.g. its 
hydrophilicity and its affinity with plasma proteins). As a rule, hydrophilic drugs will diffuse 
into the intravascular, extracellular, and possibly intracellular water, and their Vd will not 
exceed the volume of total body water (around 42 L for an average adult of 70 kg). Whereas 
lipophilic drugs or drugs with high affinity to plasma proteins will have low free plasma 
concentrations and, therefore, a large volume of distribution. As the Vd is determined only 
by concentration and dose, the plasma concentrations of a drug can be influenced by body 
composition and amount of plasma protein. Both of these can be altered in terminally ill 
patients and can change over time, an overview of the factors influencing Vd is given in 
Table 2.
Table 2. Physiological changes affecting drug distribution
Physiological change in 
palliative care
Potential pharmacokinetic change Consequence  Example drugs
Loss of body weight and 
cachexia
Decrease in Vd for lipophilic drugs Increase in drug concentration and 
effect 
Midazolam
Fluid deficit Decrease in Vd for hydrophilic drugs Increase in drug concentration and 
effect 
Morphine
Ascites, pleural effusion or 
generalised oedema
Increase in Vd for hydrophilic drugs Decrease in drug concentration and 
effect 
Morphine
Hypoalbuminemia Increase in unbound fraction of weakly 
acidic drugs
No effect unless elimination is inhibited Temazepam
Increased α-1 acid 
glycoprotein
Decrease in unbound fraction of weakly 
alkaline drugs
Prolonged effect due to decreased 
elimination and slow redistribution 
from tissues 
Morphine 
Abbreviations: Vd = volume of distribution
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Body composition
The main factors that influence body composition are loss of body weight and fluid deficit. 
Loss of body weight and cachexia are common in terminally ill patients, especially in cancer 
patients. The incidence of weight loss however differs between cancer types with the high-
est incidence (83–87%) for pancreatic or gastric cancers and the lowest frequency (31– 40%) 
for favourable non-Hodgkin lymphoma, breast cancer, acute non-lymphocytic leukaemia, 
and sarcomas.[20] Fearon et al. showed that in cachectic patients the reduction in body 
weight is mainly caused by a reduction of adipose tissue (by 80%) and muscle protein (by 
75%).[21] A reduction of adipose tissue will result in a lower Vd for lipophilic drugs which will 
result in higher peak concentrations (Cmax). 
Fluid deficit, which is also common among terminally ill patients, can also affect the body 
composition as it results in loss of total body water. The loss of water can be both intracel-
lular, in the case of dehydration, and extracellular in the case of volume depletion.[5,17] A 
loss of water will result in a lower Vd for hydrophilic drugs and, therefore, initially lead to 
higher concentrations. Alternatively, the volume of distribution of hydrophilic drugs can 
also be increased as a result of ascites, pleural effusion, or generalized oedema leading to a 
higher Vd and lower initial concentrations. [13, 22–24]
Protein binding
Besides body composition, alterations in protein binding can also affect Vd. The two main 
drug binding proteins are albumin and α-1 acid glycoprotein (AAG). Albumin typically 
binds to weakly acidic drugs (e.g. temazepam and propofol), whereas AAG binds to weakly 
alkaline drugs (e.g. morphine and fentanyl). [2] Changes in binding proteins can be caused 
by inflammatory responses. A long-lasting inflammatory response occurs in almost all types 
of solid tumours and can also be the result of cachexia, infection, and degenerative diseases. 
[17, 25–27] As a result of the inflammatory response, albumin is downregulated and AAG 
is increased. [27] Hypoalbuminemia is, therefore, often seen in various types of cancer, ca-
chectic patients, and hospitalized or institutionalized elderly patients. [14, 28–32] Increased 
plasma levels of AAG have also been shown in various types of cancer, acute illness, or 
chronic disease. [33, 34] As a result, highly AAG bound drugs will have decreased unbound 
concentrations while highly albumin bound drugs will have increased unbound concen-
tration. A decreased unbound concentration can result in decreased elimination and due 
to slow redistribution from the tissues, the effect can be prolonged. The clinical relevance 
of increased amounts of unbound drug on the other hand is limited as the elimination 
of a drug increases when the unbound concentration increases. Still if the elimination is 
otherwise inhibited, for example, in the case of renal failure, this might lead to accumulation.
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clinical considerations
As volume of distribution mainly affects the initial peak concentration (and also the time 
needed to reach steady-state concentrations), recommendations for clinical practice will 
primarily be relevant for drugs where an immediate response is desired. This is for instance 
the case in sedative or analgesic medication. For these drugs, a higher initial (loading) dose 
may be required if the volume of distribution in an individual is increased. For instance, to 
achieve adequate sedation, an obese patient will probably require a higher initial dose of 
midazolam (a lipophilic drug) than a cachectic patient. In addition, for pain management 
a patient with oedema may probably need a higher initial dose of morphine (a hydrophilic 
drug) than a dehydrated patient.
metaBolism
Conversion of drugs into metabolites primarily takes place in the liver and largely deter-
mines the duration of a drug’s action, elimination, and toxicity. Hepatic clearance (ClH), the 
ability of the liver to remove drugs from the systemic circulation, is dependent on both liver 
blood flow and hepatic extraction ratio. The hepatic extraction ratio is the fraction of drug 
that is removed from the blood after a single passage through the liver. Drugs with a high 
extraction ratio will have a ClH that is primarily dependent on the liver blood flow. While for 
drugs with a low extraction ratio, this will be mainly dependent on intrinsic clearance (i.e. 
liver function). In patients with terminal illness, there are several factors that might influence 
drug metabolism, an overview is given in Table 3.
Table 3. Physiological changes affecting drug metabolism
Physiological change in 
palliative care
Potential pharmacokinetic change Consequence  Example drugs
Decreased liver blood flow Decrease in ClH of drugs with a high 
extraction ratio
Increase in drug concentration and 
effect 
Morphine
Liver injury Possible decrease in ClH  mainly for 
drugs metabolised by CYP450 enzymes
Possible increase in drug 
concentration and effect 
Midazolam
Malnutrition or cachexia Possible decrease in ClH, yet still 
inconclusive 
Possible increase in drug 
concentration and effect 
Midazolam
Acute phase reaction Possible decrease in ClH, yet still 
inconclusive
Possible increase in drug 
concentration and effect 
Midazolam
Abbreviations:  ClH = hepatic clearance
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liver blood flow
Liver blood flow reduces with age, and can also be decreased in dehydrated patients due 
to decreased cardiac output, in patients with liver cirrhosis due to intrahepatic and extrahe-
patic portal systemic shunting, or in patients with heart failure as a result of passive conges-
tion or low cardiac output. [10, 17, 35, 36] These patients can, therefore, have a decreased 
metabolism of drugs with a high extraction ratio, such as fentanyl, morphine, and propofol. 
As a result, the effect of these drugs can be increased and prolonged. 
intrinsic clearance 
Intrinsic clearance is determined by the enzymatic capacity. There are two main enzymatic 
systems that are responsible for drug metabolism, i.e. phase I and phase II metabolism. Phase 
I metabolism includes oxidation, reduction, and hydrolysis and occurs predominantly by en-
zymes of the cytochrome P450 (CYP450) family. Phase II metabolism consists of conjugation 
with an endogenous substance (e.g. glucuronidation, acetylation, or sulfation). There are 
several factors that influence the metabolic capacity including genetic variability, enzyme 
induction, or inhibition (usually drug induced) and disease states including malignancies.
[14] Liver injury in terminally ill cancer patients can be due to primary liver tumours or 
more often due to the presence of liver metastases or as a result of chemotherapy. In non-
malignant terminally ill patients liver function can also be affected, for instance in the case of 
alcoholic liver cirrhosis or in Chronic Obstructive Pulmonary Disease (COPD) patients, who 
have been also shown to be more at risk for hepatobiliary diseases. [37] 
The effect of liver pathology on metabolic capacity is, however, highly variable and dif-
ficult to predict. In fact, most liver functions can be maintained with some degree of liver 
injury, therefore liver pathology (including the presence of multiple liver metastases) can ex-
ist without affecting liver function. It is believed that unless liver cirrhosis is present, chronic 
liver diseases have little significant clinical impact on pharmacokinetics. In addition, phase 
II metabolism tends to be better preserved than phase I metabolism, only in advanced cir-
rhosis this pathway may also be impaired substantially. [18, 38] 
As the metabolic capacity depends on nutrients and cofactors, it is probable that mal-
nutrition can result in altered metabolism. Indeed, some studies showed that deficiency of 
specific nutrients (e.g. proteins, lipids, vitamin C, vitamin B6, and vitamin E) can result in a 
decrease in metabolic rate. However, some deficiencies, such as riboflavin and iron have also 
shown to increase CYP450 metabolism by a still unknown mechanism. [39] A reduction in 
the enzyme levels of some CYP450 enzymes (CYP2C8/10 and CYP2E1) have been shown, 
but this was not the case for some other CYP450 enzymes (CYP1A2 and CYP3A). [40] Studies 
on the direct effect of malnutrition/ cachexia on plasma drug levels are sparse and despite 
similar metabolic pathways, the influence of cachexia was divergent. Most of the drugs 
showed increased plasma levels after oral administration; however, with only plasma levels 
of the drug it is not possible to differentiate between changes in absorption, metabolism, 
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or elimination. One study on oxycodone in cachectic cancer patients also measured the 
metabolite, noroxycodone, formed via the CYP3A enzyme and did show higher plasma 
levels of oxycodone and a lower noroxycodone/oxycodone ratio in patients with a higher 
GPS score (a measurement for cachexia) indicating that cachexia decreases the hepatic me-
tabolism of oxycodone. [41] This suggests a decrease in metabolic capacity, yet the overall 
effect of malnutrition and cachexia on metabolism is still unclear. 
Another possible method by which CYP450 metabolism can be reduced in cancer 
patients is by inflammatory response. This is mediated largely through downregulation 
of gene transcription caused by pro-inflammatory cytokines. [27] This effect has not been 
studied extensively but it has been shown in some studies for the metabolism of CYP3A4 
and CYP2C19. [42–44] In addition, there are also implications that inflammation may reduce 
the metabolic capacity of CYP1A2. [45–47] The clinical relevance of these reduction in 
metabolism, however, remains to be further investigated.
clinical considerations
For clinical practice, one should be aware that drug metabolism can be altered in patients 
with heart failure or those that suffer from decreased cardiac output due to dehydration 
(resulting in decreased hepatic blood flow) or patients with liver disease. In addition, drugs 
that are metabolized via the CYP450 enzyme system are likely to be affected more than 
drugs which are metabolized via phase II metabolism. As the effect of liver disease, dehy-
dration, inflammation, and cachexia on liver metabolic capacity, is difficult to predict no 
specific recommendations can be made. Instead, care givers should be aware of the fact 
that patients with liver diseases can have a different reaction to medication, and they should 
look out for signs of altered efficacy and side effects in these patients, especially in the case 
of drugs with active metabolites.
elimination
The elimination of drugs and metabolites can occur through a number of different routes 
(e.g. bile, sweat, and saliva); however, the main route of elimination is via the kidneys through 
glomerular filtration. Renal function, including glomerular filtration rate, decreases with 
increasing age. This alone means that most terminally ill patients will have a reduced elimi-
nation, as they are usually older (on average 63 years) than the healthy volunteers in which 
most pharmacokinetic studies are performed (on average 25–29 years).[2,48] Renal elimina-
tion can also be decreased in terminally ill patients as a result of renal insufficiency, which 
occurs in a large portion (50–60%) of the cancer patients.[49] Most terminally ill patients 
have a diminished fluid intake, which will cause prerenal kidney failure. Co-administration 
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of non-steroidal anti-inflammatory drugs (NSAIDs) in this situation will severely compromise 
renal function. [24]
It is important to note that although renal insufficiency is common in this population, it 
might not be recognized using the standard blood chemistry tests. This is because glomular 
filtration is estimated using serum creatinine levels. In the case of terminally ill patients, this 
can be misleading as the production of creatinine is reduced as muscle mass is decreased. 
Therefore, glomular filtration rate can decrease without a change in serum creatinine 
concentrations. It is therefore important to realize that the eGFR provided by modification 
of diet in renal disease (MDRD) formula gives an overestimation of the renal function in 
patients with low muscle mass. For drugs that are not eliminated via kidneys but undergo 
hepatic elimination, accumulation can occur if the liver decompensates in the terminal 
phase. This can also happen if the bile is the primary route of elimination and the patient 
becomes icteric. [24] An overview of the factors affecting elimination is given in Table 4.
clinical considerations
In clinical practice, renal-eliminated drugs (or metabolites) will accumulate in the final days 
of life, if fluid intake is limited. Measuring renal function based on serum creatinine will not 
be very helpful in these patients. It is therefore recommended to either determine renal 
function using other parameters that correct for the loss of muscle for instance albumin 
or weight besides creatinine clearance or to measure drug concentrations. As both these 
interventions require blood sampling, it is probably of more practical value, to be aware 
of the fact that accumulation of certain drugs can occur and to monitor fluid intake and 
urinary output and look out for (increased) side effects in patients where these functions 
are diminished.
Table 4. Physiological changes affecting drug elimination
Physiological change in 
palliative care
Potential pharmacokinetic change Consequence  Example drugs
Renal insufficiency or 
pre renal failure due to 
dehydration 
Decrease in renal elimination Increase in drug concentration and 
effect  for renally eliminated drugs or 
metabolites 
Morphine-
metabolites 
Liver decompensation Possible decrease in hepatic elimination Increase in drug concentration and 
effect  for hepatic eliminated drugs or 
metabolites
Midazolam
Icterus Possible decrease in elimination of drug 
that are excreted via bile
Increase in drug concentration and 
effect for drugs or metabolites that are 
excreted via bile
Lorazepam 
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conclusion
In conclusion, there are numerous ways by which comorbidities and other physiological 
changes can alter pharmacokinetics in patients with terminal illness. The net effect of these 
alterations and the clinical relevance will be dependent on both the status of the individual 
patient and the properties of the drug in question. For clinical practice, we will discuss three 
commonly prescribed drugs in the terminal phase, i.e. morphine, midazolam, and haloperi-
dol.
morPhine
Morphine is widely used to treat pain and dyspnoea in terminally ill patients. [50] In a pal-
liative setting, it is usually administered either orally (as normal release liquid or modified 
release tablets) or subcutaneously (as bolus injection or continuous infusion). Morphine 
is a relatively hydrophilic drug and is only partially bound (34–37.5%) to plasma proteins, 
predominantly albumin. [51] The metabolism of morphine takes place primarily in the liver. 
Morphine has a high extraction ratio and is metabolized mainly by Uridine 5ʹ-diphospho-
glucuronosyltransferase (UGT) enzymes into morphine-3-glucuronide (M3G) for 60%, and 
morphine-6-glucuorinide (M6G) for 10%. [52–54] The M6G metabolite is pharmacologically 
active and is 10–60 times as potent as morphine.[53–60] Its ability to cross the blood–brain 
barrier is, however, far less (1/57th) than that of morphine.[61] Nonetheless after chronic 
morphine administration, the gradual accumulation of M6G in the brain can account for 
increased potency compared to single administration.  [53, 60, 62, 63] The M3G metabolite 
does not bind to the opioid receptors and, therefore, does not possess analgesic properties. 
[56, 64–67] Conversely, it has been suggested that M3G may be responsible for the side 
effects of morphine. [54, 68] Both glucuronide metabolites are eliminated through renal 
excretion. Overall, this pharmacokinetic profile of morphine means that its concentrations 
and effect may be influenced by changes in total body water (by influencing Vd), liver blood 
flow (by influencing metabolism and also via first pass absorption), and renal function (by 
influencing elimination of the metabolites). 
The effect of total body water on the Vd of morphine have been shown by Baillie et 
al. [69]. Their results showed a decreased volume of distribution in elderly patients when 
compared to younger adults, which is in line with the fact that total body water declines 
with age. The clinical relevance of this will, however, be limited for terminally ill patients as 
the volume of distribution only determines the initial peak concentration and most patients 
will receive multiple doses of morphine.
An increased interpatient variability in morphine metabolism in terminally ill patients 
has been shown. This has been suggested to be due to reduced hepatic blood flow and 
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subsequent reduction in morphine clearance in these patients.[69] As a result of variability 
in metabolism, interpatient variability in oral bioavailability (between 15% and 49%) has also 
been shown.[70,71] The fact that this is caused by liver metabolism instead of absorption 
in the GI tract is supported by the fact that patients with icterus had an even higher oral 
bioavailability of 64%.[70] In addition, the fact that first-pass metabolism determines its 
bioavailability also means that the ratio of morphine to its metabolites will differ for different 
routes of administration.[72–74] This can be relevant as the metabolites of morphine can 
influence both its efficacy and side effects.
As the kidneys are responsible for the elimination of the glucuronide metabolites, renal 
function is an important aspect in morphine pharmacokinetics. This is especially relevant in 
terminally ill patients as renal insufficiency is common in this population. Accumulation of 
M3G and M6G in patients with renal insufficiency has been shown in several studies. [72, 73, 
75–77] This can be advantageous due to the increased levels of the active M6G metabolite. 
It has indeed been shown that patients with renal insufficiency had an increased response 
to morphine and that they required lower doses. [77–80] Another advantage is that M6G 
has a lower risk of respiratory depression or hypoxia compared to morphine itself.[67,81–83] 
However, other side effects, such as delirium, myoclonus, and hyperalgesia/allodynia have 
been related to higher metabolite levels in terminally ill patients and are probably caused 
by accumulation of the M3G metabolite.[84–91]
In clinical practice, this means that physicians and nurses should be aware that if renal 
function declines (for instance if fluid intake ceases) delirium and myoclonus can occur. 
At the same time, the pain symptoms can both increase (hyperalgesia due to M3G accu-
mulation) or decrease (due to M6G accumulation). If the pain is not increased, a reduction 
in morphine dose can be considered, otherwise switching to an analgesic without active 
metabolites (for instance fentanyl) may be an option. Furthermore, dosing forms that bypass 
the portal vein and, therefore, do not undergo first-pass metabolism (e.g. intravenous or 
subcutaneous injections) will probably have less side effects as the morphine–metabolites 
ratio is higher. This might therefore also be beneficial in patients with renal insufficiency.
midazolam
Midazolam can be used intermittently for the night times and is the drug of choice for 
palliative sedation in terminally ill patients. [6, 92–94] It is commonly administered via 
subcutaneous infusion but can also be administered orally to treat anxiety or insomnia. 
Midazolam is a highly permeable drug and is, therefore, believed to be completely absorbed 
through the GI tract, if given orally.[95] However, midazolam has limited bioavailability due 
to first-pass metabolism via CYP3A enzymes in the liver and gut wall. As midazolam is a 
highly permeable drug, the extent of first-pass metabolism can be influenced by variability 
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in intestinal blood flow. [95] In addition, it has also been proposed that midazolam bioavail-
ability can be influenced by CYP3A metabolizing activity in the intestine. [96] Midazolam is 
highly lipophilic at physiological pH and is also highly bound to albumin (96–97%), resulting 
in a large volume of distribution.[97,98] It is metabolized in the liver, mainly by CYP3A into 
1-hydroxymidazolam, which is then glucuronidated and excreted via the kidneys. 1-Hy-
droxymidazolam is pharmacologically active, although to a lesser extent than midazolam.
[97] Midazolam has an intermediate extraction ratio its metabolism is, therefore, dependent 
on both liver blood flow and enzymatic activity.[99–101] Overall, this pharmacokinetic pro-
file of midazolam means that its concentrations and effect may be influenced by changes in 
total body fat and albumin levels (by influencing Vd), liver blood flow, intestinal blood flow 
and CYP3A activity (by influencing metabolism and also via first-pass absorption) and renal 
function (by influencing elimination of the metabolites).
The effect of total body fat on the volume of distribution of midazolam has been studied 
primarily in obese patients. As expected, obese patient had a larger volume of distribu-
tion for midazolam. [96,102–104] We would therefore expect the opposite in terminally ill 
patients, and a study on cancer cachexia in rats did indeed show a decrease in Vd after the 
animals became cachectic. Increased plasma concentrations as a result of a decrease in Vd 
can be further enhanced as a result of hypoalbuminemia. Increased plasma concentrations 
as result of decreased Vd or hypoalbuminemia can have an impact on the onset of sedation 
after first administration. Halliday et al. showed that hypoalbuminemia was associated with 
shorter time to induction suggesting that higher levels of free midazolam will give a more 
rapid response. [105] On the other hand, if midazolam is given continuously over a longer 
period of time the higher free plasma levels will also result in a higher elimination.
Midazolam metabolism can be reduced in terminally ill patients as a result of reduced liver 
blood flow. This has been shown in elderly patients who compared to younger adults had 
a decreased midazolam clearance. [102] As midazolam is primarily metabolized by CYP3A, 
a reduction of CYP3A activity can also lead to decreased midazolam metabolism. Reduced 
CYP3A activity as a result of cachexia has been suggested to occur in cachectic patients 
and decreased midazolam clearance has also been shown in an animal model of cancer 
cachexia.[41,106] Reduced CYP3A activity can also occur as a result of liver disease and a 
correlation between midazolam clearance and liver failure has been shown in intensive care 
unit (ICU) patients.[107] In palliative patients, no correlation was found between midazolam 
concentrations and liver disease, probably because liver diseases in this population are not 
as severe as in ICU patients.[108] Finally, CYP3A metabolism can also be affected by the use 
of other drugs. In the palliative setting, there might be a relevant interaction with dexa-
methasone. Dexamethasone is used for a variety of symptoms in the terminal phase, and 
there are suggestions that it may induce CYP3A. [109,110] However, the extent by which 
dexamethasone induces CYP3A has not been completely clarified.
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Finally, the elimination of the glucuronidated metabolites by the liver is reduced in 
patients with renal insufficiency, resulting in accumulation. Although glucuronidated 
1-hydroxymidazol has only 1/10th of the potency of midazolam itself, this can result in 
prolonged sedation. [111]
In clinical practice, the onset of sedation can be different between patients due to 
changes in Vd. Patients with higher body weight may, therefore, require a higher initial 
dose, whereas hypoalbumineamic patients may require a lower initial dose. Patients who 
have used a CYP3A inducer, such as carbamazepine, in the past week may need higher 
midazolam doses to achieve accurate sedation. Finally, in patients with renal insufficiency, 
the sedative effect may be prolonged. This will probably be of little clinical relevance in 
the case of palliative sedation as most patients will only require sedation for less than 48 h. 
Nevertheless, it is something to keep in mind if midazolam is given for anxiety or insomnia.
haloPeridol
Haloperidol is a typical antipsychotic drug that is used in palliative care to treat delirium 
and might also be prescribed to treat nausea and vomiting. [1,112] In terminally ill patients, 
it is administered either orally or as a subcutaneous injection. [113] If given orally, it has a 
bioavailability of 60–70% due to first-pass metabolism.[112,114,115] For the subcutaneous 
route, there is no information available but bioavailability is probably around 100% as it 
diffuses from the subcutaneous tissue directly to the systemic circulation. Haloperidol is a 
lipophilic drug, and it is bound to albumin for more than 90%. Therefore, haloperidol has a 
large volume of distribution. [116,117] The hepatic metabolism of haloperidol is extensive 
(<1% is excreted unchanged) and includes both irreversible and reversible metabolic bio-
transformation. The main metabolic pathway is glucuronidation by UGT, which accounts for 
50–60% of the total metabolism. [118] An estimated 20–30% of haloperidol is metabolized 
via CYP3A4 and CYP2D6. [119] Both these pathways are irreversible. The reversible part of the 
haloperidol metabolism is its conversion into reduced haloperidol by carbonyl reductase, 
which accounts for approximately 23% of the total metabolism.[120–122] The reduction 
of haloperidol is reversible as reduced haloperidol can be converted back into haloperidol 
through oxidation by CYP3A4.[119,123,124] Haloperidol has an intermediate extraction 
ratio therefore its metabolism is dependent on both enzymatic activity and liver blood flow.
[114] Haloperidol metabolites are eliminated both with the urine and via the bile.[125,126] 
Overall, this pharmacokinetic profile of haloperidol means that its concentrations and effect 
may be influenced by changes in body fat and albumin levels (by influencing Vd), liver blood 
flow and metabolic activity (by influencing metabolism and also via first-pass absorption). 
In terminally ill patients, a reduction in body fat, and consequently Vd, can result in higher 
initial plasma concentrations. Furthermore, hypoalbuminemia can also result in higher free 
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haloperidol concentrations and thereby possibly shorter the time-to-peak plasma concen-
trations. These changes can be clinically relevant as a rapid onset of action is desired in 
treating delirium. A large interpatient variability in time-to-peak plasma concentrations, be-
tween 2 and 6 h, has been shown in patients taking oral haloperidol.[114,127] It is, however, 
not known if this is due to changes in plasma albumin if there are other explanations, for 
instance delayed gastric emptying.
Haloperidol metabolism might be reduced in terminally ill patients as a result of reduced 
liver blood flow. It has been shown that elderly patients had higher steady-state plasma 
concentrations than younger patients.[127] As steady-state concentrations are only influ-
enced by changes in clearance (not in Vd) a decrease in liver blood flow, which is common 
in elderly, might explain this.
Finally, differences in metabolic capacity might also influence haloperidol metabolism 
and thereby plasma concentrations. Interpatient variability in metabolism is unlikely to be 
caused by changes in UGT activity, as its capacity is relatively large compared to the other 
metabolic pathways.[114] The conversion of haloperidol into reduced haloperidol is also 
unlikely to cause much interpatient variability as little variation in enzyme activity has been 
shown for carbonyl reductase. [114] Changes in CYP3A4 or CYP2D6 activity on the other 
hand may lead to altered plasma concentrations. In the case of CYP3A4, it has been shown 
that co-administration of haloperidol with carbamazepine, a CYP3A4 inducer, resulted in sig-
nificantly lower haloperidol concentrations. [128–131] The combination of carbamazepine 
and haloperidol might be relevant in patients with brain tumours or metastases. Another 
drug that might induce CYP3A is dexamethasone, this is commonly used in palliative care 
but the relevance of this combination remains to be determined.[109,110] A decrease in 
haloperidol metabolism in terminally ill patients is also possible as result of reduced CYP3A 
activity due to cachexia.[41] Variability in CYP2D6 metabolic capacity may also influence 
haloperidol concentrations. This has been shown by Mihara et al. for patients with a genetic 
variation in CYP2D6 enzyme. [132] In terminally ill patients, this could be relevant in the case 
of co-administration of haloperidol with CYP2D6 inhibitors, like fluoxetine or paroxetine. 
Although these drugs are not commonly given in the terminal phase. There have been 
some studies on the effect of fluoxetine on haloperidol levels and this showed a 20–35% 
increase in plasma levels. However, this was not associated with clinical effects. [133–136] 
So far, the effect of alteration in haloperidol metabolism due to cachexia, dexamethasone 
use or fluoxetine, or paroxetine use are merely theoretical and more research on its clinical 
relevance is needed. 
In clinical practice, it may be the case that patients with hypoalbuminemia or loss of 
body fat will have a more rapid onset of action, and a lower initial dose might be sufficient. 
In addition, patients with reduced liver blood flow, or co-administration of dexamethasone 
might also need a lower dose. While patients with cachexia or fluoxetine or paroxetine use 
might need higher doses, it is not yet possible to make any real recommendations as there 
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has been very little research on haloperidol pharmacokinetics in terminally ill patients, 
especially about the use of the subcutaneous injections.
exPert oPinion
The pharmacokinetics of drugs in terminally ill patients can be complex due to the patho-
physiological changes that occur near the end of life. Although there are several guidelines 
for symptom management in terminally ill patients, limited evidence exists on guided drug 
use in these patients. Even for the most commonly used medications in this population 
(i.e. morphine, midazolam, and haloperidol) much is still unknown. The medication dose 
is therefore usually guided by experience and clinical effect, resulting in adaptation of a 
universal starting dose rather than defining a personalized dose beforehand based on solid 
PK characteristics. 
Besides comorbidities, co-medication can also influence the action of drugs (both on the 
level of pharmacokinetics as pharmacodynamics). If a new drug, which could potentially 
interfere with the current medication, is added to the regimen caution is essential and short 
acting formulations are preferred when treatment is initiated and polypharmacy should be 
avoided. This may be more relevant in the pre-terminal phase as medication is reassessed 
in the terminal phase and most medication (besides analgesic and anxiolytics) is usually 
discontinued.
Such personalized treatment may significantly improve the quality of life for these pa-
tients and their family members, especially in the final days of life. To achieve this not only 
more knowledge but also more studies on the pharmacokinetics in terminally ill patients 
are necessary. A growing number of pharmacokinetic studies are being performed in spe-
cial patient populations (e.g. ICU patients), yet these studies in terminally ill patients are 
still lacking to a large extent. In addition, there is also a need for pharmacodynamic (Pd) 
studies in this population as pharmacokinetics will give information on the achieved drug 
concentrations but not on the preferred clinical effect. Pd studies that measure the effect on 
for instance pain, sedation, or delirium would be of great clinical importance. The fact that 
so little studies are being performed in terminally ill patients might be because terminally 
ill patients are considered a vulnerable population, and it has been argued that including 
them in clinical research is inappropriate or even unethical. These ethical concerns are, 
however, often unjustified and studies in this population, if carefully designed and executed, 
can be very valuable.[137] A crucial aspect is to minimize the burden for patients and their 
families. Population Pk/Pd studies using limited sampling strategies may therefore provide a 
solution and may eventually lead to individualized dosing guidelines.
While Pk/Pd studies are lacking, there are several studies on factors predicting death in 
terminally ill patients. [19, 25, 26,138] These studies give valuable insight in the changes in 
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body functions that occur in the final days of life. Together with the knowledge of pharma-
cokinetics mentioned in this review this should provide a base on which pharmacological 
interventions can be made which will improve the quality of life of terminally ill patients. 
The difficulty in this is, however, that although a common final pathway is hypothesized, 
the terminally ill population can be very heterogeneous, they require different types of 
medication and will have different comorbidities. As the net result of drug concentrations 
is dependent on both physiological changes as well as chemical drug properties, these are 
probably best assessed by a multi-disciplinary team with a specialist pharmacist or clinical 
pharmacologist with specific knowledge of the last phase of life.
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aBstract 
Purpose
To assess the frequency of potential drug-drug interactions in a palliative care centre. The 
secondary objectives are to study the most commonly involved drugs, drug-drug inter-
action characteristics (severity, clinical relevance, mechanism, scientific evidence) and to 
identify which risk factors are associated with the potential drug-drug interactions. 
methods
A retrospective systematic analysis of potential drug-drug interactions was performed using 
the electronic prescription and drug monitoring system FarMedRx, which is linked to the 
“G-Standaard”, the Dutch drug database for clinical decision support. Potential interactions 
were then independently scored by two experts to determine the clinical relevance within 
a palliative setting. Descriptive statistics and multivariate logistic regression analysis were 
used for assessment of the primary and secondary outcomes.
results
Among 127 included patients, 90 drug-drug interactions were identified in 42 patients 
(33.1%, 95% CI = 25.2 – 42.5%). The most commonly involved drugs were NSAIDs, glucocor-
ticoids, SSRIs, dopamine (ant)agonists and antipsychotics. Most of the interactions (45.6% in 
19.7% of patients) would lead to long-term discomfort without sequelae, and 51.1% were 
scored as clinically relevant by our expert team, affecting 29 patients (22.8%, 95% CI = 15.0 
– 29.9%). The number of drugs used by patients was a potential risk factor of drug-drug 
interactions (adjusted OR = 1.50, 95% CI = 1.24 – 1.82). 
conclusion
Although not all interactions are clinically relevant in end of life care, certain drug-drug 
interactions may still have serious consequences. As the number of drugs is a potential risk 
factor of interactions, unnecessary drugs should be stopped in the palliative setting. The use 
of some drugs, like NSAIDs and SSRIs should be carefully considered because of their side 
effects and the fact that the treatment may also be carried out by other drug classes.   
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introduction
Medication use in the terminal phase is focused on symptom control. In 2007, in response to 
a request of the World Health Organization (WHO), the International Association for Hospice 
and Palliative Care (IAHPC) prepared the list ‘Essential Medicines in Palliative Care’ based on 
the recommendations of palliative care experts from around the world. [1, 2] Terminally ill 
patients often suffer from a variety of complications. The management of these complica-
tions require the use of different drugs, which can lead to an increased risk of adverse ef-
fects, high pill burden and increased healthcare costs. In a randomized trial, discontinuation 
of statins in patients with a life expectancy of less than one year improved the quality of 
life and led to cost savings. The combined use of drugs could also lead to a higher risk 
of drug-drug interactions, which may have serious consequences even at the end of life. 
[3, 4, 5] However, insufficient attention is being paid to drug-drug interactions in palliative 
care. Literature that describes the prevalence of drug-drug interactions in palliative care is 
limited. Riechelmann et al. evaluated the epidemiology of drug-drug interactions in cancer 
patients. These patients were exclusively receiving supportive care in hospital. This study 
showed that one-third of these patients were exposed to at least one drug-drug interaction. 
Nearly 70% of the drug-drug interactions were of major or moderate severity and almost 
42% were supported by levels 1-3 of scientific evidence. [6] Gaertner et al. identified the 
combination of drugs with the potential to interact in patients in a palliative care unit. This 
study showed that drug-drug interactions are mainly based on interactions via histamine, 
acetylcholine or dopamine receptors. In addition, non-steroidal anti-inflammatory drugs 
(NSAIDs) are frequently involved. [7] Frechen et al. identified which combinations of drugs 
and risk factors had the potential for drug-drug interactions in patients of two hospices. 
They also assessed the clinical relevance of these drug-drug interactions. According to this 
study, drug-drug interactions, were seen in 60% of patients. Of the 796 reported DDIs 419 
(53%) were therapeutically relevant occur in 46% of patients. [8] Furthermore, Morgan et al. 
found that 72% of patients, who were referred to specialist palliative care, were at risk of one 
or more potential drug-drug interaction. [9] Due to the potential importance of drug-drug 
interactions in palliative care, this study is aimed at giving more insight into the frequency 
of drug-drug interactions in patients in an inpatient palliative care centre. The secondary 
objectives are to study (i) the most commonly involved drugs with the potential to interact, 
(ii) the degree of severity, clinical relevance, mechanism and level of scientific evidence 
of the potential drug-drug interactions, and (iii) which risk factors are associated with the 
potential drug-drug interactions 
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materials and methods 
study design and setting 
A retrospective observational study was designed to determine the drug-drug interactions 
in terminally ill patients admitted to the Regional Palliative Centre Laurens Cadenza in Rot-
terdam. This palliative care centre is a 20 beds high-care hospice. Around 200-250 patients 
are admitted to and die in Laurens Cadenza each year. The average length of admission for 
terminal care is approximately three weeks. The Medical Ethics Review Committee (METC) 
of Erasmus University Medical Centre approved the study.
study population
Patients were eligible to participate in this study if they were treated with one or more 
drugs. Exclusion criteria were (i) age < 18 years, (ii) life expectancy of less than two days, 
(iii) patients not deceased in the palliative care centre. Patients who did not decease in the 
palliative care centre were excluded due to incomplete medication use data. 
outcome measures
The primary outcome measure was the frequency of potential drug-drug interactions in 
a palliative care centre. The secondary outcome measures were (i) the most commonly 
involved drugs with the potential to interact, (ii) the degree of severity, clinical relevance, 
mechanism and the level of scientific evidence of the potential drug-drug interactions and 
(iii) the potential risk factors that were associated with the drug-drug interactions. 
data collection 
Demographic patient characteristics like age, gender, primary diagnosis, number of comor-
bidities, number of drugs used and duration of admission were derived from the electronic 
medical records (mijnCaress, pinkroccade healthcare). The primary diagnosis of the patients 
was assigned by using the ICD-10, International Classification of Diseases and Related Health 
Problems, of WHO. [10]
To identify potential drug-drug interactions, as needed prescriptions, as well as regular 
prescriptions, were included for analysis. For fixed-dose combinations (e.g. triamterene/
hydrochlorothiazide) each active pharmaceutical ingredient was evaluated separately. How-
ever, when a drug was used in different formulations (e.g. short- and long-acting morphine), 
the interaction was counted only once. 
Potential interactions were identified using FarMedRx (FarMedvisie, Woerden, The Neth-
erlands), an electronic prescription and drug monitoring system for healthcare facilities [11]. 
This system is linked to the so-called ‘G-Standaard’, the Dutch drug database for clinical 
decision support which is monthly updated by the Royal Dutch Pharmacist Association 
(KNMP). [12] The level of severity according to this system, the mechanism and the level 
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of scientific evidence of the potential interactions were derived from the G-Standaard. The 
level of severity of a drug-drug interaction was reported using a six-category scale (A-F), 
which were in order of increasing severity. Drug-drug interactions were categorized as 
pharmacokinetic (PK) and pharmacodynamic (PD) interactions, based on the underlying 
mechanism of the interaction. The level of scientific evidence for a drug-drug interaction 
was reported using a five-category scale (0-4). [12, 13] Potential interactions were scored 
independently by two experts to determine the relevance. One of the experts was a hospital 
pharmacist and clinical pharmacologist and the other one was a resident and a researcher 
in the area of palliative care. The scores of the experts were then compared and in case of 
disagreement on the scores, the two experts met to reach consensus. 
statistical analysis
IBM SPSS Statistics 21 (IBM Corp., Armonk, New York, USA) was used for data collection and 
analysis. 
Descriptive statistics were used to evaluate demographic patient characteristics, primary 
diagnosis, number of comorbidities, number of drugs used, duration of admission. Normally 
distributed variables were presented as mean with standard deviation (SD), while non-
normally distributed variables were presented as median with interquartile range (IQR). 
Descriptive statistics were also used to evaluate the frequency of drug-drug interactions. 
Normally distributed variables were presented as mean with standard deviation (SD), while 
non-normally distributed variables were presented as median with minimum-maximum 
range (range) and 95% confidence intervals (CIs) were calculated for proportions. The most 
commonly involved drugs with the potential to interact and drug-drug interaction charac-
teristics (severity, clinical relevance, mechanism and scientific evidence) were also evaluated 
by using descriptive statistics and 95% CIs were calculated for proportions. 
Potential risk factors of drug-drug interactions were determined by using univariate 
and multivariate binary logistic regression analyses. The dependent variable was defined 
as one or more drug-drug interactions per patient. Age, sex, number of drugs used, and 
number of comorbidities were included as predictor variables. A multivariate logistic regres-
sion analysis was performed using all predictor variables with p < 0.05 in the univariate 
analyses and leaving them in the model if the regression coefficient changed by >10%. For 
all analyses, p-values of less than 0.05 were regarded as statistically significant and 95% CIs 
were calculated for odds ratios (ORs). 
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results
demography
A total of 146 patients were screened for eligibility, of which 127 patients were included for 
analysis (Figure 1). Mean age of included patients was 73.3 years (SD 12.4), of which 48.8% 
were male. The median duration of admission of these patients was 16 (IQR 7-35) days. The 
most frequent primary diagnosis was neoplasm, mainly of the digestive or respiratory and 
intrathoracic organs (85.8% of patients). Patients had a median of four comorbidities (IQR 
2-5) and the median number of drugs used per patient was 4.7 (IQR 3.3-6.7). Demographic 
patient characteristics are presented in Table 1. 
drug interactions
A total of 90 potential drug-drug interactions (Supplementary table 1) were identified in 42 
patients (33.1%, 95% CI = 25.2 – 42.5%), with a median of 2 (range 1-7) potential drug-drug 
interactions per patient. Drugs most often involved in drug-drug interactions were NSAIDs, 
glucocorticoids, selective serotonin reuptake inhibitors (SSRIs), dopamine (ant)agonists and 
Table 1. Patient characteristics (n=127)
Characteristics
Gender, n (%)
Male 62 (48.8)
Age, in years 
Mean ± SD 73 ± 12
Duration of admission, in days 
Median (IQR) 16 (7-35)
Primary diagnosis, n (%)
Neoplasm
Lip, oral cavity and pharynx
Digestive organs
Respiratory and intrathoracic organs
Melanoma and other malignant neoplasms of skin
Breast
Female genital organs
Urinary tract
Eye, brain and other parts of central nervous system
Ill-defined, secondary and unspecified sites
Lymphoid, hematopoietic and related tissue
109 (85.8)
3 (2.7)
37 (33.9)
27 (24.8)
4 (3.7)
4 (3.7)
5 (4.6)
4 (3.7)
6 (5.5)
5 (4.6)
6 (5.5)
Other
Diseases of the circulatory system
Other  
8 (7.3)
11 (8.7)
7 (5.5)
No. of comorbidities per patient 
Median (IQR) 4 (2-5)
No. of drugs used per patient 
Median (IQR) 4.7 (3.3-6.7)
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antipsychotics. When looking at the types of drug-drug interactions, the severity could be 
determined by using a pre-determined scoring system [1, 2]. According to this systematic 
approach 21.1% of the interactions could lead to long term (>7 days) clinical effects with 
possible sequelae, 2.2% could result long term severe clinical effects and 7.8% to very severe 
effect and death. These interactions affected 9.4%, 1.6% and 5.5% of patients respectively 
(figure 2). Most of the interactions (45.6% in 19.7% of patients) would lead to long-term (2-7 
days) discomfort without sequelae. Of all drug-drug interactions, 51.1% were pharmacody-
namic interactions and 62.2% were supported by controlled, published interaction studies 
in patients/volunteers with relevant surrogate endpoints.
As these pre-determined severity scores may not be applicable in the terminally ill 
population our team of experts also scored each interaction for clinical relevance. The in-
dependent scoring was consistent between the experts for 54 (60.0%) potential drug-drug 
interactions. The experts met to reach consensus about the other 36 (40.0%) potential drug-
drug interactions and determined finally that 46 (51.1%) of these 90 potential drug-drug 
interactions qualified as relevant and affected 29 patients (22.8%, 95% CI = 15.0 – 29.9%). 
The mechanism of drug-drug interactions, level of severity, level of scientific evidence and 
the relevance are presented in the supplementary material and figure 2.
Potential risk factors
The results of the logistic regression analysis are presented in Table 2. In the univariate 
analysis, age and number of drugs were risk factors with a high potential for drug-drug 
interactions. In the multivariate analysis, only the number of drugs remained statistically sig-
nificantly associated with drug-drug interactions (adjusted OR = 1.50, 95% CI = 1.24 – 1.82). 
Figure 1.  Study design
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2% 
19% 
28% 
51% 
Drug interaction mechanism 
PK and PD
Unknown
PK
PD
6% 
8% 
10% 
45% 
21% 
2% 
8% 
Severity No information
No clinical effect
Short term clinical effect
without sequelae
Long term clinical effect
without sequelae
Long term clinical effect
with possible sequelae
Long term severe clinical
effect
Very severe clincial effect
/death
4% 2% 
21% 
11% 62% 
Scientific evidence No support
Animal studies and in
vitro studies of limited
predictive value
Incomplete, published
case reports
Well documented,
published case reports
Controlled, published
studies with relevant
surrogate endpoints
Figure 2.  Mechanism of drug-drug interactions, level of severity, level of scientific evidence and relevance as 
scored by the expert team. 
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Table 2. Univariate and multivariate binary logistic regression analysis
Variable Crude OR (95% CI) Adjusted OR (95% CI)
Age 0.96 (0.93-0.99) 0.97 (0.94-1.01)a
Gender 0.93 (0.45-1.95) ̶
No. of drugs 1.52 (1.26-1.85) 1.50 (1.24-1.82)b
No. of comorbidities 1.05  (0.87-1.27) ̶
Abbreviations: CI = confidence interval, OR = odds ratio.
aAdjusted for no. of drugs.
bAdjusted for age.
discussion
In the present study, drug-drug interactions were identified in 33.1% of patients. The most 
commonly involved drugs were NSAIDs, glucocorticoids, SSRIs, dopamine (ant)agonists and 
antipsychotics. Of these interactions, 7.8% can lead to serious clinical effects in 5.5% of pa-
tients, 2.2% to failure of live-saving therapy or severe clinical effects in 1.6% of patients and 
21.1% to long-term/permanent sequelae or disability in 9.4% of patients. More than half of 
the drug-drug interactions were pharmacodynamic interactions and 62.2% were supported 
by controlled, published interaction studies in patients/volunteers with relevant surrogate 
endpoints. According to the experts, 51.1% of these drug-drug interactions were relevant 
and affected 22.8% of patients. 
Similar to the study of Riechelmann et al., one third of terminally ill patients receiving 
palliative care were exposed to at least one drug combination with the potential to interact 
[6]. In other studies, this proportion was more than 60% [7-9]. Drugs most commonly in-
volved in the interactions were NSAIDs, glucocorticoids, SSRIs, dopamine (ant)agonists and 
antipsychotics. These results correspond well with other studies. [6-8]
Drugs that belong to the interaction category ‘severe’ are combinations of drugs that 
might prolong the QT interval. In the present study, these concerned combinations of 
haloperidol with other QT prolonging drugs. Prolongation of the QTc interval is associated 
with serious and fatal risks, like torsade de pointes. [14] Other studies also identified these 
combinations as drug-drug interactions for which monitoring or adjustment is needed 
[7, 8]. In the palliative care setting EEG monitoring is not performed, therefore the pos-
sible benefit of haloperidol and the required dose should be carefully considered. Another 
interesting finding is that NSAIDs are a class of drugs that is often involved in drug-drug 
interactions. Considering the limited life expectancy of the patients, these drugs should 
perhaps be switched to opioids when drug-drug interactions occur. This could possibly 
prevent shortness of breath in the case of congestive heart failure or the risk of GI bleeding 
in elderly patients with corticosteroid use. 
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One of the possible events that is in general classified as serious are electrolyte dis-
turbances. In our study we found two drug-drug interactions that increases the risk of 
electrolyte disturbances, i.e. SSRIs with thiazide diuretics and cotrimoxazole with captopril. 
Drug combinations of SSRIs and thiazide diuretics may potentiate the risk of hyponatremia. 
[15-17] The combination of cotrimoxazole and captopril could also lead to severe clinical 
effects by increasing the risk of hyperkalaemia [17, 18]. In a clinical setting sodium and 
potassium levels should be monitored closely, in the palliative setting however this is not 
standard practice. The use of drugs causing these interactions should therefore be carefully 
considered especially with regard to the risk of hyponatraemia for which some dehydrated 
patient may already be at risk.  These combinations were not identified as drug-drug in-
teractions in other studies [6-8]. This may be due to the fact that these drugs were not 
among the most frequently prescribed drugs in palliative care and their use depends on the 
comorbidities of patients. In the present and other studies, the most frequent underlying 
disease was cancer. [6-8, 19] 
Combinations of central acting dopaminergic agents with antiemetic (antidopaminer-
gic) drugs could result in serious effects or disability by antagonizing the pharmacological 
effects of dopamine agonists [20, 21]. The use of other antiemetic drugs, like domperidon, 
should be considered in case of nausea/vomiting and levodopa use. Domperidon leads 
to a reduced risk of extrapyramidal adverse effects by not crossing the blood-brain bar-
rier. [21] Frechen et al. also identified these combinations as drug-drug interactions and 
classified them as ‘contraindicated as a precaution’. [8] Combinations with antipsychotics 
also belong to this category. However, this combination is not detected in other studies 
[6-8]. As mentioned before, this may be due to the fact that these drugs were not among 
the most frequently prescribed drugs in palliative care, thus reducing the chance that this 
interaction will also be found in other studies. Another drug-drug interaction of this cat-
egory is the combination of NSAIDs with diuretics or RAAS-inhibitors. These combinations 
are associated with worsening of existing heart failure. Therefore, NSAIDs should be used 
with caution in patients with a history of cardiac disease. [22] Other studies also identi-
fied these combinations as drug-drug interactions for which monitoring or adjustment is 
needed in certain cases. [7, 8] Combination of coumarins with certain drugs could enhance 
(antibiotics, SSRIs, (es)omeprazole) or antagonize (vitamin K) the effect of coumarins [12, 23-
26]. So, the use of coumarins in combination with one of these drugs should be monitored 
closely and the dose of coumarins should be adjusted based on the anticoagulant effects. 
These combinations with coumarins were not found in other studies. [6-8] Riechelmann et 
al. only found combinations of warfarin with corticosteroids and paracetamol, which are 
not identified in the present study. [6] Therefore, the likelihood of these drug-drug interac-
tions in palliative care depends on comorbidities of patients for which the use of different 
number of drugs are needed. Combination of corticosteroids and liver enzyme inducers are 
categorized in the same level of severity. Corticosteroids are used in the treatment of pain, 
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dyspnoea, nausea, fatigue and anorexia in palliative care [27, 28]. These combinations could 
antagonize the effect of corticosteroids and are also found in other studies [6, 7, and 29]. The 
use of these drug combinations should be monitored closely. 
Our expert team determined that 51.1% of the drug-drug interactions were relevant. 
Other studies, in which the relevance was determined by an automated scoring system, 
have reported similar or higher proportions (53-72%) [7, 8]. The higher proportion may 
be explained by the fact that these automated systems are not specifically designed for 
the palliative care setting. This can cause overestimation of clinical relevance, especially in 
the case of interactions with consequences in the more distant future. Furthermore these 
systems score the relevance of drug-drug interactions by substances irrespective of dose-, 
sequence- and time of medication administration-dependent effects, which can also lead 
to overestimation of the relevance. 
In the present study the number of drugs used by patients has been identified as a 
potential risk factor of drug-drug interactions. This result is consistent with other studies 
[6, 8]. The fact that an increase in the number of drugs used by patients is associated with 
an increase in risk for the occurrence of drug-drug interactions is not surprising. The use of 
drugs for the management of chronic diseases should be reconsidered in the final phase of 
life. The benefits of these drugs should be weighed against the potential drug-drug interac-
tions, which could affect the quality of life. Beta blocking agents for instance are beneficial 
in preventing cardiac disease in the future, however their use may cause shortness of breath 
by antagonize the effects of beta-2 adrenergic bronchodilators. Discontinuation of these 
drugs in terminally ill patients may even improve their quality of life. Furthermore, the time 
until clinical benefit of these drugs may, in any case, exceed the life expectancy of terminally 
ill patients. [3, 4, 30]
strengths and limitations
A strength of this study is the objective identification of drug-drug interactions based on 
the G-Standaard and the scoring of the relevance of interactions by two experts. Drug-drug 
interactions are identified using the G-standaard, which identifies interactions by substances 
irrespective of dose-, sequence- and time of medication administration-dependent effects. 
This can lead to overestimation of the incidence and risk of potential drug-drug interactions. 
But by having all interactions assessed with respect to relevance, this overestimation was 
reduced.
A major limitation of this study is that it has a retrospective design. Because the clinical 
relevance of an interaction will not only depend on the drug interaction itself but also on 
other risk factors, and more specifically for this population on the life expectancy. Patients 
are generally referred to a palliative care centre if their life expectancy is 3 months or less. 
This estimation can however be difficult and the actual time a patient spends in a palliative 
care centre can differ from 2 days to over a year. The lack of this information has impact 
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on the assessment of clinical consequences of the drug-drug interactions. It is therefore 
important to confirm these results by prospective studies to more accurately investigate 
the clinical consequences of drug-drug interactions in palliative care. Another limitations of 
this study is that it was a single-centre study, which means that the results cannot be simply 
extrapolated. In drugs used in palliative care may also differ between countries therefore the 
amount and relevance of interactions may also differ worldwide. Furthermore, considering 
that more than half of the drug-drug interactions were assessed as relevant by the experts, 
it is essential that palliative care specialists cooperate well with specialized palliative care 
pharmacists to prevent drug-drug interactions which may have serious consequences even 
at the end of life.
conclusion
Pharmacotherapy in palliative care should be strictly monitored. Although not all interac-
tions are relevant in end of life care, certain drug-drug interactions may still have potentially 
serious consequences in these patients. As the number of drugs is a potential risk factor of 
interactions, unnecessary drugs should be stopped in the palliative setting.
57
3
Interaction study
references
 [1] De Lima L, Doyle D. The International Association for Hospice and Palliative Care list of essential 
medicines for palliative care. J Pain Palliat Care Pharmacother. 2007;21:29-36.
 [2] WHO. Essential medicines in palliative care. http://www.who.int/selection_medicines/committees/
expert/19/applications/PalliativeCare_8_A_R.pdf. Latest update Jan 2013. Accessed Oct 2016.
 [3] Geijteman EC, van Gelder T, van Zuylen L. Sense and nonsense of treatment of comorbid diseases in 
terminally ill patients. JAMA Intern Med. 2015;175:346.
 [4] O’Mahony D, O’Connor MN. Pharmacotherapy at the end-of-life. Age Ageing. 2011;40:419-22.
 [5] Kutner JS, Blatchford PJ, Taylor DH Jr, Ritchie CS, Bull JH, Fairclough DL et al. Safety and benefit of 
discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. 
JAMA Intern Med. 2015;175(5):691-700. 
 [6] Riechelmann RP, Zimmermann C, Chin SN, Wang L, O’Carroll A, Zarinehbaf S et al. Potential drug 
interactions in cancer patients receiving supportive care exclusively. J Pain Symptom Manage. 
2008;35:535-43.
 [7] Gaertner J, Ruberg K, Schlesiger G, Frechen S, Voltz R. Drug interactions in palliative care - it’s more 
than cytochrome P450. Palliat Med. 2012;26:813-25.
 [8] Frechen S, Zoeller A, Ruberg K, Voltz R, Gaertner J. Drug interactions in dying patients: a retrospective 
analysis of hospice inpatients in Germany. Drug Saf. 2012;35:745-58.
 [9] Morgan NA, Rowett D, Currow DC. Analysis of drug interactions at the end of life. BMJ Support Palliat 
Care. 2015;5(3):281-6. 
 [10] WHO. International Classification of Diseases. http://www.who.int/classifications/icd/icdonlinever-
sions/en/. Latest update 2016. Accessed Feb 2017. 
 [11] FarMedvisie. FarMedRx: het EVS voor zorginstellingen.  http://www.farmedvisie.eu/farmedrx-2/. 
 [12] KNMP. The G-Standaard: the medicines standard in healthcare. https://www.knmp.nl/producten-
en-diensten/gebruiksrecht-g-standaard/informatie-over-de-g-standaard/the-g-standaard-the-
medicines-standard-in-healthcare. Accessed Feb 2017.
 [13] van Roon EN, Flikweert S, le Comte M, Langendijk PN, Kwee-Zuiderwijk WJ, Smits P et al. Clinical 
relevance of drug-drug interactions : a structured assessment procedure. Drug Saf. 2005;28:1131-9.
 [14] Scientific Advisory Board of the Arizona Center for Education and Research on Therapeutics (Arizona 
CERT). Torsades List - Drugs with known TdP risk. www.crediblemeds.org. Accessed Mar 2017. 
 [15] Rosner MH. Severe hyponatremia associated with the combined use of thiazide diuretics and selec-
tive serotonin reuptake inhibitors. Am J Med Sci. 2004;327:109-11.
 [16] Liamis G, Filippatos TD, Elisaf MS. Thiazide-associated hyponatremia in the elderly: what the clinician 
needs to know. J Geriatr Cardiol. 2016;13:175-82.
 [17] Bugge JF1. Severe hyperkalaemia induced by trimethoprim in combination with an angiotensin-
converting enzyme inhibitor in a patient with transplanted lungs. J Intern Med. 1996;240:249-51.
 [18] Antoniou T, Gomes T, Juurlink DN, Loutfy MR, Glazier RH, Mamdani MM. Trimethoprim-sulfamethox-
azole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a 
population-based study. Arch Intern Med. 2010;170:1045-9. 
 [19] Masman AD, van Dijk M, Tibboel D, Baar FP, Mathôt RA. Medication use during end-of-life care in a 
palliative care centre. Int J Clin Pharm. 2015;37:767-75.
 [20] Avorn J, Gurwitz JH, Bohn RL, Mogun H, Monane M, Walker A. Increased incidence of levodopa 
therapy following metoclopramide use. JAMA. 1995;274:1780-2.
 [21] Lertxundi U, Peral J, Mora O, Domingo-Echaburu S, Martínez-Bengoechea MJ, García-Moncó JC. Anti-
dopaminergic therapy for managing comorbidities in patients with Parkinson’s disease. Am J Health 
Syst Pharm. 2008;65:414-9.
 [22] Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly 
patients: an underrecognized public health problem. Arch Intern Med. 2000;160:777-84.
58
Chapter 3
 [23] Uno T, Sugimoto K, Sugawara K, Tateishi T. The role of cytochrome P2C19 in R-warfarin pharmacoki-
netics and its interaction with omeprazole. Ther Drug Monit. 2008;30:276-81.
 [24] Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R. Main comedications associated with 
major bleeding during anticoagulant therapy with coumarins. Eur J Clin Pharmacol. 2005;61:439-44.
 [25] Penning-van Beest FJ, Koerselman J, Herings RM. Quantity and quality of potential drug interactions 
with coumarin anticoagulants in the Netherlands. Pharm World Sci. 2007;29:671-5.
 [26] van Rein N, Gebuis EP, Lijfering WM, Groeneveld JJ, van der Horst FA, le Cessie S et al. Vitamin K1 in 
oral solution or tablets: a crossover trial and two randomized controlled trials to compare effects. J 
Thromb Haemost. 2014;12:2017-23. 
 [27] Simon ST, Bausewein C. Management of refractory breathlessness in patients with advanced cancer. 
Wien Med Wochenschr. 2009;159:591-8. 
 [28] Shih A, Jackson KC. Role of corticosteroids in palliative care. J Pain Palliat Care Pharmacother. 
2007;21:69-76.
 [29] Chalk JB, Ridgeway K, Brophy T, Yelland JD, Eadie MJ. Phenytoin impairs the bioavailability of dexa-
methasone in neurological and neurosurgical patients. J Neurol Neurosurg Psychiatry. 1984;47:1087-
90.
 [30] Holmes HM, Hayley DC, Alexander GC, Sachs GA. Reconsidering medication appropriateness for 
patients late in life. Arch Intern Med. 2006;166:605-9.
59
3
Interaction study
Su
pp
le
m
en
ta
ry
 T
ab
le
 1
a.
 Id
en
tifi
ed
 p
ot
en
tia
l r
el
ev
an
t d
ru
g-
dr
ug
 in
te
ra
ct
io
ns
In
te
ra
ct
io
n
In
te
ra
ct
in
g 
dr
ug
s
N
De
sc
rip
tio
n
Se
ve
rit
y
Sc
ie
nt
ifi
c 
ev
id
en
ce
PK
/P
D
Re
le
va
nc
e 
ac
co
rd
in
g 
to
 e
xp
er
ts
NS
AI
Ds
 +
 co
rti
co
ste
ro
id
s
Ac
et
yls
ali
cy
lic
 ac
id
; E
to
ric
ox
ib
; D
icl
of
en
ac
; 
Na
pr
ox
en
; Ib
up
ro
fe
n 
+ 
De
xa
m
et
ha
so
ne
; 
Pr
ed
ni
so
lo
ne
14
In
cr
ea
se
d 
ris
k o
f G
I b
lee
di
ng
 
C
3
?
6 
Re
le
va
nt
8 
No
t r
ele
va
nt
 
Di
ur
et
ics
 +
 N
SA
ID
s
Bu
m
et
an
id
e; 
Fu
ro
se
m
id
e; 
Sp
iro
no
lac
to
ne
 +
 
Di
clo
fe
na
c; 
Na
pr
ox
en
; Ib
up
ro
fe
n
5
Dr
ug
 co
m
bi
na
tio
ns
 m
ay
 ad
ve
rse
ly 
aff
ec
t r
en
al 
fu
nc
tio
n.
 A
t 
th
e 
sa
m
e 
tim
e, 
hy
po
te
ns
ive
 e
ffe
ct
 o
f t
he
 d
iu
re
tic
s m
ay
 b
e 
re
du
ce
d
D
3
PD
Re
le
va
nt
Be
ta
 b
lo
ck
er
s n
on
-se
lec
tiv
e 
+ 
be
ta
m
im
et
ics
Pr
op
ra
no
lo
l; S
ot
alo
l +
 Fo
rm
ot
er
ol
; S
alb
ut
am
ol
; 
Sa
lm
et
er
ol
4
Be
ta
 b
lo
ck
er
s m
ay
 an
ta
go
ni
ze
 th
e 
eff
ec
ts 
of
 b
et
a-
2 
ad
re
ne
rg
ic 
br
on
ch
od
ila
to
rs
C
3
PD
Re
le
va
nt
M
id
az
ol
am
/a
lp
ra
zo
lam
 +
 C
YP
3A
4 
in
hi
bi
to
rs
M
id
az
ol
am
 +
 Ve
ra
pa
m
il; 
Flu
co
na
zo
le
4
CY
P3
A4
 in
hi
bi
to
rs 
m
ay
 in
cr
ea
se
 th
e 
pl
as
m
a c
on
ce
nt
ra
tio
n 
of
 
m
id
az
ol
am
 o
r a
lp
ra
zo
lam
B
3
PK
Re
le
va
nt
QT
 p
ro
lo
ng
in
g 
dr
ug
s (
w
ith
 TD
P)
 +
 
QT
 p
ro
lo
ng
in
g 
dr
ug
s (
w
ith
 TD
P)
Ha
lo
pe
rid
ol
 +
 C
ip
ro
flo
xa
cin
; 
Le
vo
m
ep
ro
m
az
in
e; 
Ci
ta
lo
pr
am
; 
Do
m
pe
rid
on
e; 
M
et
ha
do
ne
; A
zit
hr
om
yc
in
7
Dr
ug
 co
m
bi
na
tio
ns
 ca
n 
pr
ol
on
g 
QT
 in
te
rv
al 
F
1
PD
2 
Re
le
va
nt
5 
No
t r
ele
va
nt
Do
pa
m
in
er
gi
c a
ge
nt
s +
 
an
tie
m
et
ics
 (a
nt
id
op
am
in
.)
Le
vo
do
pa
; P
ra
m
ip
ex
ol
e; 
Ro
pi
ni
ro
le 
+ 
Do
m
pe
rid
on
e; 
M
et
oc
lo
pr
am
id
e
5
Dr
ug
 co
m
bi
na
tio
ns
 m
ay
 an
ta
go
ni
ze
 th
e 
ph
ar
m
ac
ol
og
ic 
eff
ec
ts 
of
 d
op
am
in
e 
ag
on
ist
s.
D
2
PD
2 
Re
le
va
nt
 
3 
No
t r
ele
va
nt
NS
AI
Ds
 +
 se
ro
to
ni
n-
ac
tin
g 
dr
ug
s
Ac
et
yls
ali
cy
lic
 ac
id
; E
to
ric
ox
ib
 +
 D
ul
ox
et
in
e; 
Se
rtr
ali
ne
; T
ra
zo
do
ne
 
3
In
cr
ea
se
d 
ris
k o
f G
I b
lee
di
ng
 
C
2
PD
2 
Re
le
va
nt
1 
No
t r
ele
va
nt
 
M
id
az
ol
am
/a
lp
ra
zo
lam
 +
 
in
du
ct
or
s
M
id
az
ol
am
 +
 P
he
ny
to
in
; P
he
no
ba
rb
ita
l
2
In
du
ct
or
s l
ike
 p
he
ny
to
in
 an
d 
ph
en
ob
ar
bi
ta
l m
ay
 in
du
ce
 th
e 
CY
P3
A4
 h
ep
at
ic 
m
et
ab
ol
ism
 o
f m
id
az
ol
am
 o
r a
lp
ra
zo
lam
 an
d 
in
cr
ea
se
 th
eir
 cl
ea
ra
nc
e.
C
3
PK
Re
le
va
nt
Co
um
ar
in
s +
 (e
s)o
m
ep
ra
zo
le
Ac
en
oc
ou
m
ar
ol
 +
 O
m
ep
ra
zo
le
2
(E
s)o
m
ep
ra
zo
le 
m
ay
 in
hi
bi
t t
he
 h
ep
at
ic 
m
et
ab
ol
ism
 o
f 
ac
en
oc
ou
m
ar
ol
D
1
PK
Re
le
va
nt
Te
tra
cy
cli
ne
s +
 
an
ta
cid
s/
ca
lci
um
Do
xy
cy
cli
ne
 +
 C
alc
iu
m
 ca
rb
on
at
e; 
M
ag
ne
siu
m
 h
yd
ro
xid
e
2
Dr
ug
 co
m
bi
na
tio
ns
 m
ay
 in
hi
bi
t t
he
 ab
so
rp
tio
n 
of
 
te
tra
cy
cli
ne
s
C
3
PK
Re
le
va
nt
60
Chapter 3
Su
pp
le
m
en
ta
ry
 T
ab
le
 1
a.
 Id
en
tifi
ed
 p
ot
en
tia
l r
el
ev
an
t d
ru
g-
dr
ug
 in
te
ra
ct
io
ns
 (c
on
tin
ue
d)
In
te
ra
ct
io
n
In
te
ra
ct
in
g 
dr
ug
s
N
De
sc
rip
tio
n
Se
ve
rit
y
Sc
ie
nt
ifi
c 
ev
id
en
ce
PK
/P
D
Re
le
va
nc
e 
ac
co
rd
in
g 
to
 e
xp
er
ts
Th
yr
oi
d 
dr
ug
s +
 an
ta
cid
s/
ca
lci
um
Le
vo
th
yr
ox
in
e 
+ 
Al
um
in
um
 h
yd
ro
xid
e; 
M
ag
ne
siu
m
 h
yd
ro
xid
e
2
Dr
ug
 co
m
bi
na
tio
ns
 m
ay
 in
hi
bi
t t
he
 ab
so
rp
tio
n 
of
 th
yr
oi
d 
dr
ug
s 
C
  
3
PK
Re
le
va
nt
Be
ta
 b
lo
ck
er
s +
 N
SA
ID
’s
M
et
op
ro
lo
l +
 D
icl
of
en
ac
1
NS
AI
Ds
 m
ay
 at
te
nu
at
e 
th
e 
an
tih
yp
er
te
ns
ive
 e
ffe
ct
 o
f b
et
a 
bl
oc
ke
rs
C
3
PD
Re
le
va
nt
Bi
sp
ho
sp
ho
na
te
s +
 an
ta
cid
s/
iro
n/
ca
lci
um
Al
en
dr
on
ic 
ac
id
 +
 C
alc
iu
m
 ca
rb
on
at
e
1
Pr
od
uc
ts 
co
nt
ain
in
g 
alu
m
in
um
, c
alc
iu
m
, m
ag
ne
siu
m
 
an
d 
ot
he
r p
ol
yv
ale
nt
 ca
tio
ns
 su
ch
 as
 an
ta
cid
s o
r v
ita
m
in
 
w
ith
 m
in
er
al 
su
pp
lem
en
ts 
ar
e 
lik
ely
 to
 in
te
rfe
re
 w
ith
 th
e 
ga
str
oi
nt
es
tin
al 
ab
so
rp
tio
n 
of
 o
ra
l b
isp
ho
sp
ho
na
te
s.
–
–
PK
Re
le
va
nt
Co
rti
co
ste
ro
id
s +
 in
du
ct
or
s
De
xa
m
et
ha
so
ne
 +
 P
he
ny
to
in
1
Ph
en
yt
oi
n 
an
d 
ot
he
r h
yd
an
to
in
s m
ay
 in
du
ce
 th
e 
CY
P3
A4
 
he
pa
tic
 m
et
ab
ol
ism
 o
f c
or
tic
os
te
ro
id
s a
nd
 in
cr
ea
se
 th
eir
 
cle
ar
an
ce
.
D
3
PK
Re
le
va
nt
Co
um
ar
in
s +
 m
et
fo
rm
in
Ph
en
pr
oc
ou
m
on
 +
 M
et
fo
rm
in
1
M
et
fo
rm
in
 m
ay
 in
hi
bi
t t
he
 e
ffe
ct
 o
f c
ou
m
ar
in
s
B
2
?
Re
le
va
nt
Co
um
ar
in
s +
 ro
su
va
sta
tin
Ac
en
oc
ou
m
ar
ol
 +
 R
os
uv
as
ta
tin
1
Ro
su
va
sta
tin
 m
ay
 e
nh
an
ce
 th
e 
hy
po
pr
ot
hr
om
bi
ne
m
ic 
eff
ec
t 
of
 co
um
ar
in
s
–
0
?
Re
le
va
nt
Co
um
ar
in
s +
 sa
lic
yla
te
s 
an
tit
hr
om
bo
tic
 (u
p 
to
 an
d 
in
clu
di
ng
 1
00
 m
g)
Ac
en
oc
ou
m
ar
ol
 +
 A
ce
ty
lsa
lic
yli
c a
cid
1
Ac
et
yls
ali
cy
lic
 ac
id
 an
d 
de
riv
at
es
 o
f s
ali
cy
lic
 ac
id
 m
ay
 
en
ha
nc
e 
th
e 
an
tic
oa
gu
lan
t e
ffe
ct
 o
f c
ou
m
ar
in
s
–
0
PD
Re
le
va
nt
Co
um
ar
in
s +
 SS
RI
s/
Ve
nl
af
ax
in
e/
Du
lo
xe
tin
e/
Tr
az
od
on
e
Ac
en
oc
ou
m
ar
ol
 +
 Pa
ro
xe
tin
e
1
SS
RI
s, 
ve
nl
af
ax
in
e, 
du
lo
xe
tin
e 
or
 tr
az
od
on
e 
m
ay
 e
nh
an
ce
 th
e 
eff
ec
t o
f c
ou
m
ar
in
s
D
1
?
Re
le
va
nt
Do
pa
m
in
er
gi
c a
ge
nt
s +
 
an
tip
sy
ch
ot
ics
Ro
pi
ni
ro
le 
+ 
Ol
an
za
pi
ne
1
Dr
ug
 co
m
bi
na
tio
ns
 m
ay
 an
ta
go
ni
ze
 th
e 
ph
ar
m
ac
ol
og
ic 
eff
ec
ts 
of
 d
op
am
in
e 
ag
on
ist
s
D
3
PD
Re
le
va
nt
Ph
en
yt
oi
n 
+ 
co
um
ar
in
s
Ph
en
yt
oi
n 
+ 
Ac
en
oc
ou
m
ar
ol
1
Co
um
ar
in
s m
ay
 in
cr
ea
se
 th
e 
pl
as
m
a c
on
ce
nt
ra
tio
n 
of
 
ph
en
yt
oi
n.
 In
 ad
di
tio
n,
 p
he
ny
to
in
 m
ay
 aff
ec
t t
he
 m
et
ab
ol
ism
 
of
 co
um
ar
in
s. 
Th
e 
eff
ec
t o
f t
he
 co
um
ar
in
s m
ay
 in
cr
ea
se
 o
r 
de
cr
ea
se
C
3
PK
Re
le
va
nt
Iro
n 
+ 
an
ta
cid
s/
ca
rb
on
at
e
Fe
rro
us
 fu
m
ar
at
e 
+ 
M
ag
ne
siu
m
 h
yd
ro
xid
e
1
Dr
ug
 co
m
bi
na
tio
ns
 m
ay
 in
hi
bi
t t
he
 ab
so
rp
tio
n 
of
 ir
on
C
3
PK
Re
le
va
nt
61
3
Interaction study
Su
pp
le
m
en
ta
ry
 T
ab
le
 1
a.
 Id
en
tifi
ed
 p
ot
en
tia
l r
el
ev
an
t d
ru
g-
dr
ug
 in
te
ra
ct
io
ns
 (c
on
tin
ue
d)
In
te
ra
ct
io
n
In
te
ra
ct
in
g 
dr
ug
s
N
De
sc
rip
tio
n
Se
ve
rit
y
Sc
ie
nt
ifi
c 
ev
id
en
ce
PK
/P
D
Re
le
va
nc
e 
ac
co
rd
in
g 
to
 e
xp
er
ts
Ty
ro
sin
e-
kin
as
e 
in
hi
bi
to
rs 
+ 
ga
str
ic 
ac
id
 se
cr
et
io
n 
in
hi
bi
to
rs 
Pa
zo
pa
ni
b 
+ 
Om
ep
ra
zo
le
1
Ga
str
ic 
ac
id
 se
cr
et
io
n 
in
hi
bi
to
rs 
m
ay
 d
ec
re
as
e 
th
e 
or
al 
bi
oa
va
ila
bi
lit
y o
f t
yr
os
in
e-
kin
as
e 
in
hi
bi
to
rs 
an
d 
re
du
ce
 th
eir
 
co
nc
en
tra
tio
ns
 in
 p
las
m
a 
A
3
PK
Re
le
va
nt
Tr
im
et
ho
pr
im
 +
 R
AA
S i
nh
ib
ito
rs/
Sp
iro
no
lac
to
ne
Co
tri
m
ox
az
ol
e 
+ 
Ca
pt
op
ril
1
Dr
ug
 co
m
bi
na
tio
ns
 m
ay
 in
cr
ea
se
 th
e 
ris
k o
f h
yp
er
ka
lae
m
ia
E
3
PD
Re
le
va
nt
RA
AS
 in
hi
bi
to
rs 
+ 
NS
AI
Ds
Ca
pt
op
ril
 +
 D
icl
of
en
ac
 
1
NS
AI
Ds
 m
ay
 at
te
nu
at
e 
th
e 
an
tih
yp
er
te
ns
ive
 e
ffe
ct
s o
f A
CE
 
in
hi
bi
to
rs
D
3
PD
Re
le
va
nt
Se
ve
rit
y 
sc
or
e:
 A
 =
 n
o 
cl
in
ic
al
 e
ffe
ct
, B
 =
 S
ho
rt
 te
rm
 c
lin
ci
al
 e
ffe
ct
 (<
 4
8h
) w
ith
ou
t s
eq
ue
la
e,
 C
 =
 L
on
g 
te
rm
 c
lin
ic
al
 e
ffe
ct
 (4
8-
16
8h
) w
ith
ou
t s
eq
ue
la
e,
 D
 =
 L
on
g 
te
rm
 c
lin
ic
al
 e
ffe
ct
 
>
 1
68
 h
 w
ith
 p
os
sib
le
 se
qu
el
ae
, E
 =
 L
on
g 
te
rm
 se
ve
re
 c
lin
ic
al
 e
ffe
ct
s, 
F 
=
 V
er
y 
se
ve
re
 c
lin
ic
al
 e
ffe
ct
s /
 d
ea
th
Le
ve
l o
f s
ci
en
tifi
c 
ev
id
en
ce
: 0
 =
 n
o 
su
pp
or
t, 
1 
=
 a
ni
m
al
 st
ud
ie
s o
r i
n 
vi
tr
o 
st
ud
ie
s o
f l
im
ite
d 
pr
ed
ic
tiv
e 
va
lu
e,
 2
 =
 in
co
m
pl
et
e,
 p
ub
lis
he
d 
ca
se
 re
po
rt
s, 
3 
=
 w
el
l d
oc
um
en
te
d,
 p
ub
-
lis
he
d 
ca
se
 re
po
rt
s. 
Re
tr
os
pe
ct
iv
e 
an
al
ys
is 
of
 c
as
e 
se
rie
s 
of
 in
te
ra
ct
io
ns
/s
id
e 
eff
ec
ts
, 4
 =
 C
on
tr
ol
le
d,
 p
ub
lis
he
d 
in
te
ra
ci
on
 s
tu
di
es
 in
 p
at
ie
nt
s/
vo
lu
nt
ee
rs
 w
ith
 re
le
va
nt
 s
ur
ro
ga
te
 
en
dp
oi
nt
s
Ab
br
ev
ia
tio
ns
: P
K=
 p
ha
rm
ac
ok
in
et
ic
, P
D
=
 p
ha
rm
ac
od
yn
am
ic
, G
I =
 g
as
tr
oi
nt
es
tin
al
; ?
 =
 u
nk
no
w
n.
62
Chapter 3
Su
pp
le
m
en
ta
ry
 T
ab
le
 1
b.
 Id
en
tifi
ed
 n
on
 c
lin
ic
al
 re
le
va
nt
 d
ru
g-
dr
ug
 in
te
ra
ct
io
ns
In
te
ra
ct
io
n
In
te
ra
ct
in
g 
dr
ug
s
N
De
sc
rip
tio
n
Se
ve
rit
y
Sc
ie
nt
ifi
c 
ev
id
en
ce
PK
/
PD
Re
le
va
nc
e 
ac
co
rd
in
g 
to
 
ex
pe
rts
SS
RI
s/
Ve
nl
af
ax
in
e/
Du
lo
xe
tin
e/
Vo
rtr
io
xe
tin
e 
+ 
Ox
yc
od
on
e
Ci
ta
lo
pr
am
; D
ul
ox
et
in
e; 
Pa
ro
xe
tin
e; 
Se
rtr
ali
ne
; 
Ve
nl
af
ax
in
e 
+ 
Ox
yc
od
on
e
7
Dr
ug
 co
m
bi
na
tio
ns
 m
ay
 ca
us
e 
se
ro
to
ni
n 
sy
nd
ro
m
e
C
1
PD
No
t r
ele
va
nt
 
Ca
lci
um
 ca
rb
on
at
e 
+ 
ga
str
ic 
ac
id
 
se
cr
et
io
n 
in
hi
bi
to
rs
Ca
lci
um
 ca
rb
on
at
e 
+ 
Pa
nt
op
ra
zo
le
4
Ga
str
ic 
ac
id
 se
cr
et
io
n 
in
hi
bi
to
rs 
m
ay
 in
hi
bi
t t
he
 ab
so
rp
tio
n 
of
 ca
lci
um
 
ca
rb
on
at
e
A
3
PK
No
t r
ele
va
nt
Be
ta
 b
lo
ck
er
s s
ele
ct
ive
 +
 in
su
lin
Bi
so
pr
ol
ol
 +
 In
su
lin
 A
sp
ar
t; 
In
su
lin
 G
lar
gi
ne
2
Be
ta
 b
lo
ck
er
s m
ay
 in
hi
bi
t s
om
e 
of
 th
e 
no
rm
al 
ph
ys
io
lo
gi
c r
es
po
ns
e 
to
 
hy
po
gl
yc
em
ia
B
3
PD
No
t r
ele
va
nt
Co
um
ar
in
s +
 an
tib
io
tic
s (
ex
. c
ot
rim
/
m
et
ro
n/
ce
fa
m
)
Ph
en
pr
oc
ou
m
on
 +
 
Az
ith
ro
m
yc
in
; T
ob
ra
m
yc
in
2
Dr
ug
 co
m
bi
na
tio
ns
 m
ay
 e
nh
an
ce
 th
e 
hy
po
pr
ot
hr
om
bi
ne
m
ic 
eff
ec
t o
f 
co
um
ar
in
s
D
3
PD
No
t r
ele
va
nt
Al
ph
a b
lo
ck
er
s n
on
-se
lec
tiv
e 
+ 
be
ta
 
bl
oc
ke
rs/
ca
-a
nt
.
Do
xa
zo
sin
 +
 C
ar
ve
di
lo
l 
1
Dr
ug
 co
m
bi
na
tio
ns
 ca
n 
ca
us
e 
ad
di
tiv
e 
hy
po
te
ns
ive
 e
ffe
ct
s
B
3
PD
No
t r
ele
va
nt
Co
um
ar
in
s +
 an
tit
hy
ro
id
 ag
en
ts
Ac
en
oc
ou
m
ar
ol
 +
 Th
iam
az
ol
e
1
An
tit
hy
ro
id
 d
ru
gs
, b
y r
ed
uc
in
g 
th
e 
hy
pe
rth
yr
oi
d 
sta
te
, m
ay
 in
cr
ea
se
 th
e 
hy
po
pr
ot
hr
om
bi
ne
m
ic 
re
sp
on
se
 to
 o
ra
l a
nt
ico
ag
ul
an
ts
–
–
PD
No
t r
ele
va
nt
Co
um
ar
in
s +
 Vi
ta
m
in
 K
Ph
en
pr
oc
ou
m
on
 +
 
Ph
yt
om
en
ad
io
ne
1
Ph
yt
om
en
ad
io
ne
 m
ay
 an
ta
go
ni
ze
 th
e 
hy
po
pr
ot
hr
om
bi
ne
m
ic 
eff
ec
t o
f 
co
um
ar
in
s
D
1
PD
No
t r
ele
va
nt
De
xt
ro
m
et
ho
rp
ha
n/
m
id
az
ol
am
 +
 
pa
zo
pa
ni
b
M
id
az
ol
am
 +
 Pa
zo
pa
ni
b
1
Pa
zo
pa
ni
b 
m
ay
 in
cr
ea
se
 th
e 
pl
as
m
a c
on
ce
nt
ra
tio
n 
of
 d
ex
tro
m
et
ho
rp
ha
n 
or
 m
id
az
ol
am
A
3
PK
No
t r
ele
va
nt
M
et
oc
lo
pr
am
id
e 
+ 
SS
RI
s
M
et
oc
lo
pr
am
id
e 
+ 
Pa
ro
xe
tin
e
2
Dr
ug
 co
m
bi
na
tio
ns
 m
ay
 ca
us
e 
se
ro
to
ni
n 
sy
nd
ro
m
e 
an
d 
se
ve
re
 
ex
tra
py
ra
m
id
al 
re
ac
tio
ns
. In
 ad
di
tio
n,
 SS
RI
s m
ay
 in
cr
ea
se
 th
e 
pl
as
m
a 
co
nc
en
tra
tio
n 
of
 m
et
oc
lo
pr
am
id
e. 
 
C
3
PK
/
PD
No
t r
ele
va
nt
M
et
op
ro
lo
l +
 C
YP
2D
6 
in
hi
bi
to
rs
M
et
op
ro
lo
l +
 Pa
ro
xe
tin
e
1
CY
P2
D6
 in
hi
bi
to
rs 
m
ay
 in
cr
ea
se
 th
e 
pl
as
m
a c
on
ce
nt
ra
tio
n 
of
 m
et
op
ro
lo
l 
B
3
PK
No
t r
ele
va
nt
M
id
az
ol
am
/a
lp
ra
zo
lam
 +
 IN
H/
pi
ll/
(fo
s)
ap
re
pi
ta
nt
M
id
az
ol
am
 +
 Et
hi
ny
l e
str
ad
io
l/
Le
vo
no
rg
es
tre
l
1
IN
H,
 th
e 
pi
ll o
r (
fo
s)a
pr
ep
ita
nt
 m
ay
 in
cr
ea
se
 th
e 
pl
as
m
a c
on
ce
nt
ra
tio
n 
of
 
m
id
az
ol
am
 b
y i
nh
ib
iti
ng
 it
s C
YP
3A
4 
he
pa
tic
 m
et
ab
ol
ism
. 
A
3
PK
No
t r
ele
va
nt
Op
io
id
 ag
on
ist
 +
 p
ar
tia
l a
go
ni
st/
an
ta
go
ni
st 
M
or
ph
in
e 
+ 
Bu
pr
en
or
ph
in
e
1
Pa
rti
al 
ag
on
ist
s/
an
ta
go
ni
sts
 m
ay
 re
du
ce
 th
e 
an
alg
es
ic 
eff
ec
t o
f o
pi
oi
d 
ag
on
ist
s.
C
3
PD
No
t r
ele
va
nt
Su
pp
le
m
en
ta
ry
 T
ab
le
 1
b.
 Id
en
tifi
ed
 n
on
 c
lin
ic
al
 re
le
va
nt
 d
ru
g-
dr
ug
 in
te
ra
ct
io
ns
 (c
on
tin
ue
d)
In
te
ra
ct
io
n
In
te
ra
ct
in
g 
dr
ug
s
N
De
sc
rip
tio
n
Se
ve
rit
y
Sc
ie
nt
ifi
c 
ev
id
en
ce
PK
/
PD
Re
le
va
nc
e 
ac
co
rd
in
g 
to
 
ex
pe
rts
SS
RI
s/
Ve
nl
af
ax
in
e/
Du
lo
xe
tin
e 
+ 
Th
iaz
id
es
Pa
ro
xe
tin
e 
+ 
Hy
dr
oc
hl
or
ot
hi
az
id
e
1
Dr
ug
 co
m
bi
na
tio
ns
 m
ay
 p
ot
en
tia
te
 th
e 
ris
k o
f h
yp
on
at
re
m
ia 
E
2
PD
No
t r
ele
va
nt
SS
RI
s/
Ve
nl
af
ax
in
e/
Du
lo
xe
tin
e/
Vo
rtr
io
xe
tin
e 
+ 
Fe
nt
an
yl
Du
lo
xe
tin
e 
+ 
Fe
nt
an
yl
1
Dr
ug
 co
m
bi
na
tio
ns
 m
ay
 ca
us
e 
se
ro
to
ni
n 
sy
nd
ro
m
e
C
1
PD
No
t r
ele
va
nt
Se
ve
rit
y 
sc
or
e:
 A
 =
 n
o 
cl
in
ic
al
 e
ffe
ct
, B
 =
 S
ho
rt
 te
rm
 c
lin
ci
al
 e
ffe
ct
 (<
 4
8h
) w
ith
ou
t s
eq
ue
la
e,
 C
 =
 L
on
g 
te
rm
 c
lin
ic
al
 e
ffe
ct
 (4
8-
16
8h
) w
ith
ou
t s
eq
ue
la
e,
 D
 =
 L
on
g 
te
rm
 c
lin
ic
al
 e
ffe
ct
 
>
 1
68
 h
 w
ith
 p
os
sib
le
 se
qu
el
ae
, E
 =
 L
on
g 
te
rm
 se
ve
re
 c
lin
ic
al
 e
ffe
ct
s, 
F 
=
 V
er
y 
se
ve
re
 c
lin
ic
al
 e
ffe
ct
s /
 d
ea
th
Le
ve
l o
f s
ci
en
tifi
c 
ev
id
en
ce
: 0
 =
 n
o 
su
pp
or
t, 
1 
=
 a
ni
m
al
 st
ud
ie
s o
r i
n 
vi
tr
o 
st
ud
ie
s o
f l
im
ite
d 
pr
ed
ic
tiv
e 
va
lu
e,
 2
 =
 in
co
m
pl
et
e,
 p
ub
lis
he
d 
ca
se
 re
po
rt
s, 
3 
=
 w
el
l d
oc
um
en
te
d,
 p
ub
-
lis
he
d 
ca
se
 re
po
rt
s. 
Re
tr
os
pe
ct
iv
e 
an
al
ys
is 
of
 c
as
e 
se
rie
s 
of
 in
te
ra
ct
io
ns
/s
id
e 
eff
ec
ts
, 4
 =
 C
on
tr
ol
le
d,
 p
ub
lis
he
d 
in
te
ra
ci
on
 s
tu
di
es
 in
 p
at
ie
nt
s/
vo
lu
nt
ee
rs
 w
ith
 re
le
va
nt
 s
ur
ro
ga
te
 
en
dp
oi
nt
s
Ab
br
ev
ia
tio
ns
: P
K=
 p
ha
rm
ac
ok
in
et
ic
, P
D
=
 p
ha
rm
ac
od
yn
am
ic
, I
N
H
 =
 is
on
ia
zi
d;
 p
ill
 =
 e
th
in
yl
 e
st
ra
di
ol
/le
vo
no
rg
es
tr
el

Chapter 4
Pharmacokinetics of Morphine, 
Morphine-3-Glucuronide and 
Morphine-6-Glucuronide in 
Terminally Ill Adult Patients
L.G. Franken 
A.D. Masman 
B.C.M. de Winter 
B.C.P. Koch 
F.P.M. Baar 
D. Tibboel 
T. van Gelder 
R.A.A. Mathôt
Published in:  
Clinical Pharmacokinetics. 2016 Jun; 55(6): 697-709
66
Chapter 4
aBstract
Background and objective
Morphine dosing can be challenging in terminally ill adult patients due to the heteroge-
neous nature of the population and the difficulty of accurately assessing pain during seda-
tion. To determine the pharmacokinetics of morphine, morphine-3-glucuronide (M3G) and 
morphine- 6-glucuronide (M6G) in this population, and to find clinically relevant parameters 
for dose individualisation, we performed a population pharmacokinetic analysis.
methods
Blood samples were randomly collected from 47 terminally ill patients in both the pre-
terminal and terminal phases. Nonlinear mixed-effects modelling (NONMEM) was used to 
develop a population pharmacokinetic model and perform covariate analysis. 
results 
The data were accurately described by a two compartment model for morphine with two 
one-compartment models for both its metabolites. Typical morphine clearance was 48 L/h 
and fell exponentially by more than 10 L/h in the last week before death. Decreased albumin 
levels and a decreased estimated glomerular filtration rate (eGFR) resulted in lower metabo-
lite clearance. Between subject variability in clearance was 52 % (morphine), 75 % (M3G) and 
79 % (M6G), and changed to 53, 29 and 34 %, respectively, after inclusion of the covariates.
conclusions 
Our results show that morphine clearance decreased up to the time of death, falling by 
more than 10 L/h (26 %) in the last week before death, and that M3G and M6G accumulated 
due to decreased renal function. Further studies are warranted to determine whether dose 
adjustment of morphine is required in terminally ill patients.
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introduction
Morphine is widely used to treat pain and dyspnoea in terminally ill patients [1]. A recent 
study showed that at the time of death, 87 % of the patients in palliative care were treated 
with morphine [2]. Morphine is metabolised mainly into morphine-3-glucuronide (M3G) and 
morphine-6-glucuronide (M6G). M6G is pharmacologically active and contributes to the anal-
gesic effect [3–5]. M3G does not have any analgesic properties yet it has been suggested that it 
may be responsible for the side effects of morphine [6, 7]. As the morphine dose is determined 
clinically according to the patients’ need, accurate pain assessment is crucial. However, in ter-
minally ill patients this can be difficult as pain assessment can be complicated by delirium or 
palliative sedation [8–11]. Another difficulty with morphine dosing in this population is that its 
pharmacokinetics are likely to be highly variable. To date, no studies have been conducted on 
the pharmacokinetics of morphine in this specific population, although variability between 
patients is to be expected due to the heterogeneous nature of this population, e.g. differences 
in age, diagnosis and comorbidities. This variability is further increased by changes within 
patients over time, which can be caused by the physiological changes that occur as death 
approaches, such as cachexia and a decrease in renal function [12–15].
Together with the difficulty of assessing pain in these patients, this significant interpa-
tient and intrapatient variability indicates the need for a dosing algorithm. The first step in 
developing an individualised dosing regimen is to gain more insight into the pharmacoki-
netics of this specific patient population. Very few studies have been performed in hospice 
patients, and to our knowledge no population pharmacokinetics of morphine have been 
performed in terminally ill patients. To determine the pharmacokinetics in this population 
and to find clinically relevant parameters for individualised dosing, we therefore performed 
a population pharmacokinetic analysis of morphine, M3G and M6G in terminally ill patients.
materials and methods
study design
This prospective, observational study in terminally ill patients was approved by the Medical 
Ethics Committee of the Erasmus University Medical Centre, Rotterdam, and was performed 
in accordance with the principles of the Declaration of Helsinki and its later amendments. 
The study was conducted in the palliative care centre, Laurens Cadenza, Rotterdam, The 
Netherlands, over a 2-year period. Patients were included in the study upon admittance to 
the palliative care centre and were followed until the time of death. Inclusion criteria were 
terminal illness, prognosis survival of more than 2 days and less than 3 months, administra-
tion of morphine, and patients had given informed consent. Morphine was administered for 
pain and dyspnoea and was administered according to national palliative guidelines, with 
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daily doses ranging from 15 to 540 mg [16, 17]. Figure 1a shows a representative patient 
receiving increasing daily morphine doses over time. Morphine was administered orally as 
controlled release tablets or immediate-release liquid, or administered subcutaneously as a 
bolus injection or infusion. The exact times of administration were recorded in the patient 
record. Any concomitant use of codeine was also registered in the patient’s record. Demo-
graphic characteristics (age, sex, weight, race, primary diagnosis and time of death) were 
extracted from the electronic medical records. Primary diagnosis of the patient’s terminal 
illness was classified using the International Statistical Classification of Diseases and Related 
Health Problems–10th Revision (ICD-10).
Blood samples were collected randomly at various time points in both the pre-terminal 
and terminal phases. The terminal phase was defined as the last hours to days before death 
in which a patient becomes bed-bound, semi-comatose, is not able to take more than 
sips of fluid and is no longer able to take oral medication [18]. After collecting blood via 
either venapuncture or indwelling, venous catheter samples were centrifuged, after which 
the plasma was collected and stored at -80 C until analysis. Blood sampling was prefer-
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Figure 1. Dose and concentration data of a patient 
representative for the study population over time. 
This individual had a decrease in renal function with 
a drop in eGFR from 41.4 to 16.3 at T = 283 h. a Daily 
doses of subcutaneous morphine over time until the 
time of death. b Morphine concentrations over time. 
Post hoc predictions (solid line) and measured mor-
phine concentrations (open circles). c Metabolite con-
centrations over time. Post hoc predictions of M3G 
(solid line) and M6G (dashed line), as well as measured 
M3G (triangles) and M6G (crosses) concentrations. 
eGFR estimated glomerular filtration rate, M3G mor-
phine-3-glucuronide, M6G morphine-6-glucuronide.
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ably performed in combination with sampling for clinical chemistry (standard of care) for 
which serum levels of albumin, creatinine, urea, bilirubin, c-glutamyl-transpeptidase (GGT), 
alkaline phosphatase (ALP), alanine transaminase (ALT), aspartate transaminase (AST), and 
C-reactive protein (CRP) were determined. With regard to these clinical chemical values, 
blood was collected in heparin tubes, centrifuged and analysed by the clinical chemistry 
laboratory as standard care for these patients.
liquid chromatography-tandem mass spectrometry (lc-ms/ms) analysis
Morphine, M3G and M6G were analysed in the plasma samples using liquid chromatog-
raphy-tandem mass spectrometry (LC-MS/MS) with electrospray ionization in the positive 
ionization mode on a Shimadzu LC-30 (Nishinokyo-Kuwabaracho, Japan) system coupled 
to an ABSciex (Framingham, MA, USA) 5500 Qtrap MS. To 10 μL of patients’ plasma, 75 μL 
acetonitrile/methanol 84:16 (v/v %) containing the internal standards morphine-d3, M3Gd3 
and M6G-d3 was added to precipitate proteins. Samples were vortexed, stored at -20 °C for 
30 min to optimise protein precipitation, vortexed again and centrifuged. A total of 3 μL 
was injected into a Thermo Scientific Hypersil Gold HILIC (50 9 2.1 mm, 1.9 lm) column. A 
stepwise chromatographic gradient was applied using 1 % ammonium formate/2 % formic 
acid in water as mobile phase A and acetonitrile as mobile phase B. The flow rate was 0.6 
mL/min and the column was kept at 40 °C. Using multiple reaction monitoring (MRM), mor-
phine, M3G and M6G were measured as [M + H] + using the mass transitions 286.1/165.1, 
462.2/286.2 and 462.2/286.2, respectively. Retention times for morphine, M3G and M6G 
were 0.44, 2.77 and 2.58, respectively. For the internal standards, morphine-d3, M3G-d3 
and M6G-d3 were used with the same retention times and mass transitions of 289.1/165.1, 
465.2/289.2 and 465.2/289.2, respectively. 
The method was validated over a range of 2–500 μg/L for all compounds with six calibra-
tion curves each containing seven concentrations. The accuracies ranged from 93.5 to 105.5 
%. Intraday and interday precision were calculated with six replicates of four concentrations 
(2, 6, 60 and 500 μg/L) for all compounds, and resulted in intraday and interday precisions 
below 9.6 and 12.9 %, respectively. Three quality controls (low level 2 μg/L, medium level 60 
μg/L and high level 500 μg/L) were validated and used for this method.
Population Pharmacokinetic modelling
Pharmacokinetic analysis was conducted by nonlinear mixed-effects modelling using NON-
MEM® version 7.2 (ICON Development Solutions, Ellicott City, MD, USA) and PsN® version 3.7.6.
Base Model Development
The data were log-transformed and concentrations of M3G and M6G were adjusted to their 
morphine equivalents using the molecular weight. Bioavailability of subcutaneous mor-
phine was assumed to be 100 % [19, 20]. One two-and three-compartment models were 
70
Chapter 4
tested for morphine and its metabolites using the first-order conditional estimation method 
with interaction (FOCE+I) and the ADVAN5 subroutine. First, a structural model for morphine 
was developed. These parameters were then fixed to test the different structural models for 
M3G and M6G. In the final model, all parameters were estimated, with the exception of the 
transformation ratios for M3G and M6G. Since there was no information on the mass bal-
ance, the fractions of morphine transformed into metabolites and fractions excreted could 
not be determined independently. These ratios were therefore set to previously described 
values, i.e. 0.55 for M3G and 0.10 for M6G [21–23].
Between-subject variability (BSV) was assessed on each parameter using an exponential 
and additive model, and residual variability was incorporated as an additive error on the log 
scale. Model selection was based on minimum objective function values (OFVs), parameter 
precision, error estimates, shrinkage values and visual inspection of the goodness-of-fit 
plots.
Covariate Model Development
Demographic and disease characteristics, including age, sex, race, primary diagnosis, renal 
function (estimated glomerular filtration rate [eGFR], plasma creatinine and plasma urea), 
hepatic function (plasma levels of bilirubin, GGT, ALP, ALT, and AST), CRP, albumin, and the 
concomitant use of codeine, were evaluated as potential model covariates. Time to death 
(TTD) was also evaluated as a covariate. This parameter cannot be used as a covariate 
parameter for a priori prediction of individual pharmacokinetic changes but it may give 
insight into quantitative changes at the end of life that are not predicted by standard blood 
chemistry tests. As heart and respiratory rates are not measured in a palliative care centre, 
standard disease severity scoring systems used in internal medicine (e.g. the simple clinical 
score or rapid emergency medicine score) cannot be used in this situation. The relationship 
between covariates and individual estimates was first investigated graphically and was 
further tested in a univariate analysis. Covariates that significantly improved the model (p 
B 0.05) were added to the full model. A backward elimination process was then performed 
with statistical significance indicated by p B 0.001. 
Continuous covariates were normalised to the population median values and incorpo-
rated as power model functions (Eq. 1). Categorical covariates were transformed to binary 
covariates and incorporated as shown in Eq. 2. with θi being the individual model-predicted 
pharmacokinetic parameter (e.g. clearance) for an individual with covariate value covi, θpop 
being the population estimate for that parameter, covm representing the median covariate 
value and θcov representing the covariate effect. In the equation for categorical covariates, 
covi is either 1 or 0. 
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glomerular filtration rate [eGFR], plasma creatinine and
plasma urea), hepatic function (plasma levels of bilirubin,
GGT, ALP, ALT, and AST), CRP, albumin, and the con-
comitant use of codeine, were evaluated as potential model
covariates. Time to death (TTD) was also evaluated as a
covariate. This parameter cannot be used as a covariate
parameter for a priori prediction of individual pharma-
cokinetic changes but it may give insight into quantitative
changes at the end of life that are not predicted by standard
blood chemistry tests. As heart and respiratory rates are not
measured in a palliative care centre, standard disease
severity scoring systems used in internal medicine (e.g. the
simple clinical score or rapid emergency medicine score)
cannot be used in this situation. The relationship between
covariates and individual estimates was first investigated
graphically and was further tested in a univariate analysis.
Covariates that significantly improved the model
(p B 0.05) were added to the full model. A backward
elimination process was then performed with statistical
significance indicated by p B 0.001.
Continuous covariates were normalised to the popula-
tion median values and incorporated as power model
functions (Eq. 1). Categorical covariates were transformed
to binary covariates and incorporated as shown in Eq. 2.
hi ¼ hpop � covi
covm
 hcov
ð1Þ
hi ¼ hpop � hcovicov ð2Þ
with hi being the individual model-predicted pharmacoki-
netic parameter (e.g. clearance) for an individual with
covariate value covi, hpop being the population estimate
for that parameter, covm representing the median covariate
value and hcov representing the covariate effect. In the
equation for categorical covariates, covi is either 1 or 0.
To evaluate the TTD as a covariate, time dependency of
the parameters was modelled as a first-order process given
to following equation (Eq. 3),
hi ¼ hpop � hD � expð�hrate � TTDÞ ð3Þ
in which hD is the change in parameter value from its initial
value and hrate is a first-order rate constant determining the
rate with which the parameter value changes over time.
2.3.3 Model Evaluation
A bootstrap with 500 runs was performed on the final
model to evaluate the validity of the parameter estimates
and their corresponding 95 % confidence intervals (CIs).
Due to the study design, i.e. sparse sampling, different
dosing regimens and both oral and subcutaneous adminis-
trations, a visual predictive check could not be performed
to evaluate the model. We therefore evaluated the
predictive performance of the final model using a nor-
malised prediction distribution errors (NPDE) analysis.
NPDE is a simulation-based diagnostics which can be used
to evaluate models developed on datasets with variable
dosing regimens. The analytical value of this method has
been previously described by Comets et al. [24].
3 Results
A total of 47 terminally ill patients were included in the
study. Their median age was 71 years (range 43–93),
55.3 % were female and the median duration of admittance
(from moment of admittance until the time of death) was
33 days (range 7–457). Almost all patients (95.7 %) had
advanced malignancy as the primary diagnosis. Patient
characteristics are given in Table 1. From these patients, a
total of 152 blood samples were collected and analysed for
morphine, M3G and M6G concentrations. Figure 1b and c
show the concentrations of morphine, M3G and M6G over
time for a representative patient. As shown in these graphs,
the morphine concentration increases as the dose increases,
and near the end of life M3G and M6G concentrations
increase significantly. Circa 12 % of the plasma concen-
trations were below the quantification limit (BLQ), largely
due to two patients who had had blood samples taken more
than 10 days after the last morphine dose. BLQ data were
therefore discarded using the M1 method previously dis-
cussed by Ahn et al. [25].
3.1 Structural Model
The data were best described by a two-compartment model
for morphine and two one-compartment models for both its
glucuronidated metabolites (Fig. 2). Since limited data
were available in the absorption phase, the absorption
constants (Ka) could not be estimated, and were therefore
fixed to known literature values (10 h-1 for subcutaneous
injection, 6 h-1 for immediate-release liquid and 0.8 h-1
for controlled-release tablets) [26, 27]. The population
mean estimates for volume of distribution were 185 L
(relative standard error [RSE] 28 %) for the central mor-
phine compartment (V1); 243 L (RSE 33 %) for the
peripheral morphine compartment (V2); 7.65 L (RSE
33 %) for the M3G compartment; and 7.1 L (RSE 30 %)
for the M6G compartment. The population mean estimates
for clearance were 37.2 L/h (RSE 9 %) for morphine;
1.48 L/h (RSE 8 %) for M3G; and 1.87 L/h (RSE 8 %) for
M6G. An overview of all parameter estimates is given in
Table 2.
Including BSV on morphine clearance and bioavail-
ability (F) of oral morphine both significantly improved the
model fit with a change in OFV (DOFV) of -43.3 and -
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 (1)
glomerular filtration rate [eGFR], plasma creatinine and
plasma urea), hepatic function (plasma levels of bilirubin,
GGT, ALP, ALT, and AST), CRP, albumin, and the con-
comitant use of codeine, were evaluated as potential model
covariates. Time to death (TTD) was also evaluated as a
covariate. This parameter cannot be used as a covariate
parameter for a priori prediction of individual pharma-
cokinetic changes but it may give insight into quantitative
changes at the end of life that are not predicted by standard
blood chemistry tests. As heart and respiratory rates are not
measured in a palliative care centre, standard disease
severity scoring systems used in internal medicine (e.g. the
simple clinical score or rapid emergency medicine score)
cannot be used in this situation. The relationship between
covariates and individual estimates was first investigated
graphically and was further tested in a univariate analysis.
Covariates that significantly improved the model
(p B 0.05) were added to the full model. A backward
elimination process was then performed with statistical
significance indicated by p B 0.001.
Continuous covariates were normalised to the popula-
tion median values and incorporated as power model
functions (Eq. 1). Categorical covariates were transformed
to binary covariates and incorporated as shown in Eq. 2.
hi ¼ hpop � covi
covm
 hcov
ð1Þ
hi ¼ hpop � h icov ð2Þ
with hi being the individual model-predicted pharmacoki-
netic parameter (e.g. clearance) for an individual with
covariate value covi, hpop being the population estimate
for that parameter, covm representing the median covariate
value and hcov representing the covariate effect. In the
equation for categorical covariates, covi is either 1 or 0.
To evaluate the TTD as a covariate, time dependency of
the parameters was modelled as a first-order process given
to following equation (Eq. 3),
hi ¼ hpop � hD � expð�hrate � TTDÞ ð3Þ
in which hD is the change in parameter value from its initial
value and hrate is a first-order rate constant determining the
rate with which the parameter value changes over time.
2.3.3 Model Evaluation
A bootstrap with 500 runs was performed on the final
model to evaluate the validity of the parameter estimates
and their corresponding 95 % confidence intervals (CIs).
Due to the study design, i.e. sparse sampling, different
dosing regimens and both oral and subcutaneous adminis-
trations, a visual predictive check could not be performed
to evaluate the model. We therefore evaluated the
predictive performance of the final model using a nor-
malised prediction distribution errors (NPDE) analysis.
NPDE is a simulation-based diagnostics which can be used
to evaluate models developed on datasets with variable
dosing regimens. The analytical value of this method has
been previously described by Comets et al. [24].
3 Results
A total of 47 terminally ill patients were included in the
study. Their median age was 71 years (range 43–93),
55.3 % were female and the median duration of admittance
(from moment of admittance until the time of death) was
33 days (range 7–457). Almost all patients (95.7 %) had
advanced malignancy as the primary diagnosis. Patient
characteristics are given in Table 1. From these patients, a
total of 152 blood samples were collected and analysed for
morphine, M3G and M6G concentrations. Figure 1b and c
show the concentrations of morphine, M3G and M6G over
time for a representative patient. As shown in these graphs,
the morphine concentration increases as the dose increases,
and near the end of life M3G and M6G concentrations
increase significantly. Circa 12 % of the plasma concen-
trations were below the quantification limit (BLQ), largely
due to two patients who had had blood samples taken more
than 10 days after the last morphine dose. BLQ data were
therefore discarded using the M1 method previously dis-
cussed by Ahn et al. [25].
3.1 Structural Model
The data were best described by a two-compartment model
for morphine and two one-compartment models for both its
glucuronidated metabolites (Fig. 2). Since limited data
were available in the absorption phase, the absorption
constants (Ka) could not be estimated, and were therefore
fixed to known literature values (10 h-1 for subcutaneous
injection, 6 h-1 for immediate-release liquid and 0.8 h-1
for controlled-release tablets) [26, 27]. The population
mean estimates for volume of distribution were 185 L
(relative standard error [RSE] 28 %) for the central mor-
phine compartment (V1); 243 L (RSE 33 %) for the
peripheral morphine compartment (V2); 7.65 L (RSE
33 %) for the M3G compartment; and 7.1 L (RSE 30 %)
for the M6G compartment. The population mean estimates
for clearance were 37.2 L/h (RSE 9 %) for morphine;
1.48 L/h (RSE 8 %) for M3G; and 1.87 L/h (RSE 8 %) for
M6G. An overview of all parameter estimates is given in
Table 2.
Including BSV on morphine clearance and bioavail-
ability (F) of oral morphine both significantly improved the
model fit with a change in OFV (DOFV) of -43.3 and -
700 L. G. Franken et al.
 (2)
To evaluate the TTD as a covariate, time depen ency of the parameters was modelled 
as a first-order process given to following equation (Eq. 3) in which θΔ is the change in 
p rameter value f om its initial value and θrate is a first-order rate constant determining the 
rate with which the parameter value changes over time.
glomerular filtration rate [eGFR], plasma creatinine and
plasma urea), hepatic function (plasma levels of bilirubin,
GGT, ALP, ALT, and AST), CRP, albumin, and the con-
comitant use of codeine, were evaluated as potential model
covariates. Time to death (TTD) was also evaluated as a
covariate. This parameter cannot be used as a covariate
parameter for a priori prediction of individual pharma-
cokinetic changes but it may give insight into quantitative
changes at the end of life that are not predicted by standard
blood chemistry tests. As heart and respiratory rates are not
measured in a palliative care centre, standard disease
severity scoring systems used in internal medicine (e.g. the
simple clinical score or rapid emergency medicine score)
cannot be used in this situation. The relationship between
covariates and individual estimates was first investigated
graphically and was further tested in a univariate analysis.
Covariates that significantly improved the model
(p B 0.05) were added to the full model. A backward
elimination process was then performed with statistical
significance indicated by p B 0.001.
Continuous covariates were normalised to the popula-
tion median values and incorporated as power model
functions (Eq. 1). Categorical covariates were transformed
to binary covariates and incorporated as shown in Eq. 2.
hi ¼ hpop � covi
covm
 hcov
ð1Þ
hi ¼ hpop � hcovicov ð2Þ
with hi being the individual model-predicted pharmacoki-
netic parameter (e.g. clearance) for an individual with
covariate value covi, hpop being the population estimate
for that parameter, covm representing the median covariate
value and hcov representing the covariate effect. In the
equation for categor cal covariates, covi is either 1 or 0.
To evaluate the TTD as a covariate, time dependency of
the parameters was modelled as a first-order process given
to following equation (Eq. 3),
hi ¼ hpop � hD � expð�hrate � TTDÞ ð3Þ
in which hD is the change in parameter value from its initial
value and hrate is a first-order rate constant determining the
rate with which the parameter value changes over time.
2.3.3 Model Evaluation
A bootstrap with 500 runs was performed on the final
model to evaluate the validity of the parameter estimates
and their corresponding 95 % confidence intervals (CIs).
Due to the study design, i.e. sparse sa pling, different
dosing regimens and both oral and subcutaneous ad inis-
trations, a visual predictive check could not be performed
to evaluate the model. We therefore evaluated the
predictive performance of the final model using a nor-
malised prediction distribution errors (NPDE) analysis.
NPDE is a simulation-based diagnostics which can be used
to evaluate models developed on datasets with variable
dosing regimens. The analytical value of this method has
been previously described by Comets et al. [24].
3 Results
A total of 47 terminally ill patients were included in the
study. Their median age was 71 years (range 43–93),
55.3 % were female and the median duration of admittance
(from moment of admittance until the time of death) was
33 days (range 7–457). Almost all patients (95.7 %) had
advanced malignancy as the primary diagnosis. Patient
characteristics are given in Table 1. From these patients, a
total of 152 blood samples were collected and analysed for
morphine, M3G and M6G concentrations. Figure 1b and c
show the concentrations of morphine, M3G and M6G over
time for a representative patient. As shown in these graphs,
the morphine concentration increases as the dose increases,
and near the end of life M3G and 6 concentrations
increase significantly. Circa 12 % of the plasma concen-
trations were below the quantification limit (BLQ), largely
due to two patients who had had blood samples taken more
than 10 days after the last morphine dose. BLQ data were
therefore discarded using the M1 method previously dis-
cussed by Ahn et al. [25].
3.1 Structural Model
The data were best described by a two-compartment model
for orphine and two one-compartment models for both its
glucuronidated metabolites (Fig. 2). Since limited data
were available in the absorption phase, the absorption
constants (Ka) could not be estimated, and were therefore
fixed to known literature values (10 h-1 for subcutaneous
injection, 6 h-1 for immediate-release liquid and 0.8 h-1
for controlled-release tablets) [26, 27]. The population
mean estimates for volume of distribution were 185 L
(relative standard error [RSE] 28 %) for the central mor-
phine compartment (V1); 243 L (RSE 33 %) for the
peripheral morphine co partment (V2); 7.65 L (RSE
33 %) for the M3G compartment; and 7.1 L (RSE 30 %)
for the M6G co partment. The population mean estimates
for clearance were 37.2 L/h (RSE 9 %) for morphine;
1.48 L/h (RSE 8 %) for M3G; and 1.87 L/h (RSE 8 %) for
M6G. An overview of all parameter estimates is given in
Table 2.
Including BSV on morphine clearance and bioavail-
ability (F) of oral morphine both significantly improved the
model fit with a change in OFV (DOFV) of -43.3 and -
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Mod l Evaluation
A bootstrap wi  500 runs was performed on the final odel to evaluate the validity of the 
p rameter es imates and th ir corresponding 95 % confidence int rvals (CIs). Due to the 
study design, i.e. sparse sampling, different dosing regimens and both oral and subcutane-
ous administrations, a visual predictive check could not be performed to evaluate the model. 
We therefore evaluated the predictive performance of the final model using a normalised 
prediction distribution errors (NPDE) analysis. NPDE is a simulation-based diagnostics which 
can be used to evaluate models developed on datasets with variable dosing regimens. The 
alytical value of this method has been pr viously described by Comets et al. [24]. 
results
A total of 47 terminally ill patients were included in the study. Their median age was 71 years 
(range 43–93), 55.3 % were female and the median duration of admittance (from moment 
of admittance until the time of death) was 33 days (range 7–457). Almost all patients (95.7 
%) had advanced malignancy as the primary diagnosis. Patient characteristics are given in 
Table 1. From these patients, a total of 152 blood samples were collected and analysed 
for morphine, M3G and M6G concentrations. Figure 1b and c show the concentrations of 
morphine, M3G and M6G over time for a representative patient. As shown in these graphs, 
the morphine concentration increases as the dose increases, and near the end of life M3G 
and M6G concentrations increase significantly. Circa 12 % of the plasma concentrations 
were below the quantification limit (BLQ), largely due to two patients who had had blood 
samples taken more than 10 days after the last morphine dose. BLQ data were therefore 
discarded using the M1 method previously discussed by Ahn et al. [25]. 
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structural model
The data were best described by a two-compartment model for morphine and two 
one-compartment models for both its glucuronidated metabolites (Fig. 2). Since limited 
data were available in the absorption phase, the absorption constants (Ka) could not be 
estimated, and were therefore fixed to known literature values (10 h-1 for subcutaneous 
injection, 6 h-1 for immediate-release liquid and 0.8 h-1 for controlled-release tablets) [26, 
27]. The population mean estimates for volume of distribution were 185 L (relative standard 
error [RSE] 28 %) for the central morphine compartment (V1); 243 L (RSE 33 %) for the pe-
ripheral morphine compartment (V2); 7.65 L (RSE 33 %) for the M3G compartment; and 7.1 
Table 1. Patient characteristics
Characteristics N = 47
Age, years (median, range) 71 (43 - 93)
Male, n (%) 21 (44.7)
Female, n (%) 26 (55.3)
Ethnic origin, n (%)
Caucasian 45 (95.7)
Afro-Caribbean 2 (4.3)
Primary diagnosis, n (%)
Neoplasm 45 (95.7)
Disease of the circulatory system 1 (2.1)
Disease of the respiratory system 1 (2.1)
Blood chemistry, serum levels at admission (median, range)
Albumin, g/l 26 (14-39)
Urea, mmol/l 7.2 (1.5-43.4)
Bilirubin, umol/l 8 (3-256)
Gamma-glytamyl transpeptidase, U/l 64 (7-3859)
Alkaline phosphatase, U/l 112 (20-2117)
Alanine transaminase, U/l 12 (7-406)
Aspartate transaminase, U/l 32 (14-255)
C-reactive protein, U/l 67 (1-188)
Creatinine, umol/l 72 (22-229)
eGFR by standard MDRDa, ml/min/1.73 m2 96 (27-239)
eGFR by original MDRDb, ml/min/1.73 m2 83 (22-202)
Patients using codeinec, n (%) 2 (4.2)
Duration of stay, days (median, range) 33 (7 - 457)
Blood samples collected, n (median, range) 2 (1 – 10) 
eGFR: estimated glomerular filtration rate, MDRD: modification of diet in renal disease. a The abbreviated MDRD 
equation consists of 4 variables (age, gender, race and serum creatinine) as shown in Eq. 4. b the original MDRD 
formula consist of 6 variables (age, gender, race, serum creatinine, serum albumin and serum urea) as shown in 
Eq. 5 c during any moment while receiving morphine treatment
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L (RSE 30 %) for the M6G compartment. The population mean estimates for clearance were 
37.2 L/h (RSE 9 %) for morphine; 1.48 L/h (RSE 8 %) for M3G; and 1.87 L/h (RSE 8 %) for M6G. 
An overview of all parameter estimates is given in Table 2.
Figure 2. Schematic representation of the two-compartment model for morphine and its two main metabolites. 
F bioavailability of oral morphine, V1 central compartment for morphine, V2 peripheral compartment for mor-
phine, Q intercompartmental clearance of morphine, Clt total morphine clearance, Fm1 fraction of morphine 
clearance responsible for M3G formation, Fm2 fraction of morphine clearance responsible for M6G formation, 
Clr remaining morphine clearance (Clt*1-(Fm1 + Fm2)), ClM3G clearance of M3G, ClM6G clearance of M6G, M3G 
morphine-3-glucuronide, M6G morphine-6-glucuronide.
Table 2. Parameter estimates of the base model, final model and bootstrap analysis. 
Parameter
Structural 
model 
Final model RSE % Shrinkage %
Bootstrap of the final model
Estimate
95% CI 
(lower)
95% CI 
(upper)
OFV -323.7 -351.6
Morphine
F 0.28 0.30 13.6 - 0.31 0.18 0.53
Cl (L/h) 37.2 47.5 11 - 49.9 39.1 75.6
V1 (L) 185 190 28 - 190 116 369
Q (L/h) 75 76.1 35.7 - 65.1 9.95 146
V2 (L) 246 243 19 - 248 121 377
M3G
Fm1 0.55a 0.55 a N/A - 0.55 a 0.55 a 0.55 a
Cl (L/h) 1.48 1.44 4.8 - 1.44 1.30 1.59
V1 (L) 7.65 8.02 33.2 - 7.75 3.62 14.9
M6G
Fm2 0.1 a 0.1 a N/A - 0.1 a 0.1 a 0.1 a
Cl (L/h) 1.87 1.78 6.8 - 1.79 1.56 2.05
V1 (L) 7.1 8.24 30.7 - 7.97 3.77 14.0
Covariate effect on M3G and M6G clearance
eGFRb 0.83 0.673 16.8 - 0.67 0.50 1.03
Albumin - 1.1 23.3 - 1.06 0.332 1.56
Covariate effect on M3G and M6G clearance
TTDc (Δ), days - 17.6 24.7 - 19.2 9.48 46.6
TTDc (rate), days - 0.13 32 - 0.12 0.05 0.31
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Including BSV on morphine clearance and bioavailability (F) of oral morphine both signifi-
cantly improved the model fit with a change in OFV (DOFV) of -43.3 and -7.05, respectively. 
The correlation between BSV of M3G and M6G clearance was high and fixed to unity. A 
similar approach was used for BSV on the volumes of distribution of M3G and M6G. Adding 
BSV on metabolite clearance and metabolite volume significantly improved the model fit 
with a change in objective function of 157.0 and 47.1, respectively. In all cases, an exponen-
tial model for BSV proved superior to an additive model. 
Since M3G and M6G are renally cleared, and because there were patients who developed 
renal failure over time, a measure for renal failure was added to the structural model. This 
was done by evaluating the covariate effect of creatinine levels, urea levels, and eGFR on 
metabolite clearance. Glomerular filtration rate was estimated using the generally accepted, 
four-variable, Modification of Diet in Renal Disease (MDRD) equation consisting of age, sex, 
ethnicity, and serum creatinine levels (Eq. 4) [28]. Estimated GFR gave the best results (DOFV 
-75.97 vs -73.58 for creatinine levels and -66.77 for urea levels) and was therefore included 
in the structural model.
7.05, respectively. The correlation between BSV of M3G
and M6G clearance was high and fixed to unity. A similar
approach was used for BSV on the volumes of distribution
of M3G and M6G. Adding BSV on metabolite clearance
and metabolite volume significantly improved the model fit
with a change in objective function of 157.0 and 47.1,
respectively. In all cases, an exponential model for BSV
proved superior to an additive model.
Since M3G and M6G are renally cleared, and because
there were patients who developed renal failure over time,
a measure for renal failure was added to the structural
model. This was done by evaluating the covariate effect of
creatinine levels, urea levels, and eGFR on metabolite
clearance. Glomerular filtration rate was estimated using
the generally accepted, four-variable, Modification of Diet
in Renal Disease (MDRD) equation consisting of age, sex,
ethnicity, and serum creatinine levels (Eq. 4) [28]. Esti-
mated GFR gave the best results (DOFV -75.97 vs -73.58
for creatinine levels and -66.77 for urea levels) and was
therefore included in the structural model.
eGFR ¼ 186� serum creatinine (mg/dl)�1:154 � age�0:203
� ð1:210 if blackÞ � ð0:742 if femaleÞ
ð4Þ
3.2 Covariate Analysis
The structural model including eGFR on metabolite
clearance was used as a reference for the covariate analy-
sis. The univariate analysis resulted in a further eight sig-
nificant covariates, three of which were correlated with
morphine clearance (i.e. TTD, bilirubin, and urea), two
were correlated with metabolite clearance (i.e. albumin and
CRP), two were correlated with the volume of distribution
of the metabolites (i.e. creatinine and urea), and one was
correlated with bioavailability (i.e. race). The results of the
univariate analysis, in terms of decrease in OFV and
covariate effect, are shown in Table 3. After backwards
elimination of p\ 0.001, only albumin levels on metabo-
lite clearance and TTD on morphine clearance remained in
the final model.
Because the final model had both eGFR and albumin
levels as covariates on metabolite clearance, we also tested
Fig. 2 Schematic representation of the two-compartment model for
morphine and its two main metabolites. F bioavailability of oral
morphine, V1 central compartment for morphine, V2 peripheral
compartment for morphine, Q intercompartmental clearance of
morphine, Clt total morphine clearance, Fm1 fraction of morphine
clearance responsible for M3G formation, Fm2 fraction of morphine
clearance responsible for M6G formation, Clr remaining morphine
clearance (Clt*1-(Fm1 ? Fm2)), ClM3G clearance of M3G, ClM6G
clearance of M6G, M3G morphine-3-glucuronide, M6G morphine-6-
glucuronide
Table 1 Patient characteristics
Characteristics N = 47
Age [years; median (range)] 71 (43–93)
Male [n (%)] 21 (44.7)
Female [n (%)] 26 (55.3)
Ethnic origin [n (%)]
Caucasian 45 (95.7)
Afro-Caribbean 2 (4.3)
Primary diagnosis [n (%)]
Neoplasm 45 (95.7)
Disease of the circulatory system 1 (2.1)
Disease of the respiratory system 1 (2.1)
Blood chemistry, serum levels at admission [median (range)]
Albumin, g/L 26 (14–39)
Urea, mmol/L 7.2 (1.5–43.4)
Bilirubin, lmol/L 8 (3–256)
c-Glutamyl transpeptidase, U/L 64 (7–3859)
Alkaline phosphatase, U/L 112 (20–2117)
Alanine transaminase, U/L 12 (7–406)
Aspartate transaminase, U/L 32 (14–255)
C-reactive protein, U/L 67 (1–188)
Creatinine, lmol/L 72 (22–229)
eGFR by standard MDRDa, ml/min/1.73 m2 96 (27–239)
eGFR by original MDRDb, ml/min/1.73 m2 83 (22–202)
Patients using codeinec [n (%)] 2 (4.2)
Duration of stay [days; median (range)] 33 (7–457)
Blood samples collected [n; median (range)] 2 (1–10)
eGFR estimated glomerular filtration rate, MDRD Modification of
Diet in Renal Disease
a The abbreviated MDRD equation consisted of four variables (age,
sex, race and serum creatinine), as shown in Eq. 4
b The original MDRD formula consisted of six variables (age, sex,
race, serum creatinine, serum albumin and serum urea), as shown in
Eq. 5
c During any moment while receiving morphine treatment
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covariate analysis
 struct r l mod l including eGFR on metabolite clearance was used as a reference for the 
covariate analysis. The univariate analysis resulted in a further eight significant covariates, three 
of which were correlated with morphine clearance (i.e. TTD, bilirubin, and urea), two were 
correlat d with metabolite clearance (i.e. alb min and CRP), two were correlated with the vol-
Table 2. Parameter estimates of the base model, final model and bootstrap analysis.  (continued)
Parameter
Structural 
model 
Final model RSE % Shrinkage %
Bootstrap of the final model
Estimate
95% CI 
(lower)
95% CI 
(upper)
Between subject variability (%)
F 48.2 37.8 38.3 9.5 38.7 1.7 58.0 
morphine Cl 54.0 53.4 30.1 13.3 50.0 31.7 71.8 
M3G Cl 39.7 29.3 29.2 5.5 29.3 20.4 41.7 
M6G Cl 43.5 34.3 29.2 5.5 34.1 23.8 48.4 
M3G V1 135.5 151.7 31.4 6.1 147.9 80.3 203.1 
M6G V1 130.4 143.0 31.4 6.1 141.5 76.8 194.4 
Residual variability
Morphine 0.448 0.432 10.4 10 0.425 0.335 0.510
M3G 0.250 0.246 9.3 10 0.239 0.194 0.282
M6G 0.261 0.265 6.6 10 0.254 0.218 0.294
a transformation ratios for M3G and M6G were fixed to known literature values. b GFR was estimated using the 
standard 4-variable MDRD equation. c Time to death (TTD) was incorporated as a first order process With TTDΔ 
as the change in parameter value from its initial value and TTDrate as the first order rate constant 
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ume of distribution of the metabolites (i.e. creatinine and urea), and one was correlated with 
bioavailability (i.e. race). The results of the univariate analysis, in terms of decrease in OFV and 
covariate effect, are shown in Table 3. After backwards elimination of p\0.001, only albumin 
levels on metabolite clearance and TTD on morphine clearance remained in the final model.
Because the final model had both eGFR and albumin levels as covariates on metabolite 
clearance, we also tested if these two covariates could be replaced by the eGFR estimated 
using the original six-variable MDRD formula (Eq. 5) [28]. This formula calculates GFR using 
not only sex, weight, race and creatinine levels but also takes into account albumin and 
urea levels. However, this more elaborate version of the MDRD equation did not improve 
the model fit (OFV -342.9 vs. -351.6 for the standard four-variable MDRD equation). Together, 
estimated GFR and serum albumin decreased the unexplained variability on M3G and M6G 
clearance from 75.4 and 79.1 to 29.3 and 34.3 %, respectively. They hereby explained 61.1 % 
of the BSV in M3G clearance and 56.6 % of the BSV on M6G clearance. The covariate TTD did 
not decrease the unexplained variability on morphine clearance; however, it did decrease 
the RSE on the volumes of both metabolites (from 65.7 to 33.2 % for M3G, and from 63.8 to 
30.7 % for M6G).
and 34.3 %, respectively. They hereby explained 61.1 % of
the BSV in M3G clearance and 56.6 % of the BSV on
M6G clearance. The covariate TTD did not decrease the
unexplain d variability on morphine clearance; however, it
did decrease the RSE on the volumes of both metabolites
(from 65.7 to 33.2 % for M3G, and from 63.8 to 30.7 % for
M6G).
eGFR ¼ 170 � serum creatinine mg
dl
 �0:999
� age�0:176 � 1:180if blackð Þ � 0:762if femaleð Þ
� serum urea nitrogen (mg/dl)�0:170
� albumin (g/dl)0:318
ð5Þ
3.3 Simulations
Based on the final model, M3G clearance is reduced by
approximately 30 % (from 1.6 to 1.1 L/h), while eGFR
decreases from 90 to 50 mL/min and albumin concentra-
tions remain stable at 25 g/L. A further reduction of eGFR
to 30 mL/min decreases M3G clearance to a value of
0.8 L/h (Fig. 3). The effect of a reduction of eGFR on
metabolite clearance is shown in Fig. 1c, where the con-
centrations of M3G and M6G increase in the last few
hours. Indeed, this individual had a decrease in renal
function, with a drop in eGFR from 41.4 to 16.3 at
T = 283 h. The final model also implies that with a
stable eGFR of 78 mL/min, a decrease in albumin from 35
to 25 g/L produces a 31 % decrease in M3G clearance
(from 2.1 L/h to 1.4 L/h) (Fig. 4). Respective changes in
M6G clearance are also shown in Figs. 3 and 4, and are
similar to changes in M3G clearances.
Based on the covariate model, morphine clearance will
decrease by 13 %, from 46.4 L/h 3 weeks before death to
40.6 L/h 1 week before death. In the final week before
death, morphine clearance would decrease by another
26–29.9 L/h on the day of death. As a result, the area under
the curve of morphine will be significantly increased in the
final days of life, as can be seen in the simulations of
morphine concentrations in Fig. 5.
3.4 Evaluation of the Final Model
Goodness-of-fit plots of thefinalmodel showed the population
predictions and individual predictionswere evenly distributed
around the line of unity. The conditional weighted residuals
(CWRES) were normally distributed and did not show any
correlation with the population predictions (Fig. 6).
A bootstrap analysis was performed to obtain 95 % CIs
for all parameters. Results of the bootstrap are shown in
Table 2. Evaluation of the predictive performance by
NPDE analysis showed accurate predictive ability, with
distribution of the NPDEs not significantly deviating from
Table 3 Covariate effects in
univariate analysis compared
with the structural model
Covariate DOFV Covariate effect Included after backward elimination
Structural model –
Covariates on bioavailability
Afro-Caribbean racea 6.36 0.52 No
Covariates on morphine CL
Time to death 9.65 20.2 and 0.11b Yes
Plasma urea 7.04 -0.28 No
eGFRc 4.38 0.18 No
Plasma bilirubin 4.06 -0.16 No
Covariates on metabolite CL
CRP 16.4 -0.21 No
Plasma albumin 15.4 1.10 Yes
Plasma GGT 6.10 -0.11 No
Covariates on metabolite Vd
eGFRc 9.42 0.33 No
Plasma creatinine 8.16 -0.40 No
Time to death 7.92 -14.7 and 0.08b No
Plasma urea 6.65 -0.26 No
OFV objective function value, CL clearance, eGFR estimated glomerular filtration rate, CRP C-reactive protein,
GGT c-glutamyl transpeptidase, Vd volume of distribution, TTD time to death, GFR glomerular filtration rate,
MDRD Modification of Diet in Renal Disease
a Compared with subjects of Caucasian race
b 21.6 is the value for TTDD (overall change in clearance) and 0.10 is the TTD rate (change in clearance per day as
described by the first order process)
c GFR was estimated using the abbreviated MDRD equation
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Table 3. Covariate effects in univariate analysis compared to the structural model
Covariate ΔOFV Covariate effect Included after backward 
elimination
Structural model -
Covariates on Bioavailability
Afro-Caribbean Racea 6.36 0.52 No
Covariates on morphine Cl
Time to Death 9.65 20.2 and 0.11b Yes
Plasma Urea 7.04 -0.28 No
eGFRc 4.38 0.18 No
Plasma Bilirubin 4.06 -0.16 No
Covariates on metabolite Cl
CRP 16.4 -0.21 No
Plasma Albumin 15.4 1.10 Yes
Plasma GGT 6.10 -0.11 No
Covariates on metabolite Vd
eGFRc 9.42 0.33 No
Plasma Creatinine 8.16 -0.40 No
Time to Death 7.92 -14.7 and 0.08b No
Plasma Urea 6.65 -0.26 No
a Compared with subjects of Caucasian race b 21.6 is the value for TTDΔ and 0.10 is TTD rate c GFR was estimated 
using the abbreviated MDRD equation. 
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simulations
Based on the final model, M3G clearance is reduced by approximately 30 % (from 1.6 to 1.1 
L/h), while eGFR decreases from 90 to 50 mL/min and albumin concentrations remain stable 
at 25 g/L. A further reduction of eGFR to 30 mL/min decreases M3G clearance to a value of 
0.8 L/h (Fig. 3). The effect of a reduction of eGFR on metabolite clearance is shown in Fig. 
1c, where the concentrations of M3G and M6G increase in the last few hours. Indeed, this 
individual had a decrease in renal function, with a drop in eGFR from 41.4 to 16.3 at T = 283 
h. The final model also implies that with a stable eGFR of 78 mL/min, a decrease in albumin 
from 35 to 25 g/L produces a 31 % decrease in M3G clearance (from 2.1 L/h to 1.4 L/h) (Fig. 
4). Respective changes in M6G clearance are also shown in Figs. 3 and 4, and are similar to 
changes in M3G clearances. 
Based on the covariate model, morphine clearance will decrease by 13 %, from 46.4 
L/h 3 weeks before death to 40.6 L/h 1 week before death. In the final week before death, 
morphine clearance would decrease by another 26–29.9 L/h on the day of death. As a result, 
the area under the curve of morphine will be significantly increased in the final days of life, 
as can be seen in the simulations of morphine concentrations in Fig. 5.
evaluation of the final model
Goodness-of-fit plots of the final model showed the population predictions and individual 
predictions were evenly distributed around the line of unity. The conditional weighted 
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Figure 3. Simulated plasma profiles of morphine, M3G and M6G for patients with an eGFR of 10 mL/min (solid 
line), 30 mL/min (dashed line), 50 mL/min (dotted line) and 90 mL/min (dash-dotted line) with a 30 mg six-daily 
subcutaneous bolus injection dosing regimen and stable plasma albumin levels of 25 g/L. M3G morphine-3-
glucuronide, M6Gmorphine-6-glucuronide, eGFR estimated glomerular filtration rate.
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Figure 4. Simulated plasma profiles of morphine, M3G and M6G for patients with plasma albumin levels of 15 
g/L (solid line), 25 g/L (dashed line) and 35 g/L (dotted line) with a 30 mg six-daily.
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residuals (CWRES) were normally distributed and did not show any correlation with the 
population predictions (Fig. 6). 
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Figure 5. Simulated plasma profiles of 
morphine in the case of 50 mg six times 
daily subcutaneous bolus infusion, 2 
weeks (dotted line), 1 week (dashed line) 
and 1 day (solid line) before death.
A bootstrap analysis was performed to obtain 95 % Cis for all parameters. Results of the 
bootstrap are shown in Table 2. Evaluation of the predictive performance by NPDE analysis 
showed accurate predictive ability, with distribution of the NPDEs not significantly deviating 
from a normal distribution (global adjusted p value, morphine 0.84, M3G 0.19, and M6G 
0.09), and the majority of the NPDEs lay between the values -2 and 2 (Fig. 7).
discussion
This is the first population pharmacokinetic study of morphine in end-of-life patients per-
formed in a non-academic palliative care setting. We even included data of patients shortly 
before death, and were able to accurately describe the pharmacokinetics of morphine, M3G 
and M6G with a two-compartment model for morphine and two one-compartment models 
for both its metabolites. As we followed patients until the time of death, we were able to 
show a decrease in morphine clearance as patients were nearer to the time of death. We also 
showed that eGFR, together with albumin levels, were the best predictors for metabolite 
clearance, explaining approximately 60 % of the unexplained variability between patients. 
To the best of our knowledge, there have not been any population pharmacokinetic 
studies on morphine, M3G, and M6G in terminally ill patients. In the 1980s, Säwe et al. 
demonstrated that the bioavailability of oral morphine in cancer patients ranged between 
15 and 64 % [29], which is comparable with our results in which we found a variability 
in morphine bioavailability of 38 %, with individual values for morphine bioavailability of 
between 16 and 52 %. Because the bioavailability of morphine is dependent on first-pass 
metabolism, this variability is probably due to changes in liver blood flow as morphine has a 
high extraction ratio and glucuronidation is well-preserved, even in the case of severe liver 
disease [30–32].
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In this same study, Säwe and co-workers found a morphine clearance ranging from 0.3 to 
0.97 L/h/kg, which would mean 21–67 L/h for a 70-kg individual. The latter compares favour-
ably with our finding of 47.5 L/h. Two other population pharmacokinetic studies on data 
from cancer patients and one study in intensive care patients reported similar values for 
morphine clearance of 63.8 and 35 L/h, respectively [27, 33, 34]. Interestingly, in studies of 
neurosurgical patients and healthy volunteers, higher clearances have been reported (110 
L/h and 75.3 L/h, respectively) [21, 23]. This indicates that morphine clearance is reduced in 
critically ill patients [23]. 
In the referred study in healthy volunteers, Lötsch et al. showed a delay between the 
rise of morphine concentrations and the formation of M6G; this delay was modelled using 
a transit compartment [23]. In our study, the addition of transit compartments did not im-
prove the fit of the metabolite concentration to the population model due to the sampling 
Figure 6. Goodness-of-fit plots of the final model. The top two panels show the PRED and IPRED concentrations 
versus the DV for morphine (open circles), M3G (open triangles) and M6G (crosses), with the solid line display-
ing the line of unity. The bottom two panels show the correlation of CWRES with the PRED concentrations, 
including the trend line and the distribution of the CWRES in grey bars and dashed line. PRED population pre-
dicted, IPRED individual prediction, DV observed concentrations, CWRES conditional weighted residuals, M3G 
morphine-3-glucuronide, M6G morphine-6-glucuronide.
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frequency in our study being too low in comparison with the reported transit time of 17 
min for M6G [26].
In the previous studies in neurosurgical and cancer patients, a larger clearance for M3G 
and M6G was found than in our study (M3G clearance of 2.67 L/h in neurosurgical patients 
and 3.36 L/h in cancer patients; M6G clearance of 2.52 L/h in neurosurgical patients and 
3.36 L/h in cancer patients [21, 27, and 34]. A possible explanation is that the patients in 
our study were closer to the time of death and therefore had reduced renal clearance. 
Similarly, in the study by Ahlers and colleagues it was demonstrated that M3G clearance 
was significantly reduced in intensive care patients compared with healthy individuals due 
to decreased creatinine clearance [33].
Our results show large interpatient variability, especially in the volume of distribution of 
M3G and M6G, with values of 152 and 143 %, respectively. A previous study in neurosurgi-
cal patients showed much less interpatient variability, which could be explained by this 
population being less heterogenic, and also that this study only included nine patients 
[21]. The high BSV in our study was mainly due to two patients had very high estimated 
volumes of distribution for M3G and M6G. A possible explanation for the large interpatient 
variability observed in our study might be a change in body weight, which we could not test 
as a covariate. Particularly during the last phases of life, patients can have decreased lean 
body weight or may have oedema, which could influence the volume of distribution of the 
metabolites [35].
Figure 7. NPDE analysis of the final model for morphine, M3G and M6G. The top panels show the distribution 
of the NPDE quantiles (grey bars), with the shape of a normal distribution also shown (dashed line). The bottom 
panels show the NPDEs versus the log of the predicted concentrations with individual NPDE values (dots) and 
5th, 50th and 95th percentile lines with their corresponding 90 % confidence intervals (grey-shaded areas). 
NPDE normalised prediction distribution error, M3G morphine-3-glucuronide, M6G morphine-6-glucuronide.
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The covariate analysis resulted in three significant covariates, with the first being TTD. 
Morphine clearance decreased exponentially as TTD decreased, falling by more than 10 
L/h (26 %) in the last week before death. As none of the other covariates tested gave a 
similar significant effect on morphine clearance, this association may be caused by a 
combination of factors. It may be the result of a physiological change (e.g. a decrease in 
hepatic blood flow) that is not detected with standard blood chemistry tests. This observed 
decrease in clearance implicates that morphine dose may have to be decreased according 
to life expectancy. Life expectancy is difficult to predict, as is, for instance, shown by the 
range of admittance in this study being significantly longer than the 3 months stated as 
an admittance criterion for the hospice. However, the terminal phase (where a patient will 
die within hours or days) is usually well-recognised based on several clinical signs (i.e. the 
patient becoming bed-bound, semi-comatose, and that oral medication and fluid intake is 
no longer possible) [18, 36]. In this case, a clinical protocol, specific for the terminal phase, is 
started and specific domains will be registered in the patient record as standard of care [37]. 
Therefore, it might be possible to re-evaluate the morphine dose when this phase is started 
as our model showed the biggest decrease in morphine clearance in the last week of life. 
The two other covariates, eGFR and plasma albumin levels, were correlated with M3G 
and M6G clearance. The fact that eGFR is correlated with M3G and M6G clearance was 
expected as both metabolites are eliminated through the kidneys. Previous studies have 
indeed shown that M3G and M6G can accumulate in patients with impaired renal function 
[38, 39].
The effect of albumin on metabolite clearance has not been previously shown in other 
studies. As M3G and M6G are not highly bound to plasma albumin, it is unlikely that this 
effect will be due to changes in unbound fractions of the metabolites. A possible expla-
nation for this effect of albumin may lie in the fact that some terminally ill patients will 
become cachectic, which also leads to hypoalbuminemia [14]. The MDRD equation is not 
appropriate for calculating GFR in cachectic patients due to severe muscle loss and thereby 
overestimation of GFR based on creatinine levels. Therefore, low albumin levels may be an 
indicator for patients in which GFR is overestimated. Another explanation why the combina-
tion of albumin and eGFR are a better predictor than eGFR alone may be that albumin can 
be an indication that a patient is closer to the time of death. Several studies have shown that 
low albumin levels can predict prognosis in palliative cancer patients
[40–42]. If a patient is closer to the time of death, eGFR might be significantly decreased 
(for instance due to dehydration). As the MDRD formula also overestimates GFR when GFR is 
very low, in this case the addition of albumin levels in the model might partly compensate 
for this overestimation. Combining both eGFR and albumin levels will therefore result in 
better prediction of M3G and M6G clearance.
The main limitation of our study was that we lacked data to evaluate associations 
between weight and the pharmacokinetic parameters. As mentioned above, this might 
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affect the estimates of volume of distribution, and there is also a possible correlation with 
metabolite clearance since, as described before, renal function can be overestimated in 
patients with low body weight. Precise monitoring of weight is not common practice in 
palliative care because it does not contribute to the treatment and because patients might 
find it difficult to be confronted with their weight loss. However, as weight is possibly an 
important covariate, we recommend that it is monitored in future pharmacokinetic studies 
in terminally ill patients. 
Another possible limitation of the study was that the absorption constant of all three 
dosing forms was fixed to known literature values. This was necessary as there were insuf-
ficient data points in the first 30 min after a dose administration due to the sparse sampling 
design. This could have biased the estimation of volume of distribution for the central 
compartment as absorption rate and volume of distribution both affect the initial concen-
tration. In the terminally ill population, patients receive morphine for extended periods of 
time; therefore, clearance (and BSV on clearance) instead of volume of distribution is the 
predominant parameter effecting total morphine exposure.
In addition, it was not possible to determine the transformation ratios of M3G and M6G. 
These ratios were set to previously described values, i.e. 0.55 for M3G and 0.10 for M6G 
[21–23]. This could have biased the results for the parameters of metabolite clearance and 
volume of distribution as these are both proportional to the transformation ratio (CL/F and 
Vd/F). However, we consider the values of 0.55 and 0.10 to be valid as the liver’s capacity 
for glucuronidation of drugs is reasonably stable, even in critically ill patients and patients 
with mild to moderate cirrhosis [30, 31, 33]. The fact that there is BSV on morphine bioavail-
ability (which is a result of first-pass metabolism) is most likely to be caused by a variation in 
liver blood flow instead of metabolic capacity as morphine is a drug with a high extraction 
ratio [32]. In this case, the clearance of morphine will differ; however, the formation ratios 
should remain unchanged. Furthermore, setting the transformation ratios to 0.55 and 0.10 
resulted in comparable estimates for clearance and volume of distribution for both metabo-
lites (Table 2). This seems to be appropriate as both metabolites have an almost identical 
molecular structure and are therefore expected to have similar molecular properties. To 
establish whether the transformation ratios are not altered in these patients, information 
about the mass balance is required. This can be obtained by measuring the fractions of 
morphine, M3G, and M6G in urine samples.
conclusions
Our study again confirms that a reduction in eGFR resulted in a decreased clearance of M3G 
and M6G, which can have clinical consequences as M6G is a metabolite with analgesic activ-
ity, while M3G has been suggested to contribute to side effects. As a result, the morphine 
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dose may be reduced in patients with renal failure, or analgesic therapy may be switched 
to an opioid with less or no active metabolites (e.g. oxycodone or fentanyl). We also found 
that eGFR combined with albumin levels was a better predictor for M3G and M6G clearance 
than eGFR alone. Therefore, dose adjustments should also take into account albumin levels 
besides eGFR. In addition, a positive correlation was found between TTD and morphine 
clearance. This important insight into the pharmacokinetics of morphine in terminally ill pa-
tients is a first step in developing an individualised dosing regimen for terminally ill patients. 
It suggests that morphine doses might be adjusted to a patient’s creatinine and albumin 
levels and life expectancy. However, accurate prediction of the time of death can be difficult 
and the need for morphine does not solely depend on pharmacokinetics. Therefore, further 
studies on the pharmacodynamics in this patient population are needed before any firm 
conclusions can be drawn on dose adjustments.
comPliance with ethical standards
This study was approved by the Medical Ethics Committee of the Erasmus University Medical 
Centre, Rotterdam, and was performed in accordance with the principles of the Declaration 
of Helsinki and its later amendments.
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aBstract
Background and objective 
Midazolam is the drug of choice for palliative sedation and is titrated to achieve the desired 
level of sedation. Because of large inter-individual variability (IIV), however, the time it takes 
to achieve adequate sedation varies widely. It would therefore greatly improve clinical care 
if an individualised dose could be determined beforehand. To find clinically relevant param-
eters for dose individualisation we performed a pharmacokinetic study on midazolam, 1OH-
midazolam (1-OH-M) and 1OH-midazolam-glucuronide (1-OH-MG) in terminally ill patients. 
methods 
Using non-linear mixed effects modelling (NONMEM 7.2), a population pharmacokinetic 
analysis was conducted with 192 samples from 45 terminally ill patients who received mid-
azolam either orally or subcutaneously. The covariates analysed were patient characteristics, 
co-medication and blood chemistry levels. 
results 
The data were accurately described by a one-compartment model for midazolam, 1-OH-M 
and 1-OH-MG. The population mean estimates for midazolam, 1-OH-M and 1-OH-MG clear-
ance were 8.4 L/h (RSE 9%, IIV 49%), 45.4 L/h (RSE 12%, IIV 60.5%) and 5.1L/h (RSE 11%, IIV 
49.9%) respectively. 1-OH-MG clearance was correlated with the estimated glomular filtra-
tion rate (eGFR) explaining 28.4% of the IIV in 1-OH-MG clearance. In addition, low albumin 
levels were associated with decreased midazolam clearance, explaining 18.2% of the IIV.  
conclusion 
Our study indicates albumin levels and eGFR as relevant clinical parameters to optimise 
midazolam dosing in terminally ill patients. The correlation between low albumin levels and 
decreased midazolam clearance is probably a result of inflammatory response as high CRP 
levels were correlated in a similar way.
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What is known about this subject
•	 While a lot of physiological changes occur at the end of life, very little is known about 
how these changes can affect the pharmacokinetics of drugs given in this phase. 
•	 A recent study in critically ill children showed that inflammation and organ failure can 
result in decreased midazolam clearance. 
•	 Animal studies and some preliminary studies in patients with cancer have shown that 
cancer and inflammation are associated with reduced hepatic metabolism of CYP-
enzymes. 
What this study adds
•	 Using a population approach with sparse sampling, we were able to accurately describe 
the pharmacokinetics of midazolam in terminally ill patients. As this method minimises 
the patient’s burden it is a useful approach to use in future PK studies in this vulnerable 
population. 
•	 Midazolam clearance was decreased in patients with low albumin levels. This is possibly 
due to inflammatory response or a catabolic state. 
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introduction 
Midazolam is often used in terminally ill patients and is the drug of choice for palliative 
sedation (1-4). It is metabolised in a two phase process, the first step is hydroxylation 
via CYP3A mainly into α-hydroxy-midazolam (1-OH-M) and for a very small amount into 
4-hydroxy-midazolam (4-OH-M). The 1-OH-M metabolite is active with an approximate po-
tency of 80-100% of midazolam (5-7).  After hydroxylation midazolam is further metabolised 
through UDP-glucuronosyltransferases (UGT) 1A4, 2B4 and 2B7 with α-hydroxy-midazolam 
glucuronide (1-OH-MG) as its major metabolite (8). 1-OH-MG is much less active (around 
10% of the activity of midazolam) but in high concentrations, in the case of accumulation 
due to renal failure it can contribute substantially to the overall effect (5).  
When midazolam is prescribed for palliative sedation its dose is titrated to achieve the 
desired level of sedation (1, 3). Unfortunately the time it takes to reach adequate sedation 
varies widely between patients and awaking from a sedative state occurs often (9). A possible 
explanation for this might be large inter-individual variability (IIV) in midazolam pharmaco-
kinetics, which has already been shown in other populations (10-14). In terminally ill patient 
large variability is also expected due to the heterogeneity of the population including severe 
co-morbidities (e.g. renal failure) and physiological changes that occur over time (e.g. cachexia, 
inflammation and concomitant medication use) (15-18). Failure to respond (rapidly) to mid-
azolam treatment is of clinical concern, especially when sedation is required to treat refractory 
symptoms. Patients could therefore potentially benefit if an individualised dose is determined 
beforehand. A first step in developing such an individualised dosing algorithm is to gain more 
insight in the pharmacokinetics in this population. To this end and to find clinically relevant 
parameters for dose individualisation, we performed a population pharmacokinetic study of 
midazolam and its two major metabolites (1-OH-M and 1-OH-MG) in terminally ill patients. 
methods 
study design
The study (NL32520.078.10) was approved by the Medical Ethics Committee of the Erasmus 
University Medical Centre Rotterdam and was performed in accordance with the principles of 
the Declaration of Helsinki and its later amendments. The study was conducted in the palliative 
care centre, Laurens Cadenza Zuid in Rotterdam, the Netherlands, during two years. Patients 
were eligible if they had a terminal illness, survival prognosis of more than 2 days and less than 
3 months and administration of midazolam. Informed consent was asked shortly after admit-
tance to the palliative care centre and included patient were followed until the time of death. 
Midazolam was given to treat insomnia or as palliative sedation in accordance with the national 
guidelines (4). Midazolam was given orally or administered subcutaneously as bolus injection or 
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infusion. The exact times of administration were recorded in the patient record. Any concomi-
tant medication was also registered in the patient’s record. Demographic characteristics (age, 
gender, weight, race, primary diagnosis, and time of death) were extracted from the electronic 
medical records. Primary diagnosis of the patient’s terminal illness was classified using the Inter-
national Statistical Classification of Diseases and Related Health Problems–10th Revision (ICD-10).
Blood sampling and assay
Sparse sampling was performed randomly and blood samples were collected during both 
the pre-terminal and terminal stages. Where the terminal stage for a patient was defined as 
the last hours to days before death in which a patient becomes bedbound, semi-comatose, 
is not able to take more than sips of fluid and is no longer able to take oral medication 
(19). Sample collection was done either via venapuncture or indwelling venous catheter, 
samples were centrifuged after which the plasma was collected and stored at -80°C until 
analysis. Blood sampling was preferably performed at the same time as sampling for clinical 
chemistry (standard of care) for which serum levels of albumin, creatinine, urea, bilirubin, 
gamma-glytamyl transpeptidase (GGT), alkaline phosphatase (ALP), alanine transaminase 
(ALT), aspartate transaminase (AST), and C-reactive protein (CRP) were determined. 
Midazolam, 1-OH-M, 4-OH-M and 1-OH-MG were analysed in the plasma samples using 
LC-MS/MS with electrospray ionization in the positive ionization mode on a Shimadzu LC-30 
(Nishinokyo-Kuwabaracho, Japan) system coupled to an ABSciex (Framingham, MA, USA) 
API5500Q MS. To precipitate proteins 75 µl acetonitrile/methanol 84:16 (v/v%) containing the 
internal standards midazolam-d5, 1-OH-midazolam-d5, and 4-OH-midazolam-d5 was added 
to 10 µl of patients’ plasma. Samples were vortexed, stored at -20°C for 30 minutes to optimise 
protein precipitation, vortexed again and centrifuged. Three µl was injected onto a Thermo Sci-
entific Hypersil Gold (50 x 2.1 mm, 1.9 µm) column. A stepwise chromatographic gradient was 
applied using 0.05% ammonium formate / 0.10% formic acid in water as mobile phase A and 
acetonitrile as mobile phase B. The flow rate was 0.4 ml/min and the column was kept at 40°C. 
Using multiple reaction monitoring (MRM) with positive ionisation mode, midazolam, 1-OH-
M, 4-OH-M and 1-OH-MG were measured as [M+H]+ using the mass transitions 326.1/291.1, 
342.1/168.1, 342.1/234.1 and 518.1/324.1 respectively. The lower limit of quantification was 
4 μg/L for midazolam 2 μg/L for 1-OH-M and 4-OH-M and 8 μg/L for 1-OH-MG. The method 
was validated over a range of 4 – 1000 μg/L for midazolam and 2 – 500 μg/L for 1-OH-M and 
4-OH-M and 8-2000 μg/L for 1-OH-MG. The accuracies ranged from 94.3% to 104.7%. Intra-day 
precision was below 8.2% and inter-day precisions below 12.9%. 
Population pharmacokinetic method
Pharmacokinetic analysis was conducted using non-linear mixed effects modelling using 
NONMEM® version 7.2 (ICON Development Solutions, Ellicott City, MD), PsN® (version 4.4.8) 
and Pirana (version 2.9.2).
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Base model development
The data were log-transformed and concentrations of 1-OH-M and 1-OH-MG were adjusted 
to their midazolam equivalents using the molecular weight. Bioavailability of subcutaneous 
midazolam was assumed to be 100% (20). One-, two- and three-compartment models were 
tested for midazolam and its metabolites using the first-order conditional estimation method 
with interaction (FOCE+I) and the ADVAN7 subroutine. First a structural model for midazolam 
was developed. These parameters were then fixed to test the different structural models for 
1-OH-M and 1-OH-MG. The volume of distribution (V) of 1-OH-M was assumed to be equal 
to the volume of distribution of midazolam. IIV was assessed on each parameter using an ex-
ponential model. Residual variability was tested as additive, proportional and combined error 
models. Since the parent and metabolite concentrations were measured in the same samples 
using 1 assay, a correlation between the residual errors was incorporated in the model. Model 
selection was based on minimum objective function value (OFV) parameter precision, error 
estimates, shrinkage values and visual inspection of the goodness of fit plots. 
Covariate model development 
Demographic and disease characteristics including age, gender, race, primary diagnosis, 
renal function (estimated glomerular filtration rate (eGFR), plasma creatinine, and plasma 
urea), hepatic function (plasma levels of bilirubin, GGT, ALP, ALT, and AST), C-reactive pro-
tein (CRP), albumin, and the concomitant use of CYP3A inductor and inhibitors were evalu-
ated as potential model covariates. Time to death (TTD) was also evaluated as a covariate. 
This parameter cannot be used as a covariate parameter for a priori prediction of individual 
pharmacokinetic changes but it may give insight in quantitative changes at the end of life 
that are not predicted by standard blood chemistry tests. The relationship between covari-
ates and individual estimates was first investigated graphically and was further tested in a 
univariate analysis. Covariates that significantly improved the model, p ≤ 0.05 were added 
to the full model. A backward elimination process was then performed with statistical 
significance indicated by p ≤ 0.001. 
Continuous covariates were normalised to the population median values and incorporated 
as power model functions (Eq. 1). Categorical covariates were transformed to binary covariates 
and incorporated as shown in Eq. 2.  With θi being the individual model predicted pharmaco-
kinetic parameter (e.g. clearance) for an individual with covariate value covi, θpop being the 
population estimate for that parameter, covm representing the median covariate value and 
θcov the covariate effect. In the equation for categorical covariates covi is either 1 or 0.
electronic medical records. Primary diagnosis of the patient’s
terminal illness was classiﬁed using the International Statisti-
cal Classiﬁcation of Diseases and Related Health Problems –
10th Revision (ICD-10).
Blood sampling and assay
Sparse sampling was performed randomly and blood samples
were collected during both the pre-terminal and terminal
stages. The terminal stage for a patient was deﬁned as the last
hours to days before death in which a patient becomes
bedbound, semi-comatose, is not able to take more than sips
of ﬂuid and is no longer able to take oral medication [21].
Samples were collected either via venapuncture or indwelling
venous catheter, and were centrifuged after which the plasma
was collected and stored at �80°C until analysis. Blood
sampling was preferably performed at the same time as
sampling for clinical chemistry (standard of care) for which
serum levels of albumin, creatinine, urea, bilirubin, gamma-
glytamyl transpeptidase (GGT), alkaline phosphatase (ALP),
alanine transaminase (ALT), aspartate transaminase (AST),
and C-reactive protein (CRP) were determined.
Midazolam, 1-OH-M, 4-OH-M and 1-OH-MG were analy-
sed in the plasma samples using liquid chromatography–
tandem mass spectroscopy (LC–MS/MS) with electrospray
ionization in the positive ionization mode on a Shimadzu
LC-30 (Nishinokyo-Kuwabaracho, Japan) system coupled to
an ABSciex (Framingham, MA, USA) API5500Q MS. To
precipitate proteins 75 μl acetonitrile/methanol 84:16 (v/v%)
containing the internal standards midazolam-d5, 1-OH-mid-
azolam-d5, and 4-OH-midazolam-d5 was added to 10 μl of
patients’ plasma. Samples were vortexed, stored at �20°C for
30 min to optimize protein precipitation, vortexed again and
centrifuged. Three μl was injected onto a Thermo Scientiﬁc
Hypersil Gold (50 × 2.1 mm, 1.9 μm) column. A stepwise
chromatographic gradient was applied using 0.05%
ammonium formate /0.10% formic acid in water as mobile
phase A and acetonitrile as mobile phase B. The ﬂow rate was
0.4mlmin�1 and the columnwas kept at 40°C.Usingmultiple
reaction monitoring (MRM) with positive ionization mode,
midazolam, 1-OH-M, 4-OH-M and 1-OH-MG were measured
as [M+H]+ using the mass transitions 326.1/291.1, 342.1/
168.1, 342.1/234.1 and 518.1/324.1, respectively. The lower
limit of quantiﬁcation was 4 μg l�1 for midazolam, 2 μg l�1
for 1-OH-M and 4-OH-M, and 8 μg l�1 for 1-OH-MG. The
method was validated over a range of 4–1000 μg l�1 for
midazolam and 2–500 μg l�1 for 1-OH-M and 4-OH-M, and
8–2000 μg l�1 for 1-OH-MG. The accuracies ranged from
94.3% to 104.7%. Intra-day precision was below 8.2% and
inter-day precisions below 12.9%.
Population pharmacokinetic method
Pharmacokinetic analysis was conducted using nonlinear
mixed effectsmodelling using NONMEM® version 7.2 (ICON
Development Solutions, Ellicott City, MD), PsN® (version
4.4.8) and Pirana (version 2.9.2).
Base model development
The datawere log-transformed and concentrations of 1-OH-M
and 1-OH-MG were adjusted to their midazolam
equivalents using the molecular weight. Bioavailability of
subcutaneous midazolam was assumed to be 100% [22].
One-, two- and three-compartment models were tested
for midazolam and its metabolites using the ﬁrst-order
conditional estimati n method with inter ction (FOCE+I)
and the ADVAN7 subroutine. First a structural model for
midazolam was developed. These parameters were then
ﬁxed to test the different structural models for 1-OH-M
and 1-OH-MG. The volume of distribution (V) of 1-OH-M
was assumed to be equal t the volume of distribution
of midazolam. IIV was assessed on each parameter using
an exponential model. Residual variability was tested as
additive, proportional and combined error models. Since
the parent and metaboli e conc ntrat ons were measured
in the same samples using a single assay, a correlation
between the residual errors was incorporated in the
model. Model selection was based on minimum objective
function value (OFV) parameter precision, error estimates,
shrinkage values and visual inspection of the goodness of
ﬁt plots.
Covariate model development
Demographic and disease characteristics including age,
gender, race, primary diag osis, r nal function ( stimated
glomerular ﬁltration rate (eGFR), plasma creatinine, and
plasma urea), hepatic function (plasma levels of bilirubin,
GGT, ALP, ALT, and AST), C-reactive protein (CRP), albumin
and the concomitan use of CYP3A inductor and inhibitors
were evaluated as potential odel covariates. Time to death
(TTD) was also evaluated as a covariate. This parameter
cannot be used as a covariate parameter for a priori prediction
of individual pharmacokinetic changes but it may give
insight in quantitative changes at the end of life that are
not predicted by standard blood chemistry tests. The relation-
ship between covariates and individual estimates was ﬁrst
investigated graphically and was further tested in a univariate
analysis. Covariates that sig iﬁcantly (P ≤ 0.05) improved the
model were added to the full model. A backward elimination
process was then performed with statistical signiﬁcance
indicated by P ≤ 0.001.
Continuous covariates were normalized to the population
median values and i corporated as power model functions
(eq. 1). Categorical covariates were transformed to binary
covariates and incorporated as shown in eq. (2).
θi ¼ θpop � covicovm
  θcov
(1)
θi ¼ θpop � θcovcovi (2)
where θi is the individual model predicted pharmacokinetic
parameter (e.g. clearance) for an individual with covariate
value covi, θpop is the population estimate for that parameter,
covm represents the median covariate value and θcov the
covariate effect. In the equation for categorical covariates covi
is either 1 or 0.
To evaluate the time to death (TTD) as a covariate, the
time dependency of the parameters was modelled as a ﬁrst-
order process given by:
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electronic medical records. Primary diagnosis of the patient’s
terminal illn ss was classiﬁed using the I ternational Statisti-
cal Classiﬁcation of Diseas s and Related Health Problem –
10th Revision (ICD-10).
Blood sampling and assay
Sparse sampling was performed randomly and blood samples
were collected during b th the pre-terminal and ter inal
stag s. Th terminal stage for a patient was deﬁned as the last
hours to days before d ath in which a patient becomes
bedbound, semi-comatos , is not able to t ke more than sips
of ﬂuid and is no longer able to tak ral medication [21].
Samples were collected either via venapuncture or indwelling
venous catheter, and were c ntrifuged after which the plasma
was collected and stored at �80°C until analysis. Blood
sampling was preferably performed at the same time as
s li for clinical chemist y (standard of care) for which
serum levels of albumin, creatinine, urea, bilirubin, gamma-
glyta yl transpeptidase (GGT), alkalin phosphatase (ALP),
alanine transaminase (ALT), aspartate transaminase ( ST),
nd C-reactive protein (CRP) were determined.
Midazolam, 1-OH-M, 4-OH-M and 1-OH-MG were analy-
sed in the plasma samples using liquid chromatogr phy–
tandem mass spectroscopy (LC–MS/MS) with electros ray
io ization in the positive ionization mode on a Shimadzu
LC-30 (Nishinokyo-Kuwabaracho, Japan) system coupled to
an ABSciex (Framingham, MA, USA) API5500Q MS. T
precipitat proteins 75 μl acetonitrile/methanol 84:16 (v/v%)
containing the internal st ndards midazolam-d5, 1-OH-mid-
azolam-d5, and 4-OH-midazolam-d5 was dded to 10 μl of
patients’ plasma. Samples were vortexed, stored at �20°C f r
30 mi to optimize prot in precipitation, vort xed again and
centrifuged. Three μl was injected onto a Thermo Scie tiﬁc
Hypersil Gold (50 × 2.1 mm, 1.9 μm) column. A stepwise
chromatographic gradient was applied using 0.05%
ammonium formate /0.10% formic cid in water as mobile
phase A and acetonitrile as mobile ph se B. The ﬂow rate was
0.4mlmin�1 nd the columnwas kept t 40°C.Usingmultiple
reaction monitoring (MRM) ith positive ionization mode,
midaz la , 1-OH-M, 4-OH-M and 1-OH-MG were measured
as [M+H]+ using the mass transitions 326.1/291.1, 342.1/
168.1, 342.1/234.1 and 518.1/324.1, respectively. The lower
limit of quantiﬁcatio was 4 μg l�1 for midazolam, 2 μg l�1
for 1-OH-M and 4-OH-M, and 8 μg l�1 for 1-OH-MG. The
method was validated over a range of 4–1000 μg l�1 for
idazolam and 2–500 μg l�1 fo 1-OH-M and 4-OH-M, and
8–2000 μg l�1 for 1-OH-MG. The accuracies ranged from
94.3% to 104.7%. Intra-day precision was b low 8.2% and
inter-day precisions below 12.9%.
Population pharmacokinetic method
harmacokinetic analysis was conduct d using nonlinear
mixed effectsmodelling u ing NONMEM® ver ion 7.2 (ICON
Dev lopment S lutio s, Ellicott City, MD), PsN® (version
4.4.8) and Pirana (version 2.9.2).
Base model development
The datawere log-transfor ed and concentrations of 1-OH-M
and 1-OH-MG were adjuste to their midazolam
equivalents using the molec lar weight. Bioavailability of
subcutaneous midazolam was assumed to be 100% [22].
One-, two- and three-compartment models were tested
for midazolam and its metabolites using the ﬁrst-ord r
c nditional estimation method with interaction (FOCE+I)
and the ADVAN7 subroutine. First a structural model for
mi azolam was developed. These parameters were then
ﬁxed to test the different structural models for 1-OH-M
and 1-OH-MG. The volume of dist ibuti n (V) f - -
was assumed to b eq al to the volume of distribution
of midazolam. IIV ass ssed on ach p rameter sing
an exponential model. Residual variability was t sted as
dditive, proportional and combined error models. Since
the parent and met bolite ncentrations were measured
in the same samples using a singl ass y, a corr lation
betwe n th residual errors was incorpor ted in the
model. Mod l selection was based on minimum objective
function value (OFV) parameter precision, error estimates,
shrinkage values and visu l inspection f the goodness of
ﬁt plots.
Covariate model development
Demog aphic an diseas characteristics including age,
gender, race, primary di gnosis, renal function (estimated
lom ular ﬁltration r te (eGFR), plasma creatinine, n
plas a urea), hepatic function (plasma levels of bilirubi ,
GGT, ALP, ALT, and AST), C-reactive protein (CRP), albumi
and the concomitant use of CYP3A inductor and inhibitors
were evaluated as potential model covariates. Time to death
(TTD) was also evaluated as a covariate. This par m ter
cannot be used as a cov riate parameter for a priori prediction
of i divid al ph rmacokinetic changes but it may give
insight in quantit tive changes at the end of life that ar
not predicted by standard blood chemistry tests. Th relatio -
ship b twe n cov riates and individual estimates was ﬁrst
investigated graphically and was further tested in a univariate
a alysis. Cova iates that signiﬁcantly (P ≤ 0.05) improved th
model were added to the full model. A backward elimination
pr cess was th n perf rmed with statistic l signiﬁc nce
indicated by P ≤ 0.001.
Continuous covariates were normalized to the population
median val es and incorporated as power mod l functions
(eq. 1). C tegorical covariates were transformed to binary
covariates nd in orporated as shown in eq. (2).
θi ¼ θpop � covicovm
  θcov
(1)
θi ¼ θpop � θcovcovi (2)
where θi is the individual model predicted pharmacokinetic
parameter (e.g. clearance) for an in ividual with variate
value covi, θpop is the population estimate for that parameter,
covm represents t median covariate value nd θcov the
ariate eff ct. In the equation for categorical covariates covi
is either 1 or 0.
To evaluate the time to death (TTD) as a covariate, the
time dependency of the parameters was modelled as a ﬁrst-
order process given by:
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To evaluate the time to death (TTD) as a covariate, time-dependency of the parameters 
was modelled as a first order process given to following equation (Eq. 3). In which θΔ is 
the change in parameter value from its initial value and θrate is a first order rate constant 
determining the rate with which the parameter value changes over time. θrate was not 
constrained to be positive or negative so, although physiologically unlikely, an increase in 
time was also possible.
θi ¼ θpop � θΔ� exp �θrate � TTDð Þ (3)
where θΔ is the change in parameter value from its initial value
and θrate is a ﬁrst-order rate constant determining the rate at
which the parameter value changes over time. θrate was not
constrained to be positive or negative so, although physiolog-
ically unlikely, an increase in time was also possible.
Model evaluation
A bootstrap with 200 runs was performed on the ﬁnal model
to evaluate the validity of the parameter estimates and their
corresponding 95% conﬁdence intervals (CIs). Due to the
study design, i.e. sparse sampling, different dosing regimens
and both oral and subcutaneous administrations, a visual
predictive check could not be performed to evaluate the
model. We therefore evaluated the predictive performance
of the ﬁnal model using a normalized prediction distribution
errors (NPDE) analysis. This simulation-based analysis can be
used to evaluate models developed on datasets with variable
dosing regimens. The analytical value of this method has
been described previously by Comets et al. [23].
Simulations
To illustrate the effect of the signiﬁcant covariates found in
the covariate analysis, deterministic simulations were
performed. The plasma concentrations of midazolam, 1-OH-M
and 1-OH-MG were simulated over a time course of 72 h
after the administration of a 10 mg midazolam loading dose
followed by 5mgmidazolam six times daily via subcutaneous
bolus injection. To simulate the plasma concentration in the
typical patient, the IIV and residual error were set to zero.
Results
A total of 45 terminally ill patients were included in the study.
Their median age was 71 years (range 43–93), 51.1% were
female and the median duration of admittance (from
moment of admittance until time of death) was 29 days
(range 7–457). All but one patient (97.8%) had advanced
malignancy as primary diagnosis. Patient characteristics are
given in Table 1. Oral midazolam was administered as a
7.5 mg dose up to four times daily. The subcutaneous doses
used were between 2.5 and 180 mg a day. A total of 139 blood
samples were collected which were analysed for midazolam,
1-OH-M, 4-OH-M and 1-OH-MG concentrations. Figure 1
gives the plasma concentration–time proﬁles of a representa-
tive patient in the last week before death.
Structural model
The percentage of concentrations below the quantiﬁcation
limit (BQL) were 14%, 16% and 10% for midazolam, 1-OH-M
and 1-OH-MG, respectively. More than half of these BQL
concentrations where measured in samples taken more than
3 days after the last midazolam dose and 92% of these BQL
concentrations were measured in samples taken more than
12 h after the last dose. As a result midazolam, 1-OH-M and
in most cases also 1-OH-MG were no longer detectable. The
BQL data were therefore discarded using the M1 method
discussed previously by Ahn et al. [24]. The amount of BQL
data of 4-OH-M was 75% and as data on 4-hydroxy-midazo-
lam-glucuronide were lacking, this metabolite was not
incorporated in the pharmacokinetic model.
The data were best described by a one-compartment
model for midazolam and two one-compartment models for
both its metabolites (1-OH-M and 1-OH-MG) (Figure 2,
Table 2) with an additive residual error on logarithmic trans-
formed concentrations. As there was limited data available in
the absorption phase, the absorption constants (Ka) could not
be estimated. They were therefore derived from literature
Table 1
Patient characteristics over the time course of the study
Characteristics n = 45
Age, years (median, range) 71 (43–93)
Male, n (%) 22 (48.9)
Female, n (%) 23 (51.1)
Ethnic origin, n (%)
Caucasian 41 (91.1)
Afro-Caribbean 3 (6.7)
Unknown 1 (2.2)
Primary diagnosis, n (%)
Neoplasm 44 (97.8)
Disease of the respiratory system 1 (2.1)
Blood chemistry, serum levels at admission (median, range)
Albumin, g l�1 25 (13–39)
Urea, mmol l�1 7.6 (1.5–66.9)
Bilirubin, μmol l�1 9 (2–256)
Gamma-glytamyl transpeptidase, U l�1 62 (7–3859)
Alkaline phosphatase, U l�1 118 (20–2371)
Alanine transaminase, U l�1 14 (7–632)
Aspartate transaminase, U l�1 30 (13–2710)
C-reactive protein, U l�1 92 (1–625)
Creatinine, μmol l�1 67 (20–806)
eGFR by standard MDRDa, ml min�1/1.73 m�2 104 (6–328)
eGFR by original MDRDb, ml min�1/1.73 m�2 85 (4–228)
Patients using dexamethasonec, n (%) 17 (37.8)
Patients using phenytoinc, n (%) 1 (2.2)
Duration of stay, days (median, range) 29 (7–457)
Blood samples collected, n (median, range) 2 (1–10)
eGFR: estimated glomerular ﬁltration rate, MDRD: modiﬁcation of
diet in renal disease.
aThe abbreviated MDRD equation consists of four variables (age,
gender, race and serum creatinine) as shown in eq. (4).
bThe original MDRD formula consist of six variables (age, gender,
race, serum creatinine, serum albumin and serum urea) as shown in
eq. (5).
cDuring any time while receiving midazolam treatment.
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Model evaluation 
A bootstrap with 200 runs was performed on the final model to evaluate the validity of the 
parameters estimates and their corresponding 95% confidence intervals. Due to the study 
design, i.e. spa se sampling, different do ing regimens and both oral and subcutaneous 
administrations, a visual predictive check could not be performed to evaluate the model. 
We therefore evaluated the predictive performance of the final model us ng a normalised 
prediction distribution errors (NPDE) analysis. This simulation-based analysis can be used to 
evaluate models develop d on datasets with variable dosing regimens. The analytical value 
of this method has been previously described by Comets et al (21).
Simulations 
To give an i l tratio  f the effect of the sign ficant c variates found in the covariate analy-
sis, deterministic simulations were performed. The plasma concentrations of midazolam, 
1-OH-M and 1-OH-MG are simulated over a time course of 72 hours after the administration 
of a 10 mg midazolam loading dose followed by 5 mg midazolam 6 times daily via subcu-
taneous bolus injection. To simulate the plasma concentration in the typical patient, the IIV 
and residual error were set to zero. 
results 
A total of 45 terminally ill patients were included in the study. Their median age was 71 years 
(rang  43 – 93), 51.1% were female and th  median duration of admitt nce (from moment 
of admittance until time of death) was 29 days (range 7 – 457). All but one patient (97.8%) 
had advanced malignancy as primary diagnosis. Patient characteristics are given in table 1. 
Oral midazolam was administered as a 7.5 mg dose up to four times daily. The subcutan ou  
doses used were betwe  2.5 and 180 mg a day. A total of 139 blood samples were col-
lected which were analysed for midazolam, 1-OH-M, 4-OH-M and 1-OH-MG, concentrations. 
Figure 1 gives the plasma concentration versus time profiles of a representative patient in 
the last week efore death. 
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Table 1. Patient characteristics over the time course of the study
Characteristics  N=45
Age, years (median, range) 71 (43 - 93)
Male, n (%) 22 (48.9)
Female, n (%) 23 (51.1)
Ethnic origin, n (%)
Caucasian 41 (91.1)
Afro-Caribbean 3 (6.7)
Unknown 1 (2.2)
Primary diagnosis, n (%)
Neoplasm 44 (97.8)
Disease of the respiratory system 1 (2.1)
Blood chemistry, serum levels at admission (median, range)
Albumin, g/l 25 (13-39)
Urea, mmol/l 7.6 (1.5-66.9)
Bilirubin, umol/l 9 (2-256)
Gamma-glytamyl transpeptidase, U/l 62 (7-3859)
Alkaline phosphatase, U/l 118 (20-2371)
Alanine transaminase, U/l 14 (7-632)
Aspartate transaminase, U/l 30 (13-2710)
C-reactive protein, U/l 92 (1-625)
Creatinine, umol/l 67 (20-806)
eGFR by standard MDRDa, ml/min/1.73 m2 104 (6-328)
eGFR by original MDRDb, ml/min/1.73 m2 85 (4-228)
Patients using dexamethasonec, n (%) 17 (37.8)
Patients using phenytoinc, n (%) 1 (2.2)
Duration of stay, days (median, range) 29 (7 - 457)
Blood samples collected, n (median, range) 2 (1 – 10) 
eGFR: estimated glomerular filtration rate, MDRD: modification of diet in renal disease. a The abbreviated MDRD 
equation consists of 4 variables (age, gender, race and serum creatinine) as shown in Eq. 4. b the original MDRD 
formula consist of 6 variables (age, gender, race, serum creatinine, serum albumin and serum urea) as shown in 
Eq. 5 c during any moment while receiving midazolam treatment
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Figure 1. Dose and concentration data of a patient representative for the study population in the last week 
before death. Top: Time profile of the estimated glomerular filtration rate (eGFR) (green) and albumin levels 
(blue) and the 5 mg subcutaneous midazolam doses (orange) over time in the last week before death. Bottom: 
Post-hoc predictions of concentration of midazolam (green), 1-OH-M (blue) and 1-OH-MG (orange) and their 
corresponding measured midazolam concentrations (open circles) in the last week before death. The concen-
trations of both metabolites are shown as the therapeutic equivalents of midazolam, so 1-OH-M concentrations 
are multiplied by 0.8 and 1-OH-MG by 0.1.
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structural model
The percentage of concentrations below the quantification limit (BQL) were 14%, 16% and 
10% for midazolam, 1-OH-M and 1-OH-MG respectively. More than half of these BQL con-
centrations where measured in samples taken more than 3 days after the last midazolam 
dose and 92% of these BQL concentrations were measured in samples taken more than 
12h after the last dose.  As a result midazolam, 1-OH-M and in most cases also 1-OH-MG 
were no longer detectable. The BQL data were therefore discarded using the M1 method 
discussed before by Ahn et al (22). The amount of BQL data of 4-OH-M was 75% and as data 
on 4-hydroxy-midazolam-glucuronide were lacking, this metabolite was not incorporated 
in the pharmacokinetic model.
The data were best described by a one-compartment model for midazolam and two 
one-compartment models for both its metabolites (1-OH-M and 1-OH-MG) (Fig. 2) with 
an additive residual error on logarithmic transformed concentrations. Since there was 
limited data available in the absorption phase the absorption constants (Ka) could not be 
estimated. They were therefore derived from literature (5.5 h-1 for oral administration, 10 
h-1 for subcutaneous injection) (14, 20, 23). IIV was included on midazolam clearance, F of 
oral midazolam, V of midazolam, 1-OH-M clearance and 1-OH-MG clearance as all of these 
significantly improved the model. The correlation between IIV of midazolam clearance and 
F of oral midazolam was high (0.93) and therefore fixed to unity. In all cases an exponential 
model for IIV proved superior to an additive model.  
Midazolam
1-OH-M
1-OH-MG
Oral Dose Subcutaneous Dose
*F
Cl1
Cl3
Cl2
Depot 1 Depot 2
Figure 2. Schematic representation of the 
structural model for midazolam and its 
two main metabolites. F: bioavailability of 
oral midazolam; Cl1: midazolam clearance 
and formation of 1-OH-M; Cl2: 1-OH-M 
clearance and formation of 1-OH-MG; Cl3: 
1-OH-MG clearance.
covariate analysis 
In the covariate analysis all possible covariates, as mentioned in the methods section, were 
tested on all parameters including IIV (F, V of midazolam and clearance of midazolam, 1-OH-M 
and 1-OH-MG). This univariate analysis with a p-threshold of 0.05 resulted in 16 significant 
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covariates. After backward elimination with a lower threshold of 0.001 only two covariates 
remained in the final model. The first covariate was estimated glomular filtration rate (eGFR) 
on 1-OH-MG clearance (Eq. 4), and the second covariate was the correlation of albumin on 
midazolam clearance (Eq. 5). CRP levels were also correlated with midazolam clearance, and 
depending on the order of the backwards elimination, either albumin or CRP remained in the 
final model. As the difference in these OFV between albumin and CRP was minimal the choice 
to include albumin instead of CRP was based on the fact that albumin is a more specific marker 
for overall condition than CRP. The results of the univariate analysis, in terms of decrease in OFV 
and covariate effect are shown in table 3. The addition of albumin on midazolam clearance 
reduced the IIV from 59.9 % to 49.0% thus explaining 18.2% of the IIV on midazolam clearance. 
Incorporation of eGFR as a covariate on 1-OH-MG clearance reduced the IIV from 69.7% to 
49.9% thereby explaining 28.4% of the IIV on 1-OH-MG clearance.
(5.5 h�1 for oral administration, 10 h�1 for subcutaneous
injection) [16, 22, 25]. IIV was included on midazolam
clearance, F of oral midazolam, V of midazolam, 1-OH-M
clearance and 1-OH-MG clearance as all of these signiﬁcantly
improved the model. The correlation between IIV of midazo-
lam clearance and F of oral midazolam was high (0.93) and
therefore ﬁxed to unity. In all cases an exponential model
for IIV proved superior to an additive model.
Covariate analysis
In the covariate analysis all possible covariates, as mentioned
in the methods section, were tested on all parameters
including IIV (F, V of midazolam and clearance of midazo-
lam, 1-OH-M and 1-OH-MG). This univariate analysis with a
signiﬁcance threshold of 0.05 resulted in 16 signiﬁcant
covariates. After backward elimination with a lower
threshold of 0.001, only two covariates remained in the ﬁnal
model. The ﬁrst covariate was estimated glomular ﬁltration
rate (eGFR) on 1-OH-MG clearance (eq. 4), and the second
covariate was the correlation of albumin on midazolam
clearance (eq. 5). CRP levels were also correlated withmidazo-
lam clearance, and depending on the order of the backwards
elimination, either albumin or CRP remained in the ﬁnal
model. As the difference in these OFV between albumin and
CRP was minimal, t e decision to include albu in instead
of CRP was based on the fact that albumin is a more speciﬁc
marker for overall condition than CRP. The results of the
univariate analysis, in terms of decrease in OFV and covariate
effect are shown in Table 3. The addition of albumin on
midazolam clearance reduc d the IIV from 59.9% to 49.0%,
thus explaining 18.2% of the IIV on midazolam clearance.
Incorporation of eGFR as a covariate on 1-OH-MG clearance
reduced the IIV from 69.7% to 49.9%, thereby explaining
28.4% of the IIV on 1-OH-MG clearance.
Cl1�OH�MG ¼ 5:1� eGFRml=min=104:1
 0:53 (4)
Clmidazolam ¼ 8:42� serum albuming=L25
 1:08 (5)
In the ﬁnal model the population mean estimates for
clearance were 8.42 l h�1 (RSE 9%) for midazolam;
45.4 l h�1 (RSE 12%) for 1-OH-M and 5.1 l h�1 (RSE 11%) for
1-OH-MG. The population mean estimates for volume of
distribution were 113 l (RSE 13%) for midazolam and 1-OH-
M compartments (which were assumed to be equal) and
2.98 l (RSE 71%) for the 1-OH-MG compartment. The
bioavailability (F) of oral midazolam was 27.9%. An overview
of all parameter estimates is given in Table 2.
Model evaluation
Figure 3A–F shows that both the population predictions and
individual predictions were evenly distributed around the
Figure 1
Dose and concentration data of a patient representative for the study
population in the last week before death. Top: Time proﬁle of the
estimated glomerular ﬁltration rate (eGFR) (green) and albumin
levels (blue) and the 5 mg subcutaneous midazolam doses (orange)
over time in the last week before death. Bottom: Post-hoc
predictions of concentration of midazolam (green), 1-OH-M (blue)
and 1-OH-MG (orange) and their corresponding measured midazo-
lam concentrations (open circles) in the last week before death. The
concentrations of both metabolites are shown as the therapeutic
equivalents of midazolam, so 1-OH-M concentrations are multiplied
by 0.8 and 1-OH-MG by 0.1
Figure 2
Schematic representation of the structural model for midazolam and
its two main metabolites. F: bioavailability of oral midazolam; Cl1:
midazolam clearance and formation of 1-OH-M; Cl2: 1-OH-M
clearance and formation of 1-OH-MG; Cl3: 1-OH-MG clearance
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(5.5 h�1 for oral administration, 10 h�1 for subcutaneous
injection) [16, 22, 25]. IIV was included on midazolam
clearance, F of oral midazolam, V of midazolam, 1-OH-M
clearance and 1-OH-MG clearance as all of these signiﬁcantly
improved the model. The correlation between IIV of midazo-
lam clearance and F of oral midazolam was high (0.93) and
therefore ﬁxed to unity. In all cases an exponential model
for IIV proved superior to an additive model.
Covariate analysis
In the covariate analysis all possible covariates, as mentioned
in the methods section, were tested on all parameters
including IIV (F, V of midazolam and clearance of midazo-
lam, 1-OH-M and 1-OH-MG). This univariate analysis with a
signiﬁcance threshold of 0.05 resulted in 16 signiﬁcant
covariates. After backward elimination with a lower
threshold of 0.001, only two covariates remained in the ﬁnal
model. The ﬁrst covariate was estimated glomular ﬁltration
rate (eGFR) on 1-OH-MG clearance (eq. 4), and the second
covariate was the correlation of albumin on midazolam
clearance (eq. 5). CRP levels were also correlated withmidazo-
lam clearance, and depe ding on the order of the backwards
elimination, either albumin or CRP remained in the ﬁnal
model. As the difference in these OFV between albumin and
CRP was minimal, the decision to include albumin instead
of CRP was based on the fact that albumin is a more speciﬁc
marker for overall co dition than CRP. Th results of he
univariate analysis, in terms of decrease in OFV and covariate
effect are shown in Table 3. The addition of albumin on
midazolam clearance reduced the IIV from 59.9% to 49.0%,
thus explaining 18.2% of the IIV on midazolam clearance.
Incorporation of eGFR as a covariate on 1-OH-MG clearance
reduced the IIV from 69.7% to 49.9%, thereby explaining
28.4% of the IIV on 1-OH-MG clearance.
Cl1�OH�MG ¼ 5:1� eGFRml=min=104:1
 0:53 (4)
Clmidazolam ¼ 8:42� serum albuming=L25
 1:08 (5)
In the ﬁnal model the population mean estimates for
clearance were 8.42 l h�1 (RSE 9%) for midazolam;
45.4 l h�1 (RSE 12%) for 1-OH-M and 5.1 l h�1 (RSE 11%) for
1-OH-MG. The population mean estimates for volume of
distribution were 113 l (RSE 13%) for midazolam and 1-OH-
M compartments (which were assumed to be equal) and
2.98 l (RSE 71%) for the 1-OH-MG compartment. The
bioavailability (F) of oral midazolam was 27.9%. An overview
of all parameter estimates is given in Table 2.
Model evaluation
Figure 3A–F shows that both the population predictions and
individual predictions were evenly distributed around the
Figure 1
Dose and concentration data of a patient representative for the study
population in the last week before death. Top: Time proﬁle of the
estimated glomerular ﬁltration rate (eGFR) (green) and albumin
levels (blue) and the 5 mg subcutaneous midazolam doses (orange)
over time in the last week before death. Bottom: Post-hoc
predictions of concentration of midazolam (green), 1-OH-M (blue)
and 1-OH-MG (orange) and their corresponding measured midazo-
lam concentrations (open circles) in the last week before death. The
concentrations of both metabolites are shown as the therapeutic
equivalents of midazolam, so 1-OH-M concentrations are multiplied
by 0.8 and 1-OH-MG by 0.1
Figure 2
Schematic representation of the structural model for midazolam and
its two main metabolites. F: bioavailability of oral midazolam; Cl1:
midazolam clearance and formation of 1-OH-M; Cl2: 1-OH-M
clearance and formation of 1-OH-MG; Cl3: 1-OH-MG clearance
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In th  final model the population mean estimates for clearance were, 8.42 L/h (RSE 9%) 
for midazolam; 45.4 L/h (RSE 12%) for 1-OH-M and 5.1 L/h (RSE 11%) for 1-OH-MG. The 
population mean estimates for volume of distrib tion were 113 L (RSE 13%) for midazolam 
and 1-OH-M compartments (which were assumed to be equal) and 2.98 L (RSE 71%) for the 
1-OH-MG compartment. The bioavailability (F) of oral midazolam was 27.9%.  An overview 
of ll parameter esti ates is given in table 2.  
Table 2. Parameter estimates of the base model, final model and bootstrap analysis.
Parameter
Structural 
model 
Final model RSE % Shrinkage %
Bootstrap of the final model
Average
95% CI 
(lower)
95% CI 
(upper)
OFV -109.113 -146.519
Midazolam
F 0.204 0.279 12.6 - 0.288 0.227 0.857
Cl (L/h) 7.76 8.42 9.0 - 8.52 7.18 10.4
V (L) 117 113 13.1 - 111 84.0 137
1-OH-Midazolam (1-OH-M)a
Cl (L/h) 43.8 45.4 11.5 - 46.0 36.8 60.4
1-OH-Midazolam glucuronide (1-OH-MG)
Cl (L/h) 3.82 5.10 11.0 - 5.18 4.08 6.50
V (L) 3.47 2.98 71.5 - 2.97 0.85 13.7
Covariate effect midazolam clearance
Albumin - 1.08 21.2 - 1.02 0.38 1.47
Covariate effect on 1OH-midazolam glucuronide clearance 
eGFR b - 0.53 20.7 - 0.52 0.31 0.82
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Table 3. Covariate effects in univariate analysis compared to the structural model
Covariate ΔOFV Covariate effect Included after backward 
elimination 
On midazolam clearance
Serum albumin -7.54 0.84 Yes
CRP -7.51 -0.12 No
AST -4.73 -0.16 No
Time to Deatha -4.69 2.29 and 0.05 No
On midazolam volume of distribution
ALT -6.29 0.22
AST -9.06 0.22 No
Weight -4.73 1.52 No
Dexamethasone useb -4.56 1.67 No
Time to Deatha -6.50 -71.6 and 0.05 No
On 1-OH-M clearance
eGFR-bc -3.86 -0.21 No
CRP -10.18 0.19 No
On 1-OH-MG clearance
Serum Creatinine -17.20 -0.50 No
eGFR-ac -20.92 0.47 Yes
eGFR-bc -22.49 0.49 No
Serum urea -19.74 -0.53 No
Time to Deatha -15.25 4.21 and 0.11 No
CRP: C-reactive protein, AST: aspartate transaminase, ALT: alanine transaminase, eGFR: estimated glomerular fil-
tration rate a Time to death was incorporated as a covariate as a first order process, therefore the first mentioned 
value describes the total change in the parameter value (ΔTTD) and the second value the rate in days (see equa-
tion 3). b Dexamethasone use was defined as the use of dexamethasone for at least 2, no longer than 7 days ago 
c The glomular filtration rate was calculated using both the standard 4-variable MDRD equation (eGFR-a) and 
the  original 6-variable MDRD (eGFR-b)
Table 2. Parameter estimates of the base model, final model and bootstrap analysis. (continued)
Parameter
Structural 
model 
Final model RSE % Shrinkage %
Bootstrap of the final model
Average
95% CI 
(lower)
95% CI 
(upper)
IIV (%)
F 48.7% 50.6% 17.4 12.8 48.4% 32.0% 61.3%
Midazolam Cl 59.9% 49.0% 14.0 12.8 47.5% 31.4% 60.2%
Midazolam V 72.6% 70.9% 15.1 16.6 70.2% 46.9% 93.2%
1-OH-M Cl 55.4% 60.5% 18.0 12.2 58.0% 32.8% 79.6%
1-OH-MG Cl 69.4% 49.9% 23.1 23.0 49.0% 26.7% 73.4%
Residual variability
Midazolam 26.7% 26.8% 13.3 20.4 26.8% 21.3% 34.2%
1-OH-M 42.7% 42.3% 21.6 18.5 41.3% 21.7% 56.7%
1-OH-MG 48.4% 46.4% 13.1 18.6 44.4% 30.1% 55.2%
OFV: objective function value, F: bioavailability, CL: clearance, V: volume of distribution, eGFR: estimated glo-
merular filtration rate, MDRD: modification of diet in renal disease, 1-OH-M: 1OH-midazolam, 1-OH-MG: 1OH-
midazolam-glucuronide. a The volume of distribution of 1-OH-M was set equal to that of midazolam itself. b GFR 
was estimated using the standard 4-variable MDRD equation.
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model evaluation 
Figure 3 (a-f ) shows that both the population predictions and individual predictions were 
evenly distributed around the line of unity when plotted against the observations. A 
bootstrap analysis of the final model was performed to obtain 95% confidence intervals for 
all parameters. Results of the bootstrap are shown in table 2. Evaluation of the predictive 
performance by NPDE analysis showed accurate predictive ability, with the distribution of 
the NPDEs not significantly deviating from a normal distribution (with global adjusted P 
values of 0.75, 0.20 and 0.41 for midazolam, 1-OH-M and 1OH-MG respectively), and the 
majority of the NPDEs laying between the values -2 and 2 (Figure 3: g-i).
Figure 3. Goodness of fit plots of the final model. Population predictions vs. observations of midazolam (A), 
1-OH-M (B) and 1-OH-MG (C) and individual predictions vs. observations of midazolam (D), 1-OH-M (E) and 
1-OH-MG (F) with the solid line displaying the line of unity. Normalized prediction distribution error (NPDE) plots 
for midazolam (G), 1-OH-M (H) and 1-OH-MG (I) showing NPDE quantiles (grey bars) vs. a normal distribution 
(solid line).
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simulations
Based on the final model the midazolam clearance is reduced by 30% (from 12.1 L/h to 8.4 
L/h) when albumin decreases from 35 g/L to 25 g/L. A further decrease in albumin to 15 g/L 
decreases midazolam clearance by another 42% to a value of 4.8 L/h. The effect of this drop 
in midazolam clearance on midazolam and metabolite concentrations is shown in figure 4. 
The effect of eGFR on 1-OH-MG clearance in our final model results in a reduction of clear-
ance of 27% (from 4.7 L/h to 3.5 L/h) when eGFR decreases from 90 to 50 ml/min. A further 
decline of eGFR to 30ml/min reduces the 1-OH-MG clearance by another 24 % to 2.7 L/h. 
The effect of this decrease in clearance on the plasma concentrations is shown in figure 5. 
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Figure 4. Simulated plasma profiles of midazolam and the total effective concentration (calculated as the sum 
of parent and both metabolites with 1-OH-M accounting for 80% and 1-OH-MG for 10% of the midazolam 
potency) for patients with plasma albumin levels of 15 g/l (green), 25 g/l (blue), and 35 g/l (orange) and stable 
eGFR of 90ml/min. After a 10mgmidazolam loading dose followed by 5 mg six times daily all via subcutaneous 
bolus injection.
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Figure 5. Simulated plasma profiles of midazolam and the total effective concentration (calculated as the sum 
of parent and both metabolites with 1-OH-M accounting for 80% and 1-OH-MG for 10% of the midazolam 
potency) for patients with an estimated glomerular filtration rate (eGFR) of 10 ml/min (green), 30 ml/min (blue), 
60 ml/min (orange) and 90 ml/min (light green) and stable plasma albumin levels of 25 g/l. After a 10 mg mid-
azolam loading dose followed by 5 mg six times daily all via subcutaneous bolus injection.
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discussion 
To our knowledge, this is the first population pharmacokinetic study of midazolam and 
its metabolites in terminally ill adult patients. With sparse sampling we were able to ac-
curately describe the pharmacokinetics of midazolam, 1-OH-M and 1-OH-MG. The large 
IIV in pharmacokinetics may contribute to the large inter-patient difference in sedation 
in clinical practice.  About one-third of the IIV in 1-OH-MG clearance could be explained 
by incorporating eGFR as a covariate in the model, confirming that 1-OH-MG clearance 
declined as a result of renal insufficiency. We also observed a positive correlation between 
albumin levels and midazolam clearance, explaining 18.2% of the IIV on midazolam clear-
ance. These are important findings as these patient characteristics may be used to develop 
an individualised dosing regimen. 
A positive correlation between albumin levels and midazolam clearance (with low 
albumin levels relating to a decrease in clearance) has been described before in the 80’s 
by Vree et al. (24). It was suggested that this reduced clearance was a result of decreased 
protein binding. Although midazolam is indeed highly protein bound (95-98%) primarily 
to albumin (25, 26). It seems unlikely that protein binding is the cause of the decreased 
clearance shown in our study when we take into account the following equation (eq. 6) 
for clearance. Based on this equation a decrease in albumin, which would increase the un-
bound drug concentration (Fu), would result in either an unchanged or increased clearance, 
depending on the extraction ratio of the drug (27, 28). With an increase in Fu an increase of 
volume of distribution would also be expected. This was however not the case as albumin 
was not found to be a significant covariate on volume of distribution in our study (ΔOFV 
0.014) furthermore contradicting an effect via protein binding. 
accurately describe the pharmacokinetics of midazolam,
1-OH-M and 1-OH-MG. The large IIV in pharmacokinetics
may contribute to the large inter-patient difference in
sedation in clinical practice. About one-third of the IIV in
1-OH-MG clearance could be explained by incorporating
eGFR as a covariate in the model, conﬁrming that 1-OH-MG
clearance declined as a result of renal insufﬁciency. We also
observed a positive correlation between albumin levels and
midazolam clearance, explaining 18.2% of the IIV on
midazolam clearance. These are important ﬁndings as these
patient characteristics may be used to develop an individual-
ized dosing regimen.
A positive correlation between albumin levels and
midazolam clearance (with low albumin levels relating to a
decrease in clearance) has been described before in the
1980s by Vree et al. [26]. It was suggested that this reduced
clearance was a result of decreased protein binding. Although
midazolam is indeed highly protein bound (95–98%)
primarily to albumin [27, 28], it seems unlikely that protein
binding is the cause of the decreased clearance shown in our
study when we take into account the f llowi g equation for
clearance:
Q Fu�Clintð Þ
Q þ Fu�ClintÞð (6)
Based on this equation, a decrease in albumin, which
would increase the unbound drug concentration (Fu), would
result in either an unchanged or increased clearance,
depending on the extraction ratio of the drug [29, 30]. With
an increase in Fu, an increase in volume of distribution would
also be expected. This was, however, not the case as albumin
was not found to be a signiﬁcant covariate on volume of
distribution in our study (ΔOFV = 0.014), further contradic-
ting an effect via protein binding.
We therefore propose that the mechanism behind the
reduced clearance may be due to an underlying inﬂam-
matory response or catabolic state. In cancer patients,
Table 3
Covariate effects in univariate analysis compared to the structural model
ΔOFV Covariate effect
Included after
backward elimination
Covariates on midazolam clearance
Serum albumin �7.54 0.84 Yes
CRP �7.51 �0.12 No
AST �4.73 �0.16 No
Time to deatha �4.69 2.29 and 0.05 No
Covariates on midazolam volume of distribution
ALT �6.29 0.22
AST �9.06 0.22 No
Weight �4.73 1.52 No
Dexamethasone useb �4.56 1.67 No
Time to deatha �6.50 �71.6 and 0.05 No
Covariates on 1-OH-M clearance
-bc �3.86 �0.21 No
CRP �10.18 0.19 No
Covariates on 1-OH-MG clearance
Serum creatinine �17.20 �0.50 No
eGFR-ac �20.92 0.47 Yes
eGFR-bc �22.49 0.49 No
Serum urea �19.74 �0.53 No
Time to deatha �15.25 4.21 and 0.11 No
CRP: C-reactive protein, AST: aspartate transaminase, ALT: alanine transaminase, eGFR: estimated glomerular ﬁltration rate
aTime to death was incorporated as a covariate as a ﬁrst-order process, therefore the ﬁrst mentioned value describes the total change in the parameter
value (ΔTTD) and the second value the rate in days (see eq. 3).
bDexamethasone use was deﬁned as the use of dexamethasone for at least 2 days, no longer than 7 days ago.
cThe glomular ﬁltration rate was calculated using both the standard four-variable MDRD equation (eGFR-a) and the original six-variable MDRD
(eGFR-b).
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We therefore propose that the mechanism behind the reduced clearance may be due to 
an underlying inflammatory response or catabolic state. In cancer patients, hypoalbumin-
emia can be an expression of inflammation and it has already been shown that inflamma-
tion can result in re uced CYP3A activity (17, 18, 29-31). Furthermore albumin levels showed 
some correlation (r =-0.69) with CRP levels (fig 1 supplementary material) and in the univari-
ate covariate analysis CRP also showed a correlation with midazolam clearance, supporting 
our theory of an underlying common process. Albumin and not CRP was incorporated in 
the model, because in terminally ill patients albumin is a more pronounced marker of overall 
condition and more commonly used in clinical practice (32, 33).  In addition albumin does 
not fluctuate as much as CRP, which makes it a better candidate for a future dosing regimen. 
If albumin is also a better marker for CYP3A clearance in other populations remains unclear. 
It might be that albumin has a better correlation with CYP3A activity in this population as 
101
5
Midazolam PK
it is sign of a prolonged inflammatory/catabolic state whereas CRP is more an expression 
of an acute process. To determine whether albumin, CRP or possibly another inflammatory 
marker, is the best indicator for CYP3A activity more research is needed. The correlation 
between midazolam clearance and inflammation is clinically important as inflammation 
plays a crucial role in cancer and the CYP3A enzyme metabolises not only midazolam but 
more than 50% of all therapeutic drugs (34, 35).”
Our study also showed that eGFR was correlated with 1-OH-MG clearance. This correla-
tion is a result of the fact that 1-OH-MG is renally excreted. It is relevant in the terminally ill 
population as renal insufficiency is common and, although 1-OH-MG is only 10% as potent 
as midazolam itself, high concentrations can lead to increased sedation (5). As shown in 
figure 5 an eGFR of 50 mL/min can already contribute significantly to the sedative effect of 
midazolam. Midazolam is believed to be sedative from concentrations of 100 μg/L and up 
and since 1-OH-MG has a potency of around 10%, 1-OH-MG concentrations of 500 μg/L, 
which were also seen in our study, already contribute to half of the sedative effect.  It is 
however important to note that the method to estimate the globular filtration rate probably 
overestimates the renal function in terminally ill patients as it is dependent on the creati-
nine production from muscle tissue. In our study tested eGFR calculated by the 4-variable 
modification of diet in renal disease (MDRD) equation (eq. 7) as well as eGFR calculated by 
the original 6 variable equation (eq. 8) as a covariate (36). As the difference between the two 
was minimal we incorporated the simpler 4-variable equation in our final model as this is 
the most commonly used equation. 
eGFR ¼ 186� serum creatinine mg=dl�1
 �1:154
� age �0:203
� 1:210 if blackð Þ � 0:742 if femaleð Þ
(7)
eGFR ¼ 170� serum creatinine mg
dl
 -0:999
� age -0:176
� 1:180 if blackð Þ � 0:762 if femaleð Þ
� serum urea nitrogen mg=dl-1
 -0:170
�albumin g=dl-1
 0:318
(8)
Our ﬁnding for midazolam clearance (population mean:
8.42 l h�1) is in agreement with previous studies in
critically ill patients [39, 40]. It is also comparable to the
estimated clearance found in a recent study in critically ill
children where they also found an effect of inﬂammation
(to compare these values, the results of Vet et al. were
adapted to values for a 70 kg individual) [32]. In our
model, a patient with a healthy albumin level of 45 g l�1
would have a midazolam clearance of 15.3 l h�1, which is
also in line with the results of other studies in healthy
volunteers and obese patients [16, 25, 41], although
some studies in obese patients and patients who had
undergone bariatric surgery have even higher clearance
values [25, 42]. The estimated value for volume of distribu-
tion is also similar to that of the studies in critically ill
patients and that of the most recent study in obese
patients [32, 39, 42]. However, unlike some of the other
studies, we were not able to accurately quantify a periph-
eral compartment for midazolam. This is due to the sparse
sampling in this study which has presumably resulted in
insufﬁcient data to quantify a two-compartment model.
Another contrast with previous studies is the lower esti-
mate for the volume of distribution of 1-OH-MG, of
2.98 l. As 1-OH-MG is a hydrophilic metabolite, a low
volume of distribution was expected. In terminally ill
patients this could be even more reduced as these patients
are older (median age of 71), have a diminished intake of
oral ﬂuids and become dehydrated. The high RSE of 71%
for this parameter, however, indicates that it was difﬁcult
to obtain and accurate estimate of the V of 1-OH-MG. This
is probably because patients without renal insufﬁciency
eliminate 1-OH-MG more rapidly.
Finally, a notable difference with previous studies is
the large IIV in volume of distribution of midazolam in
the ﬁnal model. Other studies also found large IIV in their
base models but were able to correct for this using weight
as a covariate [16, 42]. Unfortunately, in our study, data
on weight was available for only 53% of the patients,
and the weights that were available were only collected
at time of admission. As a result, the plots showing the
available data on weight vs. volume of distribution or
the IIV on volume of distribution did seem to show a
correlation (supplementary material). However, this effect
was not signiﬁcant in the covariate analysis. This lack of
data on weight is a limitation in our study. We therefore
highly recommend that in future pharmacokinetic studies
in the terminally ill population, weight is monitored
regularly.
A possible limitation of our study is that it did not include
intravenously administered midazolam, as this route of
administration is seldom used in palliative care. As a result,
the bioavailability of subcutaneous midazolam could not be
estimated and was assumed to be 100%. This seems reason-
able and is in line with the study of Pecking et al. [22].
However, in that study F was reported as 0.96 ± 0.14 so there
is some uncertainty in this number, which could have had a
small effect on the estimates for clearance and volume of
midazolam.
Another possible limitation of our study was that we did
not include the 4-OH-M metabolite in our model. We did
measure 4-OH-M in our samples, but as only a low percentage
of midazolam is converted into 4-OH-M, 75% of these
concentrations were below the lower limit of detection. This
lack of data meant that we were only able to estimate the
fraction of midazolam that is metabolized into 4-OH-M
(which was around 10%) but we were unable to accurately
estimate a volume of distribution or clearance for 4-OH-M.
As only a low percentage is converted into 4-OH-M and this
metabolite has a lower afﬁnity to the receptor compared to
the 1-OH-M metabolite, this is probably of low clinical
interest [43]. As the 4-OH-M metabolite was not included in
the model and the true fraction metabolized is unknown,
the clearance and distribution volumes of the other metabo-
lites are apparent values.
Overall this study shows that it is possible to accurately
describe a drug’s pharmacokinetics and ﬁnd clinically
relevant parameters for dose individualization using popu-
lation pharmacokinetics in terminally ill patients. This is
very important as large inter-patient variability in these
patients is of clinical concern and therefore more research
is needed in this population. Using a population approach
with sparse sampling minimizes the patient’s burden,
which is crucial in this vulnerable population. Concerning
midazolam, we have shown that low albumin levels may
indicate a decreased capacity to metabolize midazolam,
possibly as a result of inﬂammatory response. This is of
clinical importance as hypoalbuminaemia is common in
both cancer patients and cachectic patients. Therefore the
dose of midazolam (and possibly also other drugs that are
metabolized via CYP3A) may have to be decreased in these
patients. Another possible reason to adjust the midazolam
dose might be a decrease in renal function, as in these
patients the 1-OH-MG metabolite can accumulate. These
important insights into the pharmacokinetics of midazo-
lam and its metabolites in terminally ill patients may be a
ﬁrst step in explaining the different response to midazolam
treatment. However, it is also known that there is a large
variability in response to plasma levels [12, 13]. Therefore,
further studies on the pharmacodynamics in this popula-
tion are needed before any ﬁrm conclusions can be drawn
on dose adjustments.
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children where they also found an effect of inﬂammation
(to compare these values, the results of Vet et al. were
adapted to values for a 70 kg individual) [32]. In our
model, a patient with a healthy albumin level of 45 g l�1
would have a midazolam clearance of 15.3 l h�1, which is
also in line with the results of other studies in healthy
volunteers and obese patients [16, 25, 41], although
some studies in obese patients and patients who had
undergone bariatric surgery have even higher clearance
values [25, 42]. The estimated value for volume of distribu-
tion is also similar to that of the studies in critically ill
patients and that of the most recent study in obese
patients [32, 39, 42]. However, unlike some of the other
studies, we were not able to accurately quantify a periph-
eral compartment for midazolam. This is due to the sparse
sampling in this study which has presumably resulted in
insufﬁcient data to quantify a two-compartment model.
Another contrast with previous studies is the lower esti-
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patients this could be even more reduced as these patients
are older (median age of 71), have a diminished intake of
oral ﬂuids and become dehydrated. The high RSE of 71%
for this parameter, however, indicates that it was difﬁcult
to obtain and accurate estimate of the V of 1-OH-MG. This
is probably because patients without renal insufﬁciency
eliminate 1-OH-MG more rapidly.
Finally, a notable difference with previous studies is
the large IIV in volume of distribution of midazolam in
the ﬁnal model. Other studies also found large IIV in their
base models but were able to correct for this using weight
as a covariate [16, 42]. Unfortunately, in our study, data
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and the weights that were available were only collected
at time of admission. As a result, the plots showing the
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correlation (supplementary material). However, this effect
was not signiﬁcant in the covariate analysis. This lack of
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A possible limitation of our study is that it did not include
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the bioavailability of subcutaneous midazolam could not be
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the 1-OH-M metabolite, this is probably of low clinical
interest [43]. As the 4-OH-M metabolite was not included in
the model and the true fraction metabolized is unknown,
the clearance and distribution volumes of the other metabo-
lites are apparent values.
Overall this study shows that it is possible to accurately
describe a drug’s pharmacokinetics and ﬁnd clinically
relevant parameters for dose individualization using popu-
lation pharmacokinetics in terminally ill patients. This is
very important as large inter-patient variability in these
patients is of clinical concern and therefore more research
is needed in this population. Using a population approach
with sparse sampling minimizes the patient’s burden,
which is crucial in this vulnerable population. Concerning
midazolam, we have shown that low albumin levels may
indicate a decreased capacity to metabolize midazolam,
possibly as a result of inﬂammatory response. This is of
clinical importance as hypoalbuminaemia is common in
both cancer patients and cachectic patients. Therefore the
dose of midazolam (and possibly also other drugs that are
metabolized via CYP3A) may have to be decreased in these
patients. Another possible reason to adjust the midazolam
dose might be a decrease in renal function, as in these
patients the 1-OH-MG metabolite can accumulate. These
important insights into the pharmacokinetics of midazo-
lam and its metabolites in terminally ill patients may be a
ﬁrst step in explaining the different response to midazolam
treatment. However, it is also known that there is a large
variability in response to plasma levels [12, 13]. Therefore,
further studies on the pharmacodynamics in this popula-
tion are needed before any ﬁrm conclusions can be drawn
on dose adjustments.
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Our finding for midazolam clearance (population mean: 8.42 L/h) is in agreement with 
previous studies in critically ill patients (37, 38). It is also comparable to the estimated clear-
ance found in a r cent study i  critically ill children where t y also f und an effect of in-
flammation (to compare these values the results of Vet et al. were adapted to values for a 70 
kg individual) (30). In our model a patient with a healthy albumin level of 45 g/L would have 
 midazolam clearance of 15.3 L/h which is also in line with the results f other studies i  
healthy volunteers and obese patients (14, 23, 39). Although some studies in obese patients 
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and patients who undergone bariatric surgery have even higher clearance values (23, 40). 
The estimated value for volume of distribution is also similar to that of the studies in critically 
ill patients and that of the most recent study in obese patients (30, 37, 40). However we were 
not able to accurately quantify a peripheral compartment for midazolam where some of the 
other studies were. This is due to the sparse sampling in this study which has presumably 
resulted in insufficient data to quantify a two-compartment model. Another contrast with 
previous studies is the lower estimate for the volume of distribution of 1-OH-MG, of 2.98 
L. As 1-OH-MG is a hydrophilic metabolite a low volume of distribution was expected. In 
terminally ill patients this could be even more reduced as these patients are older (median 
age of 71), have a diminished intake of oral fluids and become dehydrated. The high RSE of 
71% for this parameter however indicates that it was difficult to estimate the V of 1-OH-MG 
accurately. This is probably due to the fact that in patients without renal insufficiency 1-OH-
MG is rapidly eliminated. 
Finally a notable difference with previous studies is the large inter-individual variability 
in volume of distribution of midazolam in the final model. Other studies also found large IIV 
in their base models but were able to correct for this using weight as a covariate (14, 40). 
Unfortunately in our study data on weight was available for only 53 % of the patients, and 
the weights that were available were only collected at time of admission. As a result the 
plots showing the available data on weight vs volume of distribution or the IIV on volume of 
distribution did seem to show a correlation (supplementary material). However this effect 
was not significant in the covariate analysis. This lack of data on weight is a limitation in 
our study. We therefore highly recommend that in future pharmacokinetic studies in the 
terminally ill population, weight is monitored regularly. 
A possible limitation of our study is that it did not include intravenously administered 
midazolam, as this route of administration is seldom used in palliative care. As a result the 
bioavailability of subcutaneous midazolam could not be estimated and was assumed to be 
100%. This seems reasonable and is in line with the study of Pecking et al. However in that 
study F was reported as 0.96 +/- 0.14 so there is some uncertainty in this number, which 
could have affected the estimates for clearance and volume of midazolam to a small extend. 
Another possible limitation of our study was that we did not include the 4-OH-M metabo-
lite in our model. We did measure 4-OH-M in our samples, however as only a low percentage 
of midazolam is converted into 4-OH-M, 75% of these concentrations were below the lower 
limit of detection. This lack of data meant that we were only able to estimate the fraction of 
midazolam that is metabolised into 4-OH-M (which was around 10%) but we were unable to 
accurately estimate a volume of distribution or clearance for 4-OH-M. As only a low percent-
age is converted into 4-OH-M and this metabolite has a lower affinity to the receptor com-
pared to the 1-OH-M metabolite, this is probably of low clinical interest (41). As the 4-OH-M 
metabolite was not included in the model and true fraction metabolised is unknown, the 
clearance and distribution volumes of the other metabolites are apparent values.
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Overall this study shows that it is possible to accurately describe a drug’s pharmaco-
kinetics and find clinical relevant parameters for dose individualisation using population 
pharmacokinetics in terminally ill patients. This is very important as large interpatient 
variability in these patients is of clinical concern and therefore more research is needed in 
this population. As a population approach can be used with sparse sampling it minimises 
the patient’s burden which is crucial in this vulnerable population. Concerning midazolam 
we have showed that low albumin levels may indicate a decreased capacity to metabolise 
midazolam, possibly as a result of inflammatory response. This is of clinical importance as 
hypoalbuminemia is common in both cancer patients and cachectic patients. Therefore the 
dose of midazolam (and possibly also other drugs that are metabolised via CYP3A) may 
have to be decreased in these patients. Another possible reason to adjust the midazolam 
dose might be a decrease in renal function, as in these patients the 1-OH-MG metabolite 
can accumulate. These important insights into the pharmacokinetics of midazolam and its 
metabolites in terminally ill patients may be a first step explaining the different response to 
midazolam treatment. However it is also known that there is a large variability in response to 
plasma levels (10, 11). Therefore, further studies on the pharmacodynamics in this popula-
tion are needed before any firm conclusions can be drawn on dose adjustments. 
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Figure S1. Correlation of albumin (g/l) and CRP (mg/l) with the corresponding linear regression line.
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Figure S2. Correlation of weight (the known weights at time of admission) vs. volume of distribution (V) of 
midazolam and the inter-individual variability (IIV) on volume of distribution (V) of midazolam with the cor-
responding linear regression lines.
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Figure S3. Simulated plasma profiles of midazolam and the total effective concentration (calculated as the 
sum of parent and both metabolites with 1-OH-M accounting for 80% and 1-OH-MG for 10% of the midazolam 
potency) for patients with an C-reactive protein (CRP) concentration of 1 mg/l (green), 50 mg/l (blue), 100 mg/l 
(orange) and 200 mg/l (light green) and stable eGFR of 90 ml/min, after a 10 mg midazolam loading dose fol-
lowed by 5 mg six times daily all via subcutaneous bolus injection
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aBstract 
introduction 
Midazolam is the drug of choice for palliative sedation and is titrated to achieve the desired 
level of sedation. A previous pharmacokinetic (PK) study showed that variability between 
patients could be partly explained by renal function and inflammatory status. The goal of 
this study was to combine this PK information with pharmacodynamic (PD) data, to evaluate 
the variability in response to midazolam and to find clinically relevant covariates that may 
predict PD response. 
method
A population pharmacodynamic analysis using nonlinear mixed effect models was per-
formed with data from 43 terminally ill patients. PK profiles were predicted by a previously 
described PK model and depth of sedation was measured using the Ramsay sedation score. 
Patient and disease characteristics were evaluated as possible covariates. The final model 
was evaluated using a visual predictive check (VPC). 
results 
The effect of midazolam on the sedation level was best described by a differential odds 
model including a baseline probability, Emax model and inter individual variability (IIV) on 
the overall effect. The EC50 value was 68.7 μg/L for a Ramsay score of 3-5 and 117.1 μg/L for 
a Ramsay score of 6. Co-medication with haloperidol was the only significant covariate. The 
VPC of the final model showed good model predictability. Conclusion We were able to ac-
curately describe the clinical response to midazolam. As expected there was large variability 
in response to midazolam. The use of haloperidol was associated with a lower probability of 
sedation. This may be a result of confounding by indication as haloperidol was used to treat 
delirium, and deliria has been linked to a more difficult sedation procedure. 
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What is known about this subject
•	 In terminally ill patients pharmacokinetic variability can be reduced by taking in to ac-
count a patients’ albumin levels and estimated glomular filtration rate.
•	 There is large inter individual variability in clinical response to midazolam. 
•	 Delirious patients are regarded as more difficult to sedate in general, as well as in the 
case of palliative sedation.    
What this study adds
•	 Using a population approach with categorical sedation scores we were able to accu-
rately describe the pharmacodynamics of midazolam in terminally ill patients. 
•	 Haloperidol as co-medication was associated with lower Ramsay scores, and therefore a 
less sedative state. 
•	 With this population pharmacodynamic model target levels of midazolam can be at-
tained that can be used in the development of an individualised dosing algorithm. 
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introduction 
In terminally ill end-of-life patients the most important goal is to provide adequate symptom 
relief (1-3). When symptoms are so severe that none of the conventional modes of treat-
ment is effective within a reasonable time frame and/or these treatments are accompanied 
by unacceptable side effects, i.e. in case of refractory symptoms, palliative sedation may be 
initiated. In a hospice setting palliative sedation is commonly used. Several studies looked 
at how often palliative sedation was initiated and showed that on average 46% (range 22 – 
67%) of the terminally ill patients in a hospice were being sedated for refractory symptoms 
at the end of life (4-8). The drug of choice to achieve palliative sedation is midazolam (4, 9). 
Although midazolam has been shown to be effective in achieving adequate sedation, the 
response between patients varies widely. In clinical practice the midazolam dose is titrated 
according to clinical response which results in a wide range of both effective dose and time 
to adequate sedation (10, 11). Furthermore, the study by Morita et al showed that almost 
half of the patients awoke at least once from the sedated state (11). 
A more individualised dose could therefore potentially lead to more adequate sedation 
in these patients. To investigate this, a population pharmacokinetic model was developed 
which demonstrated large inter individual variability (IIV) on clearance of both midazolam 
and its metabolites with values ranging from 49 to 61% (12). It also showed that IIV could be 
significantly reduced if patients’ serum albumin levels and estimated glomerular filtration 
rate (eGFR) were to be taken into account. This suggests that a dosing regimen based on 
albumin levels and eGFR may result in better clinical outcome. However, such a pharma-
cokinetic model only predicts midazolam concentrations and does not include the phar-
macodynamic variability, which is likely to be considerable and may vary with age, gender 
or disease severity (13-15). This information is crucial when generating an individualized 
dosing advice. 
To investigate the clinical response to midazolam plasma concentration on sedation 
level, to assess the amount of variability, and to find clinically significant covariates, we 
performed a population pharmacodynamic study in terminally ill adult patients using the 
Ramsay sedation score. 
methods
study design
The study (NL32520.078.10) was approved by the Medical Ethics Committee of the Erasmus 
University Medical Centre Rotterdam and was performed in accordance with the principles 
of the Declaration of Helsinki and its later amendments. The design of the study and study 
population are presented in detail in chapter 5, the article of Franken et al in which the 
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population pharmacokinetic model of midazolam is described (12). Parts of the methods 
are briefl y mentioned in this article when relevant.  The study design with sparse regimen of 
random PK and PD sampling is shown in fi gure 1.
Admission of the 
patient in the 
palliative care 
centre 
If the inclusion criteriaa
were met and informed 
consent was obtained 
the patient was inrolled
in the study 
Midazolam was administered for insomnia or palliative sedation and was dosed in accordance with the 
current guidelinesb
Blood samples were collected by vena puncture of indewelling venous catheter. This was done randomly 
via sparse sampling with a maximum 10 samples a week.   
Patients 
were 
followed 
until the 
time of 
death
Ramsay scores were obtained at random time points surrounding the midazolam dosesc
Figure 1. Regimen of pharmacokinetic and pharmacodynamic sampling. (A) The inclusion criteria for this study 
were terminal illness, a survival prognosis of more than 2 days and less than 3 months, administration of mid-
azolam.(B) The current Dutch guidelines states that midazolam can be administered either as subcutaneous bo-
lus injection (with a starting dose of 10 mg followed 5 mg every 2 h if necessary) or as a continuous subcutane-
ous infusion (with a starting dose of 1,5–2.5 mg/h and the possibility to up the dose if sedation was insuffi  cient 
with 50% every 4 h in combination with a 5-mg bolus injection). (C) In general, the Ramsay score was obtained 
at the start of the midazolam treatment with consecutive assessments at 2-h intervals.
data collection
Demographic characteristics (age, gender, ethnicity, primary diagnosis, and time of death) 
were extracted from the electronic medical records. Midazolam administration times were 
recorded in the patient record as well as any concomitant medication. Sparse blood samples 
were collected at random time points during both the pre-terminal and terminal stage of 
the disease. Using these samples midazolam and its two major metabolites, 1-hydroxymid-
azolam (1-OH-M) and 1-hydroxymidazolam glucuronide (1-OH-MG) were determined by an 
LC-MS/MS method described before (12). Blood samples for clinical chemistry were taken 
at the same time and serum levels of albumin, creatinine, urea, bilirubin, gamma-glytamyl 
transpeptidase (GGT), alkaline phosphatase (ALP), alanine transaminase (ALT), aspartate 
transaminase (AST), and C-reactive protein (CRP) were determined. Sedation was assessed 
using the Ramsay sedation score and was typically scored at the start of the midazolam treat-
ment with consecutive assessments at 2 hour intervals (16). This scale consists of 6 sedation 
levels: 1, patient is anxious and agitated or restless; 2, patient is co-operative, orientated and 
tranquil; 3, patient is drowsy or asleep and responds to commands only; 4, patient is asleep 
and has a brisk to a light glabellar tap or loud auditory stimulus 5, patient is asleep and has 
a sluggish response to a light glabellar tap or loud auditory stimulus; 6, patient is asleep and 
has no response to a glabellar tap or loud auditory stimulus. The Ramsay sedation score has 
been used before in a palliative care setting and enables doctors and nursing staff  to assess 
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the level of sedation as self-reporting is usually not possible (17, 18).  The Ramsay score was 
measured by a trained and experienced nurse, using a standard operating procedure. 
Pharmacokinetic data integration 
A previously described population pharmacokinetic model was used to predict PK pro-
files for all individual patients (12). This model was based on the same study population 
and contained data from 45 patients and 139 collected blood samples. This model was 
systematically developed based on minimum objective function value (OFV), parameter 
precision, error estimates, shrinkage values and visual inspection of the goodness of fit plots, 
bootstrapping and normalised prediction distribution errors (NPDE) analyses. In summary 
the model was a one-compartment model for both midazolam, 1-OH-M and 1-OH-MG and 
contained two covariates albumin levels on midazolam clearance and eGFR on 1-OH-MG 
clearance. Since all 43 patients for whom Ramsay scores were available, were also included 
in the PK dataset, the individual PK parameters together with the midazolam doses were 
used as input for the sequential PD model. From the remaining 2 patients, no Ramsay scores 
were available and they were excluded from the PD model. 
Population pharmacodynamic method
A population pharmacodynamic analysis using nonlinear mixed effect models was 
performed with NONMEM® 7.2, in combination with Pirana (version 2.9.2) for the model 
building process and R (version 3.3.0) and PsN (version 4.6.0) to generate diagnostic plots. 
Population PD model development
Both a proportional odds model and a differential odds model were tested for the pos-
sibilities of observing a certain Ramsay sedation score. These methods have been described 
before by Kjellsson et al and the difference between these models was tested by dichot-
omising the data and performing logistic regression (19).  In short these methods estimate 
the logit and corresponding probability of the Ramsay score being equal or greater than a 
particular value. At any given concentration, there is a finite probability of having a Ramsay 
score of 1, 2, 3, 4, 5 and 6 with the sum of these probabilities being 1. The probability (P) of 
a particular sedation score (n) follows from calculating the difference of two consecutive 
scores, as is shown in equation 1. 
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 (1)
To describe the clinical response to midazolam concentrations on the probability of a 
certain Ramsay score linear models, log linear models, Emax models and a sigmoidal Emax 
models were tested both direct and indirect (20). Model evaluation was based on objective 
function value (OFV), parameter precision, shrinkage values and visual predictive checks 
(VPC). Pharmacodynamic parameter estimates were obtained using the Laplacian estima-
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tion method.  To evaluate the eff ect of the midazolam metabolites, 1-hydroxy midazolam 
(1-OH-M) and 1-hydroxy midazolam glucuronide (1-OH-MG) an additive interaction model 
(eq 2) was used with equal maximal eff ect (Emax) for midazolam and the metabolite of 
interest. In this equation EC50,1 EC50,2 represent the half maximal eff ective concentrations of 
midazolam and the metabolite respectively and C1 and C2 represent the concentrations of 
midazolam and the particular metabolite. 
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Covariate model development 
Patient characteristics (age and gender), disease characteristics (albumin levels, C-reactive 
protein levels, estimated glomular fi ltration rate, and time to death (TTD)), all concomitant 
medication with sedative eff ects and the time of day were evaluated as possible covari-
ates in the PD model. Signifi cance of a covariate was evaluated using a forward inclusion, 
backward elimination method with P-values of 0.05 and 0.001 respectively.  Continuous 
covariates were incorporated using equation 3 and categorical covariates using equation 
4. All concomitant medication, with the exception of morphine, was tested as a categorical 
covariate with the value being 1 if the patients used that type of co-medication on the day 
of the Ramsay observations. Morphine concentrations as well as the concentrations of the 
morphine metabolites, morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) 
were tested as a continuous covariate. This was possible since the patients in this study were 
also included in a population pharmacokinetic study on morphine and its metabolites (21). 
This PK model was used to predict the morphine, M3G and M6G concentrations at the time 
of the Ramsay observation. 
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With covi being the individual covariate value, covm represents the median covariate value 
and θcov the covariate coeffi  cient. In the equation for categorical covariates covi is either 1 or 0. 
The covariate eff ect that was obtained with this equation was added to the sum of the logits. 
Because of the transformation used, a negative covariate coeffi  cient described a positive cor-
relation and vice versa. The diff erence in time between the observation and the recorded time 
of death was tested as a covariate using equation 3 as well as using a fi rst order equation. In 
this second equation (eq 5) one theta represents the maximum eff ect (θΔ and a second theta 
the rate (θrate) at which the change takes place, with TTD representing the time to death.
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Model evaluation
The intermediate and fi nal models were evaluated using the objective function value, 
parameter precision and shrinkage values. As the pharmacodynamic model predicts prob-
abilities rather than actual sedation scores, residual errors could not be calculated and the 
standard observed versus predicted plots could not be generated. We therefore used visual 
predictive checks to visually evaluate the goodness of fi t. 
results
A total of 941 Ramsay sedation scores from 43 patients were available, with a median of 14 
(IQR 7-30) observations per patient. The number of observations for the Ramsay categories of 
1 to 6 were 68 (7.2%), 161 (17.1%), 31 (3.3%), 30 (3.2%), 146 (15.5%) and 505 (53.7%), respec-
tively. Since there were very few data in category three and four these were taken together 
with category 5. This decision was made as for clinical outcome a score of 3 or more will be 
suffi  cient in most cases. For a complete overview of the patient characteristics see table 1.
Table 1. Patient characteristics of terminally ill patients receiving midazolam
Characteristics  N=43
Age, years (median, range) 71 (43 - 93)
Male, n (%) 22 (51.2)
Female, n (%) 21 (48.8)
Ethnic origin, n (%)
Caucasian 39 (90.7)
Afro-Caribbean 3 (7.0)
Unknown 1 (2.3)
Primary diagnosis, n (%)
Neoplasm 42 (97.7)
Disease of the respiratory system 1 (2.3)
Daily dose midazolam, mg/day (range) 2.5 - 180
Blood chemistry, serum levels at admission (median, range)
Albumin, g/l 24 (13 - 38)
eGFRa, ml/min/1.73 m2 69.4 (6 - 328)
C-reactive protein, U/l 128 (1 - 625)
Comedication usedb
Other benzodiazepines,c, n (%) 8 (18.6)
Haloperidol, n (%) 18 (41.9)
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structural model
Sedation in the terminally ill patients, using the Ramsay sedation scores was best described 
by a diff erential odds model including a baseline probability, midazolam eff ect and inter 
individual variability (IIV). The eff ect of midazolam on the sedation was best described by 
a direct Emax response model. IIV was tested on baseline, EC50 and overall eff ect, where 
the latter gave the best results. Incorporating more than one IIV in the model resulted in 
large eigenvalues, indicating over-parameterisation. This resulted in the structural model as 
shown by equation 6. In this model n represents a particular Ramsay score. Per Ramsay score 
there are diff erent baseline values and EC50 values, but the Emax is the same for all scores. 
Implementing the concentrations of the metabolites 1-OH-M and 1-OH-MG did not 
improve the model. The fi nal structural model resulted in baseline probabilities of 0.23, 0.49, 
0.16 and 0.13 for Ramsay scores of 1, 2, 3-5 and 6 respectively and the following EC50 values 
30.1 μg/L, 62.8 μg/L and 111.6 μg/L for Ramsay scores of 2, 3-5 and 6.  In the structural model 
the value for IIV on overall eff ect was 0.81 on the logit scale. Calculating the probability from 
that it means that 1SD is equal to a probability of 69% (eq 6a and b). 
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covariate analysis 
The forward inclusion step of the covariate analysis resulted in three signifi cant (P<0.05) co-
variates. These were age, time of day (night-time vs daytime) and concomitant use of halo-
peridol. After the backward elimination step only co-medication with haloperidol remained 
signifi cant (P<0.001). The coeffi  cient for this eff ect was 1.76. Due to the transformation used 
(Eq 4) patients who were also treated with haloperidol had a lower probability for the seda-
tion scores 2 or higher compared to patients without haloperidol co-administration. The 
Levomepromazine, n (%) 2 (4.7)
Dexamethasone n (%) 13 (30.2)
Anti-epileptic drugsd, n (%) 3 (7.0)
Anti-depressant drugse, n (%) 2 (4.7) 
Morphine, ug/L (median, range) 41.9 (0 - 609.2)
M3G, ug/L (median, range) 825.9 (0 - 5433.5)
M6G, ug/L (median, range) 119.9 (0 - 826.5)
Blood samples collected, n (median, range) 2 (1 – 10) 
eGFR: estimated glomerular fi ltration rate M3G: morphine-3-glucuronide M6G: morphine-6-glucuronide a calcu-
lated using the abbreviated MDRD equation b during the same day when Ramsay observations were collected 
c Benzodiazepines used included lorazepam, oxazepam and temazepam d Antiepileptic drugs used included 
levetiracetam and pregabaline e Antidepressant drugs included only amitriptyline
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coefficients, decrease in OFV and effect on IIV in the univariate analysis of all three covariates 
are shown in table 2. The final model including the use of haloperidol as a covariate resulted 
in baseline probabilities of 0.18, 0.48, 0.18 and 0.15 for Ramsay scores 1, 2 3-5 and 6 in patients 
without haloperidol use and baseline probabilities of 0.33, 0.57, 0.06 and 0.04 for Ramsay 
scores 1, 2 3-5 and 6 in patients with concomitant use of haloperidol (figure 2). The EC50 
values of the final model were the following for all patients with and without haloperidol: 
39.5 μg/L, 68.7 μg/L, and 117.1 μg/L for Ramsay scores of 2, 3-5 and 6.  Figure 3 shows the 
probabilities of the different Ramsay scores as a function of the midazolam concentration. 
From the upper two graphs it can be seen that without the use of haloperidol (fig 3A) the 
probability of a Ramsay score of 3 or more is 80% at a midazolam concentration of about 
50 μg/L, whereas with the concomitant use of haloperidol this concentration is around 80 
μg/L. From the bottom left graphs it is clear that at a concentration of 30 μg /L (and no 
haloperidol co-medication) the probabilities for a Ramsay score of 2, 3-5 and 6 are almost 
equal. To also show the effect of the high IIV in the model simulations were performed. 
Figure 4 shows the probabilities of a Ramsay score of 3 or more and the probability of a 
Ramsay score of 6 with their corresponding 95% confidence intervals. As mentioned before 
these confidence intervals are large and as a result, the confidence intervals of both scores 
overlap. 
Table 2. Covariate effects in univariate analysis compared to the structural model
Covariatea Parameter valueb ΔOFVc ΔIIVd Included after backward elimination
Age -1.67 -5.776 - 8.0 % No
Use of haloperidol 1.76 -11.975 + 6.3 % Yes
Day vs Night-timee 0.675 -4.919 + 4.1 % No
a: Covariates included in the full model after forward inclusion. b:Parameter value, note that due to the trans-
formation used, positive values are negative correlations and vice versa. c: Decrease in objective function value 
(OFV) after the univariate analysis. d: Decrease in inter individual variability (IIV) after the univariate analysis. e: 
with daytime being the reference value 
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Figure 2. Baseline probabilities for Ramsay scores of 1, 2, 3–5 and 6 without the use haloperidol (black bars) and 
with concomitant haloperidol use (grey bars).
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Figure 3. (A) Probabilities of a Ramsay score≥2 (blue) ≥3 (green) and ≥6 (purple) without the use of haloperidol. 
(B) Probabilities of a Ramsay score≥2 (blue) ≥3 (green) and ≥6 (purple) with concomitant haloperidol use. (C) 
Probabilities of a Ramsay score of 1 (red), 2 (blue), 3–5(green) and 6 (purple) without the use of haloperidol. (D) 
Probabilities of a Ramsay score of 1 (red), 2 (blue), 3–5 (green) and 6 (purple) with concomitant haloperidol use.
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Figure 4. Simulations of the average probabilities and corresponding 95% confidence intervals (dashed lines) 
of Ramsay score 3 or more (black) and Ramsay score 6 (grey) without the use of haloperidol on the left (A) and 
with concomitant haloperidol use on the right (B).
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model evaluation
Of the initial bootstrap of 500 runs just over 70% of the runs resulted in a successful co-
variance step and were used to calculate the 95 confidence intervals. The median values 
and 95% confidence intervals of the bootstrap are shown in table 3.  The VPC of the final 
model showed good model predictability with the observations (line) laying within 95% 
confidence interval of the model predictions (shaded area) for most of the Ramsay scores 
(figure 5). In the VPC plot it can however also be seen that at midazolam concentrations of 
around 150 to 350 μg/L, Ramsay scores of 3-5 are somewhat over predicted while Ramsay 
scores of 6 are somewhat under predicted.   
Figure 5. Visual predictive check of thefinalmodelforRamsayscoresof1, 2, 3–5 and 6. With the line depicting 
the observed probabilities and the shaded area the 95% prediction interval of the model. Yellow lines are the 
concentration intervals.
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discussion 
To our knowledge this is the first study to describe the clinical response to midazolam in 
terminally ill patients with a population pharmacodynamic model. Our study population 
consisted primarily of patients with cancer, admitted to a hospice, for terminal care in the 
last phase of life. Others have done pharmacodynamic studies with midazolam in popula-
tions of critically ill patients admitted to intensive care units (22, 23). For the lower Ramsay 
scores the EC50 values found in our study are in accordance with the results of Somma et al 
who studied the effect of midazolam in patients after heart surgery (22). However, the EC50 
value for the highest Ramsay score in our study was less than half of that found in the study 
of Somma et al (118 μg/L vs 352 μg/L). A possible explanation for this difference may be the 
different study populations. In our terminally ill patients high doses of morphine were used, 
which may have increased the sedative effect of midazolam. However as both other studies 
also had opiates as co-medication a more likely explanation may lay the advanced illness 
itself. As a consequence of their advanced illness terminally ill patients may be unable to re-
spond thereby causing the overall Ramsay scores to be higher. Furthermore, environmental 
factors may play a role. A hospice setting offers more tranquillity than a hospital’s intensive 
care unit (with more medical equipment and noises), as described in the study of Somma. 
A more stressful situation is also one of the arguments Swart and colleague used to explain 
why their study in IC patients found even higher EC50 values than Somma et al (23).     
Table 3. Population pharmacodynamic parameter estimates of the structural and final models
Parameter
Structural 
model 
Final model RSE % Shrinkage %
Bootstrap of the final model
Average
95% CI 
(lower)
95% CI 
(upper)
Baseline
B2 1.22 1.47 32 - 1.33 0.46 2.15
B3-5 -0.91 -0.72 19 - -0.81 -2.53 0.98
B6 -1.93 -1.76 38 - -1.83 -4.58 0.59
Emax model
Emax 4.08 4.62 24 - 4.54 3.57 6.30
EC502 (ug/L) 30.1 39.5 69 - 33.4 7.1 109.3
EC503-5 (ug/L) 62.8 68.7 51 - 62.8 10.9 165.0
EC506 (ug/L) 111.6 117.1 50 - 109.4 23.6 280.0
Covariate effect
haloperidol 1.76 18 - 1.74 0.88 2.41
Inter Individual Variability (IIV)  
Overall effect 0.81 0.92 29 18 0.94 0.45 1.63
Bn: baseline logit for a Ramsay score of n. Emax: maximum effect. EC50n : concentration at half of the maximum 
effect for a ramsay score of n .
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In contrast to the two previously mentioned studies, we did not only investigate the 
response to midazolam but also analysed its two major metabolites 1-OH-M and 1-OH-MG. 
Interestingly neither of these metabolites showed an additive effect, while it is known from 
the literature that 1-OH-M is about 80% as effective as midazolam and 1-OH-MG has a po-
tency of about 10% (24, 25). The lack of an additive effect can be explained by the fact that 
1-OH-M is a formation rate limited metabolite, and therefore closely follows the midazolam 
concentrations.  As a result, it is impossible to separate the effect of these two substances. 
1-OH-MG on the other hand is elimination rate limited and it has been shown before that 
this metabolite can accumulate in patients with renal failure, causing prolonged sedation 
(26).  We did not see an effect of the 1-OH-MG concentrations or renal function on sedation 
in our study. The lack of an effect may be because the treatment period is relatively short 
(palliative sedation is usually given for around 48 hours) and the dose low, compared to an 
ICU setting where the starting dose may be 10 times higher (27). As result, the treatment 
period may have been too short for any significant accumulation to occur. Furthermore in 
palliative sedation midazolam is not discontinued, therefore high 1-OH-MG concentrations 
never occurred in the absence of midazolam concentrations and as the sedation scale has 
an upper limit an additive effect of 1-OH-MG may not be seen. Furthermore, renal function 
did not seem to be that severely affected in the population, with only 6% of the patients 
having an estimated GFR below 30ml/min. Although it should be noted, that estimating 
GFR in this population is difficult due to the possible low lean body weight and muscle 
atrophy. 
The only covariate that showed a significant effect was the concomitant use of haloperi-
dol.  Patients who also used haloperidol had a higher probability of lower Ramsay scores, 
meaning that they were less likely to be sedated. A possible explanation is that this effect 
is a result of confounding by indication, as patients receive haloperidol to treat agitation or 
delirium and deliria has been mentioned to be a risk factor for a difficult sedation process 
(28, 29).  The IIV did not decrease when haloperidol use was incorporated as a covariate. This 
can be caused by the fact that the use of haloperidol could change within an individual 
patient over time, and it is therefore not a reflection of the IIV but rather a result of inter oc-
casion variability. Two other covariates, i.e. age and time of day, showed a significant effect 
in the forward inclusion that did not hold up or stay after the backward elimination. Age 
was positively correlated with sedation, meaning that elderly patients were more likely to be 
deeply sedated compared to younger patients. These data are in accordance with a study 
by Sun, who showed sedation scores after midazolam treatment differed significantly with 
age (15). However, as the age range of patients in this study is not that large, our patient 
numbers may have been too small to show a significant effect of age in the backward elimi-
nation step. Time of day was also not significant in the backward elimination step. This may 
be due to the fact that its influence was tested using a fairly basic dichotomous equation, 
with night-time vs daytime. A previous study by Peeters and colleagues used a more elabo-
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rate sinus equation to describe the circadian rhythm (30). As our study had more sparsely 
collected data this was not feasible in our model.  No correlation was found between the 
sedation level and the time to death, or albumin levels.  While we would have expected that 
if a patients is closer to the time of death (for which low albumin levels are also a marker) 
they would be more deeply sedated. Incorporating TTD and albumin as a covariate did 
show a trend (ΔOFV 3.27 for TTD and 3.32 for albumin).  However this did not meet the cri-
teria of statistical significance. . To further investigate this more continuous measurements 
of level of sedation may be helpful as the dying phase is a gradual process. Furthermore, 
we initially would have expected an effect of morphine (and possibly its metabolites) on 
sedation levels, however this was not the case (31). This could have been caused by the 
fact that in 88% of the Ramsay observations the patient also used morphine making the 
group of data without morphine too small for an adequate comparison. In addition, it is also 
possible that the sedative effect of morphine may be less prominent in patients who have 
used it for a prolonged period of time.   
This study also a few limitations, firstly the Ramsay sedation score is not validated for 
terminally ill patients. In addition, the scores are measured only at certain time points 
thereby making it difficult to evaluate a possible delay in response onset. Due to the limited 
number of observations shortly after a midazolam dose, we were unable to include an effect 
compartment and to estimate a first-order effect compartment rate constant (Ke0). Although 
midazolam has a rapid onset and we therefore would not expect a great variability in this Ke0 
value, it would be interesting to see if there is any variability on Ke0 as this would impact the 
onset of sedation and is therefore of considerable clinical interest. To evaluate this a more 
continuous PD observation method, like EEG measurements would be needed. 
Another limitation in our model is that the Ramsay scores of 3, 4 and 5 were taken to-
gether as one category due to the limited data in the 3 and 4 category. This is most likely also 
a consequences of the lack of observations shortly after a midazolam dose. We also tested 
a model with all categories separately, which resulted in similar parameter estimates and 
almost equal EC50 values and baseline probabilities for the scores 3, 4 and 5, as expected 
due to the low number of observations. This will not affect our results and conclusions. a. 
The main goal of palliative sedation is to make sure the patient is comfortable and although 
this is not exactly reflected by the Ramsay score, a score of 2 to 3 or more will be sufficient. 
The distinction between scores 3-5 and 6 may be relevant from the point of view of the 
relatives and for side effects.   
A third limitation of our study is that individual PK parameters were used from a previ-
ously performed PK modelling study, instead of a simultaneous PK PD analysis. This may 
have led to some overestimation of the IIV in the PD model. Finally, previously performed 
PD studies on midazolam included a naive pooled analysis to assess the model accuracy 
(22, 32). We instead used a visual predictive check (VPC) for the model evaluation, which is 
a newer evaluation method and has the additional benefit that it also shows the amount of 
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variability in the model. In conclusion, we described the response to midazolam on seda-
tion levels in terminally ill patients using a population pharmacodynamic model with the 
Ramsay sedation score as outcome variable. 
theraPeutic imPlications
As expected, the variability in response was large. We found that the use of haloperidol was 
correlated with a lower response. This effect is best visualised by figure 4, where the graph 
in 4a shows that without haloperidol use a typical individual (solid line) will have an 80% 
chance of a Ramsay score of 3 or mora at midazolam concentration of around 50 μg/L. The 
graph also shows that due to the large interindividual variability, a concentration of around 
200 μg/L would be needed to assure this same chance for 95% of the population (dashed 
line). The adjacent figure 4b shows that with concomitant haloperidol, the midazolam con-
centration needed to give a typical patient (solid line) an 80% change of a Ramsay score of 3 
or more would be around 80 μg/L. Again to ensure this chance for 95% of the population a 
much higher concentration would be needed (of approximately 600 μg/L) due to the large 
IIV (fig dashed line). Of course aiming for the higher midazolam concentrations will also 
increase the probability of Ramsay score of 6 (grey lines), which may not always be desirable. 
Combining these results with our previous knowledge of the pharmacokinetics of mid-
azolam we performed some simulation of dosing regimens for patients with and without the 
haloperidol as concomitant medication and different albumin levels. The results are shown 
in table 4 and it can be seen that the loading dose depends on the use of haloperidol and 
the additional doses on the albumin concentrations. For instance a loading dose of 7,5 mg 
followed by 2 mg every 4 hours to a patient without haloperidol use and an albumin levels 
of 25 g/L will on average give an 85% of a Ramsay score of 3 or more (with its 95 CI between 
48 and 97 %). This dose is slightly lower than the current guidelines. However aiming for 
an 80% change of a Ramsay of 3 or more for 95% of the population would result in higher 
doses than the current guidelines, especially in patients with haloperidol as co-medication. 
These values may be used as a reference in developing an individualised dosing regimen, 
which may improve clinical care for these terminally ill patients. However, it should be noted 
that with increasing the target concentration to ensure an adequate level of sedation for a 
larger proportion of the population, overdosing in part of the population would occur. It 
may therefore be advantageous to initially dose with the aim to achieve an 80% chance of 
an adequate sedation (Ramsay ≥3) for the typical patient and to titrate up according to the 
clinical response. To achieve an adequate response as soon as possible the dose could be 
increased if adequate sedation is not yet reached at the time of the additional dose (after 
4 hours). For patients without haloperidol increasing the additional dose with 50% with a 
bolus of 6 mg would ensure that the concentrations at which 95% of the population will 
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have an 80% chance of adequate sedation will be reached within 12 hours. For patients 
with haloperidol use, doubling the additional dose (with a maximum increase of 10mg) in 
combination with an 8mg bolus would ensure these higher concentration within around 16 
hours. Figure 6 shows the concentrations time profiles and corresponding probabilities that 
would be achieved with these dosing regimens. However as the interindividual variability 
remains high more research remains necessary to further explore possible the underlying 
causes. Other interests for future study arising from our results, would be a PD study with 
a continuous observation to investigate variability in onset of sedation and the effect of 
haloperidol on sedation. A continuous measurement using a Bispectral Index Monitor (BIS) 
has been tested before in terminally ill patients. However large variability in BIS values for 
patients with Ramsay scores of 6 were found (18). Although it may give insight in the onset 
of sedation, BIS values may be more difficult to use for clinical recommendations. The same 
goes for other continuous PD measurements like saccadic eye movement analysis (33). With 
haloperidol it would be interesting to investigate if the correlating is due to the effect of 
deliria or because of a paradoxal response on haloperidol (34, 35). Future research is com-
plicated due to the complexity of the clinical setting in palliative care, such as the process 
of disease, comorbidities and the lack of validated rating scales. However, more insight is 
needed and more PK/PD research is needed to improve the care of these patients. Validated 
PD endpoints are necessary and a focus on relevant questions such as onset of sedation of 
relief of symptoms is needed. 
Table 4.  Simulated dosing regimens and corresponding probabilities
- haloperidol + haloperidol
albumin 15 g/l albumin 25 g/L albumin 15 g/l albumin 25 g/L
Dosing regimena (mg) 7,5 / 1 25 / 4 7,5 / 2 25 / 7 10 / 1.5 75 / 12 10 / 3 75 / 21
Midazolam concentration 
(ug/L)
50 200 60 200 75 600 85 600
Ramsay ≥ 3 
Mean (95 CI) (%)
82   (42-97) 96
(80-99)
85
(48-97)
96
(80-99)
78
(36-96)
96
(81-99)
81
(41-96)
96
(81-99)
Ramsay = 6
Mean (95 CI) (%)
54
(16-88)
90
(60-98)
60
(19-90)
90
(60-98)
49
(13-86) 
94
(73-99)
54
(16-88)
94
(73-99)
A: dosing regimen in loading dose / additional doses every 4 hours
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Figure 6. Concentration time profiles and corresponding probabilities (mean: solid line 95% confidence interval: 
dashed line) of a Ramsay score of 3 or more for a patient without haloperidol and albumin level of 25 g/l (A and 
C). For this patient a dosing regimen was simulated with an initial loading dose of 7.5 mg loading dose the ad-
ditional dose of 2 mg every 4 h was increased 3 times with 50% together with a bolus dose of 6 mg to simulate 
a patient with inadequate response. B and D show the concentrations and probabilities (mean: solid line 95% 
confidence interval: dashed line) for a patient with haloperidol and albumin levels of 25 g/l. For this patient 
a dosing regimen was simulated with an initial loading dose of 10 mg loading dose the additional dose of 3 
mg every 4 h was doubled 3 times together with a bolus dose of 8 mg to simulate a patient with inadequate 
response.
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aBstract
Purpose
Over 80% of the terminally ill patients experience delirium in their final days. In the treat-
ment of delirium, haloperidol is the drug of choice. Very little is known about the pharma-
cokinetics of haloperidol in this patient population. We therefore designed a population 
pharmacokinetic study to gain more insight into the pharmacokinetics of haloperidol in 
terminally ill patients and to find clinically relevant covariates that may be used in develop-
ing an individualised dosing regimen.
methods 
Using non-linear mixed effects modelling (NONMEM 7.2), a population pharmacokinetic 
analysis was conducted with 87 samples from 28 terminally ill patients who received halo-
peridol either orally or subcutaneously. The covariates analysed were patient and disease 
characteristics as well as co-medication.
results 
The data were accurately described by a one compartment model. The population mean 
estimates for oral bioavailability, clearance and volume of distribution for an average patient 
were 0.86 (IIV 55%), 29.3 L/h (IIV 43%) and 1260 L (IIV 70%), respectively. This resulted in an 
average terminal half-life of haloperidol of around 30 h. 
conclusion 
Our study showed that the pharmacokinetics of haloperidol could be adequately described 
by a one compartment model. The pharmacokinetics in terminally ill patients was compa-
rable to other patients. We were not able to explain the wide variability using covariates. 
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introduction
In palliative care, (terminal) delirium is a frequently seen symptom with over 80% of the 
advanced cancer patients experiencing delirium in their final days [1]. Although randomised 
clinical trials are scarce, most guidelines and specialist consider haloperidol, a typical/classic 
antipsychotic, to be the first-line treatment of delirium [2–4]. Haloperidol is metabolised 
by several different pathways, involving cytochrome P450 (CYP), carbonyl-reductase and 
uridine diphosphoglucose glucuronosyltransferases (UGT) enzymes. Glucuronidation ap-
pears to be the major metabolic route followed by the reversible reduction of haloperidol 
to reduced haloperidol and CYP-mediated oxidation by CYP3A and CYP2D6.
The dose of haloperidol is determined based on the clinical effect. As haloperidol can 
cause motor (or extrapyramidal) and cardiovascular adverse/side effects, it is normally start-
ed at a low dose (0.5–2.0 mg) and increased slowly until the desired effect is reached. This 
can be disadvantageous in the case of refractory symptoms when rapid symptom relief is 
required. In addition, haloperidol has a relative long terminal half-life (t1/2) of approximately 
20 h causing steady state to be reached after 4 to 5 days. Patients could therefore potentially 
benefit if an individualised dose is determined beforehand. In palliative patients, this is even 
more important, as rapid symptom relief is essential in the last phase of life.
Several studies on the pharmacokinetics of haloperidol in healthy volunteers or psy-
chiatric patients showed large interindividual variability (IIV) [5–11]. As haloperidol has a 
moderate hepatic extraction ratio of 0.3–0.7, its metabolism may be influenced by hepatic 
blood flow as well as intrinsic enzyme activity and protein binding [7, 12, and 13]. Therefore, 
the IIV in palliative care patients may be even more pronounced as these patients may suffer 
from decreased blood flow, altered plasma protein levels and possibly hepatic dysfunction 
[14]. We performed a population pharmacokinetic study in terminally ill patients to gain 
more insight into the pharmacokinetics in this population and to find clinically relevant 
parameters for dose individualisation.
methods
The study was performed in accordance with the principles of the Declaration of Helsinki 
and its later amendments. Ethical approval was obtained from the Medical Ethics Commit-
tee of the Erasmus University Medical Centre, Rotterdam, and all patients provided written 
informed consent.
data
Data was collected in the palliative care centre, Laurens Cadenza Zuid in Rotterdam, The 
Netherlands, during 2 years. Patients were eligible if they had a terminal illness, survival 
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prognosis of more than 2 days and less than 3 months and administration of haloperidol. 
Informed consent was asked shortly after admittance to the palliative care centre, and 
included patient were followed until the time of death, unless informed consent was 
withdrawn at any point. Only patients who can give their consent themselves were asked 
for consent. The patients gave consent after contacting their family about the study. The 
partner/legal representative co-signed the informed consent form as witness of the con-
sent. The investigator kept close contact with the patients and their family during the study. 
In the terminal phase, when the patient cannot be asked anymore, all aspects of the study 
were communicated with the family.
Haloperidol was given to treat deliria and was dosed in accordance with the current 
guidelines [4]. Haloperidol was administered orally (either as tablets or as a liquid formula-
tion) or via subcutaneous bolus injection. The exact times of administration were recorded 
in the patient record. Any concomitant medication was also registered in the patient’s 
record. Demographic characteristics (age, gender, weight, race, primary diagnosis and time 
of death) were extracted from the electronic medical records. 
Blood sampling and assay 
Blood samples were collected randomly via sparse sampling in both the pre-terminal and 
terminal phases on average at one to two occasions during the day, with a maximum of ten 
a week, 0.5 to 1 mL of blood. The moment of sampling is not strictly defined, but follows 
the clinical condition of the patient. For example, before and after the change to another 
administration route or in case of inadequate effect of a drug, blood will be sampled. Blood 
for clinical chemistry is routinely sampled by venous puncture. For this study, sampling is as 
much as possible combined with those venous punctures. Otherwise, sampling from an in-
dwelling venous catheters is preferred. With the terminal phase being the last hours or days 
before death, a patient becomes bedbound, semi-comatose, and is not able to take more 
than sips of fluid [15]. During the terminal phase, blood is sampled only from an indwelling 
venous catheter. This method prevents repeated puncturing and causes minimal or no dis-
comfort to the patient. The samples were centrifuged after which the plasma was collected 
and stored at −80 °C until analysis. The blood samples were preferably collected at the same 
time as sampling for clinical chemistry (standard of care). In the clinical chemistry samples, 
serum levels of albumin, creatinine, urea, bilirubin, gamma-glutamyl transpeptidase (GGT), 
alkaline phosphatase (ALP), alanine transaminase (ALT), aspartate transaminase (AST) and 
C-reactive protein (CRP) were determined.
Haloperidol concentrations were analysed in the plasma samples using LC-MS/MS with 
electrospray ionisation in the positive ionisation mode on a Shimadzu LC-30 (Nishinokyo-
Kuwabaracho, Japan) system coupled to an AB Sciex (Framingham, MA, USA) API5500Q 
MS. Seventy-five microliters of acetonitrile/methanol 84:16 (v/v%) containing the internal 
standard haloperidol-d4 was added to 10 μL of patient’s plasma to precipitate proteins. 
137
7
Haldol PD
Afterwards, samples were vortexed and stored at −20 °C for 30 min to optimise protein 
precipitation, vortexed again and centrifuged. A three microliter sample was injected onto a 
Thermo Scientific Hypersil Gold (50 × 2.1 mm, 1.9 μm) column. A stepwise chromatographic 
gradient was applied using 0.05% ammonium formate/0.10%formic acid in water as mobile 
phase A and acetonitrile as mobile phase B. The flow rate was 0.4 mL/min and the column 
was kept at 40 °C. Using multiple reaction monitoring (MRM) with positive ionisation mode, 
haloperidol was measured as [M + H]+ using the mass transition 376.1/ 165.1. The lower 
limit of quantification was 0.5 μg/L and the method was validated over a range of 0.5–125 
μg/L. The accuracies ranged from 93.5 to 107.4%. 
software
Pharmacokinetic analysis was conducted by the NONMEM® Version 7.2 (ICON Development 
Solutions, Ellicott City, MD), PsN® (version 4.4.8), R (version 3.3.0) and Pirana (version 2.9.2).
Population pharmacokinetic method
Model development
Log-transformed plasma haloperidol concentrations were used and the bioavailability of 
subcutaneous haloperidol was assumed to be 100% [16]. One-compartment and two com-
partment models were tested for haloperidol using the first-order conditional estimation 
method with interaction (FOCE + I). To account for the two different administration routes 
(oral and subcutaneously), the ADVAN5 subroutine was used. Interindividual variability 
(IIV) was assessed on each parameter using an exponential model. Residual variability was 
included as a combined error model. 
As weight has been shown to be a covariate in other haloperidol pharmacokinetic mod-
els, and as the relationship between body weight and clearance is well documented, this 
effect was tested using algometric scaling [11, 17]. In the covariate analysis, demographic 
and disease characteristics including weight, age, gender, primary diagnosis, renal function 
(plasma creatinine and plasma urea), hepatic function (plasma levels of bilirubin, GGT, ALP, 
ALT and AST), Creative protein (CRP), albumin and the concomitant use of
CYP2D6 and CYP3A inductors and inhibitors were evaluated for their influence on clear-
ance (CL), volume of distribution (Vd) and bioavailability (F). Time to death (TTD) was also 
evaluated as a covariate. This parameter cannot be used as a covariate parameter for a priori 
prediction of individual pharmacokinetic changes but it may give insight into quantitative 
changes at the end of life that are not predicted by standard blood chemistry tests. The 
relationship between covariates and individual estimates was first investigated graphically 
and was further tested with a forward inclusion, backward elimination approach with P 
values of 0.05 and 0.001, respectively.
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Continuous covariates were normalised to the population median values and incorpo-
rated as power model functions (Eq. 1). Categorical covariates were transformed to binary 
covariates and incorporated as shown in Eq. 2. with θi being the individual model predicted 
pharmacokinetic parameter (e.g. clearance) for an individual with covariate value covi, θpop 
being the population estimate for that parameter, covm representing the median covariate 
value and θcov the covariate eff ect. In the equation, for categorical covariates, covi is either 
1 or 0. 
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To evaluate the time to death (TTD) as a covariate, time dependency of the parameters 
was modelled as a fi rst-order process given to following equation (Eq. 3). In which θΔ is 
the change in parameter value from its initial value and θrate is a fi rst-order rate constant 
determining the rate with which the parameter value changes over time.
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Model evaluation
Intermediate models were evaluated based on minimum OFV parameter precision, error 
estimates, shrinkage values and visual inspection of the goodness of fi t plots. A bootstrap 
with 500 runs was performed on the fi nal model to evaluate the validity of the parameters 
estimates and their corresponding 95% percentile ranges. The fi nal model was evaluated 
with a normalised prediction distribution error (NPDE) analysis. NPDE is a simulation-based 
diagnostics which can be used to evaluate models developed on datasets with variable 
dosing regimens. The analytical value of this method has been previously described by 
Comets et al. [18].
Simulations
To give an illustration of the eff ect of dose on the plasma concentrations of haloperidol and 
the variability, deterministic simulations were performed. The haloperidol plasma concen-
trations were simulated over a time course of 72 h in which six subcutaneous doses were 
administered every 12 h. To show the interpatient variability, the mean and 90% confi dence 
interval are shown graphically.
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results
A total of 28 terminally ill patients were included in the study. Their median age was 69.5 
years (range 43–93), 54% were male and all patients had advanced malignancy as primary 
diagnosis with the majority (87%) having epithelial tissue as the primary malignant site. On 
average at one to two occasions during the day, with a maximum of ten a week, 0.5 to 1 mL 
of blood was collected from the patient by vena puncture or indwelling venous catheter to 
determine drug concentrations. 
An overview of all patient characteristics is given in Table 1. Oral doses of haloperidol 
ranged from 0.5 to 2 mg a day and subcutaneous doses ranged from 0.5 to 5 mg a day. 
A total of 86 blood samples were collected. 26.7% of the concentrations were below the 
quantifi cation limit (BQL). On closer inspection, half of these plasma concentrations were 
measured in samples taken over 200 h after the last haloperidol dose. Discarding these 
resulted in 14.6% BQL data left within 200 h after the last dose. As this is still more than 10%, 
the M3 method of handling BQL data was used to estimate if BQL data were indeed below 
the lower limit of quantifi cation of 0.5 mg/L [19, 20]. As this resulted in similar parameter 
estimates but stability issues, the M1 method (of discarding the BQL data) was used for the 
fi nal model.
structural model
The data were best described by a one-compartment model with an additive residual er-
ror on logarithmic transformed concentrations. Since there was limited data available in 
the absorption phase, the absorption constants (Ka) could not be estimated. We therefore 
derived this value from literature, and as there was no literature available for the absorption 
time of subcutaneous injection of the iv formulation, intramuscular administration was used 
as a reference [21]. Changing this assumption to half of the absorption rate did not aff ect 
the other parameters, which indicates that the model is stable and not infl uenced by this 
assumption. IIV was included on the parameters CL, F and Vd. As the IIV on CL and F showed 
a high degree of correlations (99%), these were fi xed to unity with the addition of an extra 
theta.
covariate analysis
Allometric scaling was tested both with an estimated scaling factor for CL and Vd as well 
as fi xed scaling factors of 0.75 and 1, respectively (Eq. (4)). As the values of 0.75 and 1 lay 
within the 95 confi dence intervals of the estimated scaling factors, and because estimating 
the scaling factors did not signifi cantly improve the model fi t, fi xed values of 0.75 and 1 
were used. Including allometric scaling signifi cantly improved the model fi t (ΔOFV 7.47, P 
< 0.05) and decreased the IIV on Vd with 13%. If the weight of an individual was unknown, 
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the median weight of the population (67 kg) was imputed. This was the case for 35% of the 
study population. 
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Besides bodyweight, plasma bilirubin concentration was signifi cant on the volume of 
distribution in the forward inclusion. This resulted in statistically signifi cant improvement of 
the model fi t, with a drop in objective function value (OFV) of 7.22 points and a decrease 
in IIV on Vd from 61 to 43.2%, thereby explaining 31% of the IIV on Vd. Both parameters 
were not signifi cant in the backward elimination. After inspecting the individual infl uence 
on the decrease in OFV using sharkplots, it was shown that for both covariates, there were 
two very infl uencing individuals, with just one individual being responsible for reaching the 
statistical signifi cance. Bodyweight and plasma bilirubin were therefore not included in the 
fi nal model. An overview of all parameter estimates is given in Table 2.
model evaluation
Figure 1a, b shows that both the population predictions and individual predictions were 
evenly distributed around the line of unity when plotted against the observations. A 
bootstrap analysis of the fi nal model was performed to obtain 95% percentile ranges for 
all parameters. Results of the bootstrap are shown in Table 2. Evaluation of the predictive 
performance by NPDE analysis showed accurate predictive ability, with the distribution of 
the NPDEs not signifi cantly deviating from a normal distribution (with a global adjusted P 
values of 0.4), and the majority of the NPDEs laying between the values −2 and 2 (Fig. 1c).
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Figure 1. Goodness of fi t plots of the fi nal model. Population predictions (PRED) versus observations of halo-
peridol (a), individual predictions (IPRED) versus observations of haloperidol (b) and the normalised prediction 
distribution error (NPDE) distribution plot (c) for of the fi nal model showing NPDE quantiles.
141
7
Haldol PD
simulations
The eff ect of 0.5 mg of subcutaneously administered haloperidol every 12 h is shown in Fig. 
2. The plasma concentration is very variable between patients.
Figure 2. Simulated plasma profi les of halo-
peridol 0.5 mg every 12 h. The mean con-
centration and 90% confi dence interval 
are presented from a simulation of 1000 
patients.
discussion
To our knowledge, this is the fi rst population pharmacokinetic study of haloperidol in 
terminally ill adult patients. We were able to describe the pharmacokinetics of haloperidol 
with adequate accuracy using a sparse sampling method. The simulations show the high 
interpatient variability in the pharmacokinetics and the eff ect of the long terminal half-life 
of haloperidol. The t1/2 of around 30 h from our study means it would take a long time to 
reach steady-state levels and it would take about 6 days to completely eliminate a single 
haloperidol dose from the body.
The covariate analysis did not result in any signifi cant covariates. Initially, body weight 
and plasma bilirubin levels seemed to be correlated; however, as this was mainly due to in-
fl uence of one or two individuals, these were not included as a covariate in the fi nal model. 
Body weight was shown to be correlated in other studies [11, 17]. In our study, body weight 
was not registered for all patients and can vary a lot in the terminal phase, which might 
explain the lack of this correlation in this group of patients. It does not seem likely that he-
patic dysfunction is correlated with the volume of distribution. A correlation with clearance 
seems more logical as haloperidol has a moderate hepatic extraction ratio of 0.3–0.7. The 
fact that none of the hepatic markers showed a correlation with clearance may be because 
of the limited data in our study or because of the fact that the liver has a high over capacity 
for metabolising drugs. Furthermore, the fact that none of the co-medication showed a cor-
relation with clearance may also be due to the low number of patients using concomitant 
medication at the time of haloperidol use. This is common in the palliative population as the 
majority of medication is discontinued in the palliative phase. In addition, a lack of eff ect of 
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co-medication may have been expected as there are several different metabolic pathways 
involved in the metabolism of haloperidol; therefore, co-medication that affects only one of 
these routes will most likely have no effect on the overall clearance of haloperidol. 
There have been previous studies in patients with schizophrenia which showed esti-
mates for clearance which were 1.5 to more than 2 times higher than the 29.3 L/h found 
in our study, when corrected for bioavailability of 86% [10, 11]. However, as both studies 
also reported higher estimates for the total volume of distribution, these together result 
in t1/2 values of 25 and 39.5 h which is comparable to the t1/2 of 30 h found in our study. 
It seems reasonable that terminally ill patients have a lower clearance and a lower volume 
of distribution compared to schizophrenia patients, who on average are younger and are 
less physically ill. Another difference with the study by Pilla Redy et al. is that they found 
haloperidol to be best described by a two-compartment model. This can possibly be ex-
plained by the fact that in our study, we had more sparse data and were therefore unable to 
accurately describe a peripheral compartment and inter-compartmental clearance. This is 
supported by the fact that their study had over 500 samples which still resulted in a broad 
95% CI for the peripheral volume of distribution.
Both studies had weight incorporated in their final model. Unfortunately, one of the limi-
tations of this study is that for about one third of the patients, the weight was unknown, and 
in fact, if the weight was known, this was a single value reflecting the weight at admission 
rather than several measurements over the study period. One of the reasons for the lack of 
data on weight is that almost none of the drugs given in the hospice setting were based on 
the patient’s weight, and therefore, it was unnecessary for clinical practice to collect data 
on weight. Another reason is that doctors and nurses were reluctant to weigh patients as it 
could be disturbing for the patient to be faced with their weight loss. There are several ways 
to handle missing covariate data in population pharmacokinetic analysis [22]. We tried to 
incorporate these methods in our model. However, as we did not find a correlation between 
weight and any of the other known covariates, a method to handle missing data was not 
feasible. We also tested a model with different population values or IIV values for known 
and unknown weights. This did not result in significant improvements and resulted in large 
shrinkage values and model instability due to the already sparse sample numbers, and it 
was therefore not feasible to use in the final model. 
Probably, the most important limitation, in general, is the fact that an effective plasma 
concentration of haloperidol is still unknown. The study of Pilla Redy et al. showed that the 
overall EC50 value was 2.7 mg/L on an overall scale of schizophrenia, with considerably 
lower effective concentrations for the positive symptoms (0.5 mg/L) than the negative 
symptoms (31 mg/L). When we look at deliria, this may show more similarities with the 
positive symptoms of schizophrenia than the negative. However, the underlying cause in 
the case of (terminal) deliria is completely different, making it difficult to give any target 
concentrations for haloperidol in terminally ill population. Reference values of haloperidol 
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are only based on schizophrenia dosing and more studies on delirium and PK/PD of halo-
peridol are needed.
Overall, this study showed that it is possible to describe the pharmacokinetics of halo-
peridol with adequate accuracy in terminally ill patients. We were not able to explain the 
variability in the pharmacokinetics using covariates. Before any recommendations can be 
made, more research is necessary, especially to the pharmacodynamic effects of haloperidol 
in this population as well as the possible effect of liver failure. The current Dutch guidelines 
recommends a dose of 0.5–2mg subcutaneously every half an hour until an adequate effect 
is reached. Looking at the simulated plasma profiles in our study and keeping in mind the 
lack of any known effective dose, this seems a very reasonable recommendation, as the 
absorption constant of haloperidol is fast. The effect can probably be adequately assessed 
after half an hour and titrating up. Too fast dosing may result in adverse events that would 
take a long time to wear off due to the long terminal half-life.
In conclusion, this study describes the pharmacokinetics of haloperidol with adequate 
accuracy in terminally ill patients. More information on pharmacodynamics are needed to 
optimise dosing regimens of haloperidol in this patient group
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summary and discussion
In the Netherlands, every year around 108.500 terminally ill patients will receive some form 
of palliative care [1]. With palliative care (gradually) replacing curative therapy the focus will 
shift form curation to symptom management in order to improve the quality of life for these 
patients. Adequate symptom control is crucial as the symptoms that occur in the final year 
of life (like fatigue, pain and dyspnoea) can cause severe distress [2]. Relieving distress form 
these symptoms be achieved by treating the underlying cause or trigger, by symptomatic 
treatment (both with and without medication) and with supportive care. However, in some 
cases symptoms remain uncontrolled, in that case palliative sedation can be initiated to 
relieve distress by reducing consciousness. Previous research on the efficacy and safety of 
palliative sedation however showed that it can take up to 48 hours until adequate sedation 
is reached and in 17% of the cases symptoms remain uncontrolled [3]. As these patients 
are in severe distress it is of the greatest importance to improve these numbers. This high 
variability in response may be caused by the fact that the terminally ill population is very 
heterogeneous, with differences in co-morbidities, concomitant medication and disease 
severity. These differences can influence both pharmacokinetic (PK) and pharmacodynamic 
(PD) process. Which can result in variability in response between patients as well as within 
a single patient over time. The current guidelines on symptom management in palliative 
care however lack individualised dosing recommendations. Instead doses are often titrated 
according to their clinical effect. Such dose adjustments however take time and this is un-
wanted in the case of severe distress and a limited life expectancy. In order to improve clini-
cal care for these patients, individualised dosing regimens should be developed. A first step 
in this process is to expand our knowledge on pharmacokinetics and pharmacodynamics in 
terminally ill patients which we have done with the research presented in this thesis. 
In the first chapter, we explored the different factors that could affect drug efficiency and 
safety in palliative care patients. In this review, we focused mainly on how the pathophysi-
ological changes at the end of life, could affect drug concentrations. Looking at the four 
main processes in pharmacokinetics (i.e. absorption, distribution, metabolism and elimina-
tion) we found that terminal illnesses may influence each of these processes substantially. 
The whole process however is complex and the eventual impact on drug concentrations 
can differ both between patients (depending on their symptoms) and between drugs 
(depending on their chemical properties). It is therefore impossible to give a “one size fits all” 
recommendation and dosing strategies will have to be evaluated on a case by case basis. To 
provide the prescribers with more guidance we made recommendations on the three most 
prescribed drugs in palliative care, i.e. morphine, midazolam and haloperidol. However as 
pharmacokinetic studies in terminally ill patients are very limited these recommendations 
remained partly theoretical. 
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Another factor, besides pathophysiological changes, that may alter the efficacy and 
safety of drugs are drug-drug interactions. As terminally ill patients often suffer from several 
co-morbidities and may use multiple drugs for symptom management polypharmacy is 
common. As know from other studies that this increases the risk of (serious) drug-drug in-
teractions, we evaluated this risk in the palliative population in chapter two [4]. In the study 
presented here we did not solely evaluated the amount of drug-drug interactions but also 
focused on the clinical relevance of the interactions. As clinical relevance may be different in 
a palliative care setting compared to a general hospital (with less focus on the interactions 
that can cause damage in the long term), the relevance was assessed by an expert team 
instead of an automated scoring system. Our study showed that drug-drug interactions 
occurred in a third of the population and half of these interactions were regarded as clini-
cally relevant. We also found that the number of drugs used by a patient was a potential risk 
factor of drug-drug interactions (adjusted OR = 1.50, 95% CI = 1.24 – 1.82). Although not all 
interaction are clinically relevant in a palliative care setting, certain drug-drug interactions 
may still have serious consequences. As the number of drugs is a potential risk factor of 
interactions, unnecessary drugs should be stopped in the palliative setting.
As both pathophysiological changes and co-medication can cause alteration in drug 
concentration, we performed three population pharmacokinetic studies on morphine, 
midazolam and haloperidol. The use of population pharmacokinetics has three important 
advantages. Firstly, this method makes it possible to study pharmacokinetic parameters 
with only sparse sampling. This minimizes the burden for patients which is important in 
this fragile population. Secondly it allows us to not only estimate the average values for the 
pharmacokinetic parameters like clearance volume of distribution etc. but it also makes it 
possible to quantify the variability. Several covariates can be tested (e.g. disease character-
istics and co-medication) to examine their influence on the pharmacokinetic parameters. 
Based on these results, the amount of variability can be decreased by taking these covari-
ates into account. Finally, population pharmacokinetic modelling enables us to evaluate 
new dosing regimens by simulating concentration time curves for different circumstances, 
using the covariate effects found. 
In chapter 3 the population pharmacokinetic study on morphine in terminally ill pa-
tients is described. Morphine is used by over 80% of the terminally ill patients in the last 
days of life and is dosed according to the clinical response. Assessing pain may however 
be challenging in the final days of life when patients are unresponsive due to advanced 
illness or palliative sedation. In our study, we did not only look at the concentrations of 
morphine but also included the two major metabolites morphine-3-glucuronide (M3G) and 
morphine-6-glucuronide (M6G) in our analysis, as literature data support that they are active 
metabolites. The M6G metabolite has been shown to have analgesic properties [5-7]. While 
M3G on the other hand is being linked to the side effects seen with morphine use [8, 9]. Our 
study confirms the results of previous studies by showing that clearance of M3G and M6G is 
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reduced in patients with decreased renal function [10, 11]. Our study also showed that low 
albumin levels were also associated with decreased clearance of the glucuronide metabo-
lites. This may be due to the fact that hypoalbuminemia can be caused by a catabolic state 
or cachexia, and that in these severely ill patients eGFR is overestimated. Finally, this study 
revealed that morphine clearance decreases as a patient is closer to the time of death. This 
is an interesting finding that indicates that there may be another factor that is influencing 
the pharmacokinetics that is not detected with standard blood chemistry analysis. This may 
for instance be due to reduced liver blood flow. 
The current guideline on pain management mentions the fact that in the case of renal 
dysfunction (stated as an eGFR < 50 ml/min) morphine metabolites can accumulate. Based 
on the results from our study we hypothesize that it would be better to not only take eGFR 
as a measurement for renal function but to also include albumin levels as a risk factor for 
metabolite accumulation. It is however important to note that creatinine and albumin are 
not routinely measured in terminally ill patients, as this is seen as an unnecessary burden 
for the patient. These values may therefore be unknown and since morphine clearance 
reduces when a patient is closer to its time of death (which may also be difficult to predict) 
the eventual balance between morphine and metabolite concentrations may be difficult 
to predict. The current guideline does discriminate between the different opioids and 
morphine remains the most commonly used opioid probably due to physician preferences. 
However, given the outcome of our study, drugs without active metabolites, like fentanyl 
or oxycodone, should perhaps have a more prominent role in the treatment of pain in 
terminally ill patients.
The fourth chapter of this theses describes the pharmacokinetics of midazolam. As 
mentioned before there is a high degree of variability in response to midazolam [12, 13]. 
Currently it is dosed according to clinical response, this is however disadvantageous in the 
case of refractory symptoms as it may take a long time to achieve adequate relief [3]. As in 
the study of morphine, with this study we also incorporated the active metabolites of mid-
azolam i.e. 1-OH-midazolam (1-OH-M) and 1-OH-midazolam glucuronide (1-OH-MG) in our 
model. Similar to M3G and M6G the clearance of the glucuronide metabolite of midazolam 
was shown to be decreased in patients with renal dysfunction, which is in accordance with 
previous research [10]. In this study, we also found an effect of albumin on the pharmacoki-
netics, however not on the clearance of the glucuronidated metabolite but on midazolam 
itself. This is an interesting finding as low albumin levels were associated with decreased 
midazolam clearance. A possible explanation for this effect may be that hypoalbuminemia 
is related to an inflammatory response or catabolic state, which may result in a decreased 
activity of CYP3A, as seen in other studies [14, 15]. In the current guideline for palliative 
sedation hypoalbuminemia and renal dysfunction are already mentioned as risk factors for 
overdosing, as well as body weight of less than 60kg and hepatic impairment. In the case 
of any of these risk factors the guideline recommends a lower starting dose (0.5 to 1.5 mg/
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hour instead of 1.5-2.5 mg/hour) and a longer interval before the dose should be increased 
in the case of no effect (6-8 hours instead of at least 4 hours). Using our pharmacokinetic 
model, we simulated the plasma concentration that would be achieved with these dosing 
recommendations. 
In figure 1 the top row shows the total effective concentration (calculated as the mid-
azolam concentrations plus 0.8 times the 1-OH-M concentration and 0.1 times the 1-OH-
MG concentration) achieved by following the current guidelines for a patient with normal 
eGFR and albumin levels (albumin of 35 g/l and eGFR of 90 ml/min) in black as well as for 
a patient with decreased albumin levels (25g/L in dark blue and 15g/L in light blue) and 
for a patient with decreased renal function (eGFR of 50ml/min in dark green, 30 ml/min 
in medium green and 10 ml/min in light green). As the current guideline advises a 10mg 
starting dose followed by either 1.5 or 2.5 mg per hour via continuous infusion (with the 
ability to increase the dose with 50% after 4 hours combined with a 5mg bolus injection), 
we simulated concentrations for both the lower and upper range of this recommendation. 
The graph on the left depicts the lower range of the recommendations and the graph on 
the right the upper range. It can be seen that in a patient without low albumin or decreased 
renal function the concentration increases much faster (shown by the steep increase of the 
black curve) than for patients with low albumin or decreased renal function. To improve this, 
we suggest to only reduce the dose but not increase the dosing interval. Simulation of this 
recommendation are shown in the lower to graphs and it can be seen that this results in 
    





 






 



    





  
  
  
  
  
 






 



    





 






 



    





  
  
  
  
  
 






 



Figure 1. Simulated concentration time profiles of the current guideline (top row), and suggested individualised 
dosing regimens for patients with different albumin levels and renal function.
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a similarly steep increase in concentrations for patients with low albumin or reduced renal 
function compared to a “normal” patient.    
Since dosing recommendations cannot be made solely on pharmacokinetic data we also 
performed a study on the pharmacodynamics of midazolam, shown in chapter 4. In this 
study, the inter-individual variability of response to midazolam was high, with a wide range 
of sedation scores occurring at the same midazolam concentrations. Therefore, dose titra-
tion according to response seems logical. However, dose titration takes time and symptom 
relief is required as soon as possible in the case refractory symptoms. It would therefore be 
very useful if there was a way to identify patients who are at risk for under-dosing. Our results 
showed that co-medication with haloperidol was associated with a less sedative states. This 
is probably an effect of the delirium for which haloperidol is used.  The current guideline on 
palliative sedation only gives risk factors for overdosing (e.g. age > 60, and the use of co-
medication with sedative effects). It therefore does not mention delirium as an indication to 
increase midazolam dose. In fact, according to this guideline patients with haloperidol may 
even be given a lower dose than normal since haloperidol can be considered a drug with 
sedative effects. We therefore propose that patients with haloperidol, or agitated delirium 
should receive a higher dose of midazolam. 
The population pharmacodynamic model showed that a midazolam concentration of 
50 µg/L would give the typical patient without haloperidol use an 80% chance of adequate 
sedation, however as there is large inter-individual variability a target concentration of 200 
µg/L would be required to give 95% of the patients without haloperidol co-medication an 
80% chance of adequate sedation. With haloperidol as co-medication the target levels for 
the typical patient and 95% of the population would be even higher (80 µg/L and 600 µg/L 
respectively). 
Combining this with the knowledge of our PK model we performed some simulations of 
different dosing regimens. First we simulated a dosing regimen with the aim of achieving 
an 80% chance of adequate sedation (given by a Ramsay score of 3 or more) for 95% of 
the population. The results of this can be seen in figure 2. The far-right graph shows that a 
loading dose of 25 mg followed by a 10mg dose every 4 hours should result in an average 
plasma concentration of 200 µg/L for a patient with a plasma albumin level of 35 g/L. The 
middle and right graphs show that average plasma concentrations of 200 µg/L are reached 
by administering the same loading dose followed by 7 mg and 4 mg every 4 hours in the 
case of respective albumin levels of 25g/L and 15 g/L. To achieve a target concentrations of 
600 µg/L the dose would have to be tripled. Meaning a loading dose of 75 mg followed by 
30 mg every 4 hours for an albumin level of 35 g/L and 21mg and 12mg every 4 hours in the 
case of an albumin level of 25 or 15g/L respectively. 
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Figure 2. Simulated concentration time profiles of dosing regimens adjusted to plasma albumin levels.
Compared to the current guidelines, these dosing regimens are much higher, especially 
in the case of haloperidol co-medication. It should also be noted that by setting the target 
level for 95% of the population, a large part of the population will be overdosed. It may 
therefore be more desirable to develop a dosing regimen that is initially based on the typical 
patient, but with the option to escalate the dose quickly in case of inadequate response. We 
have therefore also developed a dosing regimens that aims for an initial concentration of 50 
µg/L (and 80 µg/L for patients with haloperidol use) and can reach the higher concentra-
tions of 200 µg/L (and 600 µg/L for patients with haloperidol use) within 16 hours. For a 
patient with an albumin level of 25 g/L and no concomitant haloperidol use this would 
mean a loading dose of 7.5 mg followed by 2 mg every 4 hours. Which is slightly lower 
than the current guideline. In the case of inadequate response increasing each additional 
dose with 50% combined with a bolus of 6 mg would ensure that the concentrations at 
which 95% of the population will have an 80% chance of adequate sedation will be reached 
within 12 hours. For patients with haloperidol use, a slightly higher initial dose of 10mg with 
3mg every 4 hours should result in an initial concentration of 80 µg/L. For these patients, 
doubling the additional dose (up to a maximum dose of 10mg) combined with an 8mg 
bolus in the case of inadequate response should ensure that a concentration of 600 µg/L is 
reached within 16 hours. 
From our pharmacokinetic and pharmacodynamic studies on midazolam we can con-
clude that patients who are treated with haloperidol should receive doses that are 25-33% 
higher than patients without haloperidol co-medication, and that the additional dose of a 
patient with an albumin level of 15g/L should be half of that of a patient with an albumin 
level of 25g/L (which in turn should be half of that of a patient with an albumin level of 
35g/L). As these suggestions are only based on simulations, a prospective study with these 
new dosing regimens is still needed. 
The fact that haloperidol was associated with a less sedative state in our pharmacody-
namic study on midazolam may indicate that haloperidol is not effective enough in reducing 
delirium and agitation. We therefore also looked at the pharmacokinetics of haloperidol in 
the terminally ill population. As described in chapter 5, this study showed that the terminal 
half-life of haloperidol is long (around 30 hours). The current guideline for delirium gives a 
dosing recommendation of 0.5-2 mg every half hour until an effect is reached. This recom-
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mendation seems adequate, since overdosing should be avoided especially because of its 
long terminal half-life. However, like with palliative sedation this dose titration takes time 
which is unwanted in a population with limited life expectancy. Unfortunately our study did 
not find any relevant covariates on which to adjust the initial dose. Therefore more research 
into the pharmacokinetics of haloperidol is necessary. However, making any recommenda-
tion based on pharmacokinetic information remains difficult as there is no target concentra-
tion available and the evidence for haloperidol in the treatment of (terminal) delirium in 
general is very sparse.
General conclusions and future PersPectives
With the studies described above we have gained more insight in the pharmacokinetics and 
pharmacodynamics in terminally ill patients. This is first step in the process to developing 
more evidenced based and individualised dosing guidelines. The research on midazolam for 
instance show that to achieve adequate sedation in a large proportion of the population the 
doses recommended should probably be higher, especially in agitated patients. However, 
before these recommendations can be incorporated in new guidelines the developed 
models will have to be externally validated in a new set of patients and a prospective study 
evaluating a new dosing algorithm should be performed. 
Nevertheless, our work has a first step in this process and has shown it is feasible to per-
form clinical studies in the palliative care population with minimal burden for the patients. 
We therefore hope that our work will generate more studies in terminally ill patients, as 
there are still many aspects that require investigation. First of all, the covariates tested in 
our studies e.g. blood chemistry levels provide insight in the underlying processes that can 
affect pharmacokinetics. However, measuring these parameters is not part of the regular 
clinical care, and recommendations based on these covariates may be of limited value in 
clinical practise. Furthermore, the study in morphine showed us that there are also factors 
influencing PK that may not be even detected by these blood chemistry tests. It would 
therefore be very interesting to see if other factors that are part of the regular care, and do 
not require blood sampling, may also be associated with pharmacokinetics. Fluid intake or 
urinary output may for instance serve as a proxy for clearance of drugs eliminated by the 
kidney. And although time of death remains difficult to predict there is a clinical pathway 
that is followed in clinical care when a patient has a life expectancy of days or hours, and 
the staff of a palliative care centre is well trained in estimating this life expectancy. It would 
therefore be very interesting to see if this moment can be used as a cut of point to possibly 
adjust medication. Investigating these kinds of covariates will also make it more easily to 
eventually incorporate them in dosing recommendations. There will probably always be 
unexplained variability in this heterogeneous population however by combining pharma-
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cokinetic aspects with the clinical knowledge of the palliative care staff we should be able 
to improve clinical care.
Other interesting aspects of future research may result from some of the limitations 
of our current studies. In the current research presented in this thesis we for instance 
lacked enough data to test pharmacogenetic factors as covariates. Since we know that 
pharmacogenetic polymorphisms can influence the metabolic capacity of CYP3A (by 
which midazolam is metabolised) and CYP2D6 (which also plays a role in the metabolism 
of haloperidol) more research including these polymorphisms is needed. Especially since 
pharmacogenetics do not change over time this could be of interest as patients would only 
need to be tested once, which can even be done before treatment is started. We also lacked 
data on weight for a substantial proportion of the patients, and if weight was recorded this 
was only done at the time of admission. In future research, it would be recommended to 
weigh patients more than once as in this population weight loss is very common and this 
may affect pharmacokinetics. One of the reasons weight was not recorded was that it may 
be emotionally difficult for patients to see their weight loss. A recommendation for future 
research may therefore be not to physically weigh each patient but to have their weight 
estimated by the nursing staff. To do this a pilot study will have to be performed first to see 
how accurate these estimations would be. The lack of data sometimes came from the sparse 
sampling method, which made it sometimes necessary to make assumptions based on 
literature. For all three pharmacokinetic studies, we lacked blood samples shortly after dose 
administration. As a result, it was not possible to estimate an absorption constant. A study 
that focuses on this absorption phase would be of clinical interest as it gives information 
about the onset of the effect which is highly relevant in the case of symptomatic treatment, 
and may differ between patients according to their gastro intestinal motility, or fat tissue in 
the case of subcutaneous administration. Also in the pharmacodynamics of midazolam it 
would be beneficial to perform a study with a more continuous measurement for sedation. 
This would also provide information on the onset of sedation. Furthermore, it might possibly 
also show an effect of disease severity on depth of sedation, as this effect (represented in 
the form of hypoalbuminemia or measured retrospectively from the time of death) did not 
meet our criteria of statistical significance in the study but did show a trend.
Another important recommendation for future research would be a pharmacodynamic 
study on haloperidol for the treatment of delirium. As mentioned before evidence on the 
efficacy of haloperidol in delirium is lacking. It would therefore be interesting to combine 
our pharmacokinetic results with a pharmacodynamic measurement. Also, a study on the 
efficacy of haloperidol and possibly other psychotic drugs that are used for this indication 
(e.g. clozapine, olanzapine risperidone and quetiapine) in delirium would be of great clinical 
interest. This would not only be of value for palliative care but also for other populations, 
like elderly and critically ill patients in hospital.  Finally, our study in midazolam showed that 
inflammation may have an effect on the metabolic capacity of CYP3A. This is an interest-
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ing finding more than half of the drugs are metabolised by CYP3A and inflammation is 
also common in other diseases. Therefore, more research on the effect of inflammation on 
pharmacokinetics in general and CYP3A in particular is needed. 
All further research needs financial support and in the beginning of our studies we 
observed that this was difficult to obtain for studies in palliative care. This may be due to 
a number of causes. For instance, pharmaceutical industries may be unwilling to support 
studies as the population is fragile and the drugs that are generally used have been on the 
market for a long time. Funding from the private sector proved difficult to obtain as ques-
tions were raised about the feasibility and ethical aspects. Our studies have showed that it is 
feasible to preform research in this population. And by using population based approaches 
the burden for patients is minimal. Furthermore, we found that although it is indeed a fragile 
population, the willingness to participate in research was high and patients were capable 
of making a well-informed decision on whether or not to participate. Of course, there is an 
important task for medical ethical committees to assure that fragile patients are not subject 
to unnecessary invasive research. However, it is important to keep in mind that participating 
in academic research may also give a sense of purpose to patients and to respect their 
autonomy in making this decision. We therefore hope that our studies not only provide 
more insight the changes in pharmacokinetics and pharmacodynamics in the final months 
of life, but also help to gain more awareness for palliative care as a research field. 
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samenvattinG en discussie 
In Nederland, ontvangen jaarlijks 108.500 terminaal zieke patiënten palliatieve zorg [1]. 
Wanneer een curatieve behandeling (geleidelijk) overgaat in palliatieve zorg zal de focus 
verschuiven van genezing naar symptoombestrijding, om op deze manier te zorgen voor de 
best mogelijke de kwaliteit van leven in de laatste dagen. Adequate symptoombestrijding 
is hierbij cruciaal omdat de symptomen waaraan men in het laatste levensjaar lijdt, zoals 
vermoeidheid, pijn en dyspneu, het leven aanzienlijk kunnen verzwaren [2]. Om dit lijden 
te verlichten kan men proberen de oorzaak weg te nemen, de bestaande symptomen 
behandelen (al of niet met behulp van medicatie) of ondersteunende zorg bieden. Helaas 
zijn er gevallen waarbij ondanks deze interventies het lijden ondragelijk blijft. In dergelijke 
situaties kan palliatieve sedatie worden ingezet. Hiermee wordt het lijden van de patiënt 
verlicht door het bewustzijn te verminderen. Eerder onderzoek naar de effectiviteit en 
veiligheid van palliatieve sedatie liet ziet dat het tot 48 uur kan duren voordat adequate 
sedatie wordt bereikt, en dat in 17% van de gevallen de symptomen onvoldoende onder 
controle blijven [3]. Gezien de ondragelijke toestand voor de patiënten is het essentieel om 
deze therapie te verbeteren. De grote variabiliteit die bij palliatieve sedatie gezien wordt, 
wordt mogelijk veroorzaakt door het feit dat de palliatieve populatie zeer heterogeen is. Zo 
verschillen hebben de patiënten verschillende co-morbiditeiten, gebruiken zij verschillende 
typen medicatie en zal er ook een verschil zitten in hun mate van ziekte op het moment dat 
palliatieve sedatie wordt gestart. Deze verschillen kunnen ervoor zorgen dat patiënten bij 
eenzelfde dosis andere concentraties van het geneesmiddel in het lichaam zullen hebben 
(een verschil in farmacokinetiek). Ook kan het zijn dat er bij dezelfde concentraties van een 
geneesmiddel bij patiënten verschillende effecten op treden (een verschil in farmacodyna-
miek). Deze verschillen in farmacokinetiek en farmacodynamiek kunnen resulteren in een 
variabele respons tussen patiënten alsmede een variatie in respons binnen één patiënt over 
de tijd. Ondanks deze verschillen zijn in de huidige richtlijnen voor symptoombestrijding 
geen geïndividualiseerde doseerregimes terug te vinden. In plaats daarvan wordt de dosis 
veelal gestuurd op geleide van het klinisch effect. Een groot nadeel van dergelijke dosis 
titratie is dat het tijd kost en dit is nadelig voor patiënten met ondragelijk lijden en een 
zeer beperkte levensverwachting. Meer geïndividualiseerde doseerrichtlijnen zijn dan ook 
nodig om de klinische zorg voor deze patiënten te verbeteren. Om dit te bereiken is een 
belangrijke eerste stap, het in kaart brengen van de farmacokinetische en farmacodynami-
sche processen in deze populatie. Dit is dan ook waar de onderzoeken in dit proefschrift op 
gericht zijn. 
In het eerste hoofdstuk hebben we onderzocht welke factoren van invloed kunnen zijn 
op de effectiviteit en veiligheid van geneesmiddelen bij palliatieve patiënten. In dit review 
focussen we ons voornamelijk op de pathofysiologische veranderingen die optreden aan 
het eind van het leven en hoe deze de concentratie van geneesmiddelen in het lichaam 
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kunnen beïnvloeden. Kijkend naar de vier algemene farmacokinetische principes (te weten: 
absorptie, distributie, metabolisme en eliminatie) zagen we dat elk van deze processen sub-
stantieel beïnvloed kan worden door het ziekteproces. De uiteindelijke invloed van de ziekte 
op de geneesmiddelconcentraties is echter lastig te voorspellen en kan sterk verschillen, 
zowel tussen patiënten (afhankelijk van hun co-morbiditeiten) als tussen geneesmiddelen 
(afhankelijk van hun chemische eigenschappen). Dit maakt het geheel complex en het is 
dan ook onmogelijk een eenduidig advies te geven wat geldt voor alle geneesmiddelen 
in deze populatie. In plaats daarvan zal de dosering per individueel geval bekeken moeten 
worden. Om behandelaars meer handvaten te bieden bij het voorschrijven van geneesmid-
delen aan palliatieve patiënten, hebben we in dit review een aantal aanbevelingen gedaan 
voor de meest gebruikte geneesmiddelen in de palliatieve zorg, d.w.z. morfine, midazolam 
en haloperidol. Omdat farmacokinetische studies in palliatieve patiënten erg schaars zijn, 
is het belangrijk op te merken dat de genoemde aanbevelingen vooral gebaseerd zijn op 
theoretische gronden. 
Naast pathofysiologische veranderingen kunnen ook interacties tussen geneesmid-
delen de effectiviteit en veiligheid ervan beïnvloeden. Doordat palliatieve patiënten vaak 
meerdere co-morbiditeiten hebben en verschillende geneesmiddelen gebruiken voor 
symptoombestrijding, is polyfarmacie niet ongebruikelijk. We weten van studies in andere 
populaties dat polyfarmacie het risico op geneesmiddelinteracties verhoogt [4]. Daarom 
hebben we in hoofdstuk 2 het risico op geneesmiddelinteracties en de gevolgen hiervan 
bij palliatieve patiënten geëvalueerd. In deze studie is niet alleen gekeken naar het aantal 
geneesmiddel interacties dat voor kwam maar is tevens de klinische relevantie beoordeeld. 
De klinische relevantie in een palliatieve setting kan verschillen van de klinische setting, 
waarbij in de palliatieve setting interactie de focus minder op de lange termijn gevolgen 
ligt. In onze studie is de relevantie daarom gescoord door een team van experts in plaats 
van door een automatisch scoring systeem. Uit deze studie bleek dat bij een derde van de 
patiënten een geneesmiddel interactie optrad en de helft hiervan werd als klinisch relevant 
beschouwd. Daarnaast bleek dat het aantal geneesmiddelen dat een patiënt gebruikt een 
risico factor was voor het voorkomen van geneesmiddel interacties (aangepaste OR = 1.50, 
95% CI = 1.24-1.82). Doordat de palliatieve setting verschilt van die in het ziekenhuis zijn niet 
alle geneesmiddel-interacties relevant. Desalniettemin zijn er nog steeds interacties die wel 
serieuze gevolgen kunnen hebben voor de patiënt, omdat het risico op een interactie toe-
neemt met het geneesmiddelengebruik is het belangrijk de medicatie kritisch te evalueren, 
en waar nodig te switchen of middelen te saneren. 
Omdat zowel pathofysiologische veranderingen als interacties tussen geneesmiddelen 
de uiteindelijke concentraties van een geneesmiddel in het bloed kunnen veranderen, heb-
ben we van de drie meest gebruikte middelen (morfine, midazolam en haloperidol) een 
populatie farmacokinetiek studie uitgevoerd. Het gebruik van populatie farmacokinetiek 
heeft een aantal belangrijke voordelen. Ten eerste maakt deze methode het mogelijk om 
165
Nederlandse Samenvatting
9
de kinetiek van een middel te bestuderen met slechts enkele bloedmonsters per patiënt. 
Hierdoor is de belasting voor patiënten minimaal, wat een belangrijke voorwaarde is voor 
het doen van onderzoek bij een dergelijk kwetsbare populatie. Een tweede voordeel is dat 
met behulp van deze methode niet alleen gemiddelde waardes voor parameters zoals kla-
ring en verdelingsvolume kunnen worden geschat, maar dat ook de mate van variabiliteit 
gekwantificeerd kan worden. Hiermee kan door middel van een covariaat analyse vervol-
gens gekeken worden welke factoren (zoals patiënteigenschappen of comedicatie) van 
invloed zijn op de kinetiek. En vervolgens kan bekeken worden of door rekening te houden 
met deze factoren de variabiliteit verminderd kan worden. Tot slot maakt modeleren met 
populatie farmacokinetiek het mogelijk om nieuwe doseerregimes te simuleren. Zo kan er 
gesimuleerd worden wat voor concentraties men bereikt met een nieuw geïndividualiseerd 
doseer regime, op basis van de gevonden covariaten. 
In hoofdstuk 3 wordt de populatie farmacokinetische studie naar morfine bij palliatieve 
patiënten beschreven. 80% van de palliatieve patiënten gebruikt morfine de laatste dagen 
van hun leven. Het doseren gebeurt veelal op geleide van het klinisch beeld. Echter kan het 
inschatten van pijn in de laatste levensdagen lastig zijn. Zo kan het vermogen van patiënten 
om zich te uiten sterk verminderd zijn door hun vanwege hun vergevorderd ziekte, of door 
de inzet van palliatieve sedatie. In onze studie is niet alleen gekeken naar de concentraties 
van morfine zelf maar zijn ook de twee belangrijkste metabolieten, morfine-3-glucuronide 
(M3G) en morfine-6-glucuronide (M6G) meegenomen in de analyse. Deze twee afbraak-
producten van morfine zijn mee geanalyseerd omdat er uit de literatuur bekend is dat het 
actieve metabolieten zijn. Van M6G is het bekend dat het net als morfine een analgetische 
werking heeft [5-7]. De M3G metaboliet daarentegen wordt juist geassocieerd met de 
bijwerkingen van morfine worden [8, 9]. Onze studie bevestigde de resultaten van eerder 
studies door aan te tonen dat de klaring van M3G en M6G verminderd is in patiënten met 
een verminderd nierfunctie [9, 10]. Daarnaast liet onze studie een associatie zien tussen lage 
albumine waardes en een verminderde klaring van de metabolieten. Dit zou kunnen komen 
doordat hypoalbuminemie vaak samenhangt met cachexie of een katabole toestand, en 
in dergelijk zieke patiënten kan de nierfunctie (zoals berekend met de MDRD formule) een 
overschatting zijn. Tot slot liet onze studie zien dat de klaring van morfine afnam naarmate 
patiënten dichter bij het tijdstip van overlijden kwamen. Dit is een interessante bevinden en 
dit laat zien dat er waarschijnlijk nog een factor is die niet te beschrijven is met de standaard 
klinisch chemische test maar die wel de farmacokinetiek kan beïnvloeden. Een verminde-
ring van de leverdoorbloeding is een factor die hier aan ten grondslag zou kunnen liggen. 
In de huidige richtlijnen voor pijnbestrijding in de palliatieve fase, wordt reeds vermeld 
dat bij een verminderd nierfunctie (gedefinieerd als een eGFR < 50ml/min) morfine 
metabolieten kunnen accumuleren. Op basis van onze resultaten kunnen we stellen dat 
het beter is om niet enkel de eGFR als maat voor nierfunctie te nemen maar om ook de 
albumine waarden als risico factor mee te nemen. Het is echter wel belangrijk om op te mer-
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ken dat creatinine (die nodig zijn voor de berekening van de eGFR) en albumine waardes 
niet standaard worden bepaald bij palliatieve patiënten, en dat de bloedafname hiervoor 
als een onnodige belasting kan worden gezien. Deze waardes zijn daarom in de klinische 
praktijk mogelijk niet bekend. Aangezien ook de morfine klaring afneemt wanneer patiën-
ten dichter bij het moment van overlijden zijn (wat weer voor lagere metaboliet spiegels 
zorgt), is de uiteindelijke balans tussen morfine en de metabolieten moeilijk te voorspellen. 
Bovendien is het uiteraard lastig te voorspellen wanneer een patiënt exact zal komen te 
overlijden. De huidige richtlijnen maken nu geen onderscheid tussen de verschillende 
opioïden die ingezet kunnen worden voor pijnbestrijding. En morfine blijft vanwege de 
uitgebreide ervaring ermee, het meest gebruikte middel. Uit bovenstaande resultaten kan 
echter geconcludeerd worden dat een opioïd zonder actieve metabolieten, zoals fentanyl 
of oxycodon, wellicht een meer prominente rol zou moeten krijgen in de behandeling van 
pijn bij terminale patiënten. 
Het vierde hoofdstuk van deze thesis beschrijft de farmacokinetiek van midazolam. De 
reactie van patiënten op midazolam is, zoals reeds gezegd, in grote mate variabel [11, 12]. 
Ook midazolam wordt gedoseerd op geleide van effect, wat als nadeel heeft dat het tijd 
kost. Dit is ongewenst bij de refractaire symptomen waarvoor het wordt ingezet omdat 
het hierdoor lang kan duren voordat er symptoomverlichting wordt bereikt [3]. Ook bij 
deze studie zijn de concentraties van de metabolieten, d.w.z. 1-OH-midazolam (1-OH-M) en 
1-OH-midazolam glucuronide (1-OH-MG), meegenomen. Uit onze resultaten bleek dat net 
als bij de morfine metabolieten ook de klaring van 1-OH-MG afnam bij patiënten met een 
verminderde nierfunctie, wat overeenkomt met eerder onderzoek [13]. Daarnaast zagen we 
ook in deze farmacokinetiek studie een correlatie met albumine, echter dit maal niet met 
betrekking op de klaring van de metaboliet maar op de klaring van midazolam zelf. Het feit 
dat lage albuminewaardes geassocieerd waren met een verminderde midazolam klaring is 
een interessante bevinden. Een mogelijke verklaring hiervoor is dat hypoalbuminemie het 
gevolg kan zijn van een inflammatoire reactie of katabole toestand, wat mogelijk leidt tot 
een verminderde activiteit van het CYP3A enzym wat betrokken is bij het metabolisme van 
midazolam [14, 15]. In de huidige richtlijn voor palliatieve sedatie worden zowel hypoal-
buminemie als renale dysfunctie genoemd als mogelijke risicofactoren voor overdosering 
(samen met een gewicht van minder dan 60kg en hepatische dysfunctie). In het geval 
van dergelijke risicofactoren wordt een lagere startdosering (0,5 tot 1,5 mg/uur i.p.v. 1,5 
tot 2,5 mg/uur) geadviseerd alsmede een langer interval (6 tot 8 uur i.p.v. 4 uur) tot dosis 
ophoging in het geval van onvoldoende klinisch effect. Met het farmacokinetisch model uit 
onze studie hebben we de concentraties men bereikt worden op basis van deze richtlijnen 
gesimuleerd. 
In figuur 1 geven de bovenste twee grafieken de totale effectieve concentratie weer 
(berekend als de midazolam concentratie plus 0,8 maal de 1-OH-M concentratie en 0,1 maal 
de 1-OH-MG concentratie) wanneer er gedoseerd wordt volgens de geldende richtlijnen. 
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In deze grafiek zijn in het zwart de gesimuleerde concentraties te zien voor een patiënt 
met een normale nierfunctie en albumine waardes (eGFR 90 ml/min en albumine 35 g/l)/ 
Daarnaast zijn ook de concentraties voor een patiënt met verminderde albumine waardes ( 
25g/l in donkerblauw en 15g/l in lichtblauw) en een patiënt met verminderde nierfunctie ( 
eGFR van 50ml/min in donkergroen, 30ml/min in groen en 10ml/min in lichtgroen) te zien. 
De huidige richtlijn adviseert een startdosering van 10mg en geeft vervolgens een range 
van 1,5 tot 2,5 mg per uur via continue infusie (met de mogelijkheid om de dosering elke 4 
uur met 50% te verhogen in combinatie met een 5mg bolus injectie). Omdat er een range 
wordt gegeven hebben we simulaties gemaakt voor zowel de hoogste als laagste doserin-
gen hierin (met in figuur 1 links de lage en rechts de hoge dosering). In deze simulaties valt 
te zien dat bij een patiënt met normale nierfunctie en albumine waardes, de concentratie 
veel sneller stijgt dan bij de andere patiënten. Om dit te verbeteren hebben we een alter-
natief doseerregime opgesteld waarin enkel de keerdosis wordt verlaagd maar het interval 
niet wordt verlengt. Deze simulaties zijn weergegeven in de onderste twee grafieken. Hier 
valt te zien dat met deze aanpassing de curves van de patiënten met verminder nierfunctie 
of albumine waardes even hard stijgen als die van een “normale” patiënt. 
Aangezien een doseeradvies niet enkel gebaseerd kan worden op farmacokinetische 
studies hebben we tevens een studie uitgevoerd naar de farmacodynamiek van midazolam, 
    





 






 


    





  
  
  
  
  
 






 


    





 






 


    





  
  
  
  
  
 






 


Figuur 1. Gesimuleerde concentratie tijd curves van de huidige richtlijn (bovenste rij), en voorgestelde geïndi-
vidualiseerde doseer regimes voor patiënten met verschillende albumine waardes en nierfunctie. 
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te lezen in hoofdstuk 4. Deze studie liet een hoge interindividuele variabiliteit in effect zien, 
met een grote variatie in sedatie scores bij dezelfde midazolam concentraties. Doseren op 
geleide van effect lijkt dan ook logisch. Zoals reeds gezegd kost een dergelijke dosistitratie 
echter tijd en aangezien symptoomverlichting zo snel mogelijk dient te worden bereikt is 
dit niet gewenst. Het zou daarom nuttig zijn als er een manier was om patiënten met een 
verminderde respons op midazolam van te voren te identificeren. Een van de belangrijkste 
resultaten van onze studie was dan ook dat 
comedicatie met haloperidol geassocieerd was met een lagere kans op diepe sedatie. 
Dit is waarschijnlijk niet een effect van de haloperidol zelf maar van het delier of de onrust 
waarvoor haloperidol wordt gebruikt. In de huidige richtlijn worden geen risicofactoren 
gegeven voor onderdosering maar worden enkel enkel risicofactoren voor overdosering 
gegeven (namelijk leeftijd > 60 en het gebruik van comedicatie met een sederend effect).
Delier wordt dan ook niet als reden genoemd om de midazolam dosering te verhogen. 
In tegendeel, doordat haloperidol gezien kan worden als geneesmiddel met een sederende 
werking zou volgens de geldende richtlijn zelfs met een lagere dosering midazolam kun-
nen worden gestart. Op basis van onze resultaten zouden we dan ook willen adviseren 
patiënten met haloperidol, of een geagiteerd delier, een hogere startdosis midazolam voor 
te schrijven. 
Het farmacodynamisch model liet zijn dat bij een midazolam concentratie van 50 µg/l de 
gemiddelde patiënt zonder haloperidol gebruik een 80% kans heeft op adequate sedatie 
(gedefinieerd als een Ramsay-score van 3 of meer). Door de grote variabiliteit is echter een 
streefspiegel van 200 µg/l nodig om deze zelfde kans te garanderen voor 95% van deze 
populatie. Voor patiënten met haloperidol gebruik liggen deze streefconcentraties hoger. 
Voor de gemiddelde patiënt is hier een midazolam concentratie van 80 µg/l nodig om een 
80% kans op adequate sedatie te bereiken en om dit te bereiken bij 95% van de populatie is 
zelfs een concentratie van 600 µg/l nodig. 
De resultaten van onze farmacokinetiek en farmacodynamiek studies combinerend, heb-
ben we een aantal doseerregimes gesimuleerd. Allereerst hebben we een simulatie gemaakt 
waarbij het streven een 80% kans op adequate sedatie voor 95% van de populatie was. Deze 
resultaten zijn te zien in figuur 2. In de meest linker figuur laat de onderste lijn zien dat een 
regime met een oplaaddosis van 25 mg gevolgd door 10mg elke 4 uur bij een patiënt met 
een albumine waarde van 35 g/l leidt tot de gewenste plasmaconcentraties van 200 µg/l. 
De onderste lijn in de middelste en rechter grafiek laten zien dat deze plasmaconcentratie 
van 200 µg/l bij patiënten met een albumine waarde van 25 en 15 g/l worden bereikt door 
de dezelfde startdosering gevolgd door een onderhoudsdosis van respectievelijk 7 en 4 mg 
elke 4 uur. Om de hogere concentraties van 600 µg/l te bereiken (wat nodig is om 95% van 
de haloperidol gebruikers een 80% kans op adequate sedatie te geven) is het noodzakelijk 
de dosering te verdrievoudigen. Dit komt neer op een oplaaddosis van 75 mg gevolgd door 
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30 mg elke 4 uur bij een albumine waarde van 35 g/l en 21 en 12 mg elke 4 uur bij albumine 
waardes van respectievelijk 25 en 15g/l.
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Figuur 2. Gesimuleerde concentratie tijd curves van doseerregimes aangepast aan de albumine waardes. 
Deze doseringen liggen hoger dan de huidige richtlijn, met name in het geval van ha-
loperidol gebruik. Het is daarom belangrijk om op te merken dat het streven naar een ade-
quate sedatie voor 95% van de populatie, een overdosering in een groot gedeelte van de 
patiënten tot gevolg zal hebben. Het zou dan ook beter zijn een doseerrichtlijn op te stellen 
waarbij initieel wordt uitgegaan van de gemiddelde patiënt, maar met de mogelijkheid om 
snel op te hogen in geval van onvoldoende respons. Hiervoor hebben we doseerregimes 
gesimuleerd met als initiële streefwaarde 50 µg/l (en 80 µg/l voor patiënten met haloperidol 
als comedicatie) die vervolgens binnen 16 uur op kan lopen tot de hogere concentratie van 
200 µg/l (en 600 µg/l voor patiënten met haloperidol als comedicatie). Voor een patiënt met 
een albumine waarde van 25g/l zonder haloperidol gebruik komt dit neer op een oplaad-
dosis van 7,5 mg gevolgd door 2mg elke 4 uur. Dit is iets lager dan de huidige richtlijn, maar 
door de mogelijkheid te bieden de onderhoudsdosering met 50% te verhogen i.c.m. een 
bolus van 6mg zal binnen 12 uur de concentratie van 200 µg/l worden bereikt waarbij 95% 
van de populatie 80% kans op adequate sedatie heeft. Voor patiënten met haloperidol ge-
bruik (en albumine waardes van 25 g/l) is een iets hogere dosering nodig van 10mg gevolgd 
door 3mg elke 4uur om te resulteren in een initiële midazolam concentratie van 80 µg/ll. Bij 
deze patiënten zal het verdubbelen van de onderhoudsdosering (met een maximum dosis 
van 10mg) in combinatie met een 8mg bolus ervoor zorgen dat de concentratie van 600 
µg/l binnen 16 uur wordt bereikt. 
Uit onze farmacokinetiek en farmacodynamiek studies naar midazolam kunnen we con-
cluderen dat patiënten die haloperidol als comedicatie gebruiken een 25-33% hogere dosis 
nodig hebben dan patiënten zonder haloperidol. Bovendien zal de onderhoudsdosering 
van een patiënt met een albumine spiegel van 15 g/l de helft moeten zijn van die van een 
patiënt met een albumine spiegel van 25 g/l (die op zijn beurt weer de helft dient te zijn van 
die van een patiënt met een albumine spiegel van 35 g/l). Aangezien deze aanbevelingen 
enkel gebaseerd zijn op simulaties is eerst nog een prospectieve studie naar deze doseer-
regimes nodig alvorens deze geïmplementeerd kunnen worden in de dagelijkse praktijk. 
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Het feit dat haloperidol geassocieerd was met een mindere mate van sedatie bij dezelfde 
concentraties midazolam, impliceert dat haloperidol wellicht niet effectief genoeg is in 
het behandelen van delier en agitatie in de palliatieve fase. Om meer inzicht te krijgen in 
de farmacokinetiek van haloperidol hebben we ook hiernaar een studie uitgevoerd. Zoals 
beschreven in hoofdstuk 5, laat deze studie zien dat haloperidol een lange halfwaardetijd 
heeft van ongeveer 30 uur. De huidige richtlijn voor delier beveelt een dosering van 0,5 tot 2 
mg haloperidol aan elke 30 minuten totdat het gewenste effect wordt bereikt. Deze aanbe-
veling lijkt adequaat aangezien een te hoge startdosis zou kunnen lijden tot overdosering, 
wat vervolgens lang aan kan houden. 
Echter geldt ook hier dat het titreren van de dosis op geleide van klinisch effect tijd kost 
en ongewenst is bij patiënten met een korte levensverwachting. Helaas heeft ons onder-
zoek geen relevante covariaten aan kunnen tonen op basis waarvan de haloperidol dosis 
geïndividualiseerd kan worden. Meer onderzoek is dan ook nodig naar de farmacokinetiek 
van haloperidol. Bovendien is het lastig aanbevelingen te geven op basis van elke farma-
cokinetische informatie aangezien er geen streefwaarde bekend zijn. Daarbij is het bewijs 
voor de effectiviteit van haloperidol voor de behandeling van (terminaal) delier überhaupt 
niet onomstreden. 
alGemene conclusie en aanBevelinGen
Met de hierboven genoemde studies hebben we meer inzicht gekregen in zowel de 
farmacokinetiek als de farmacodynamiek bij palliatieve patiënten. Dit is een belangrijke 
eerste stap op weg naar meer evidence-based en geïndividualiseerde richtlijnen. Zo liet 
het onderzoek naar midazolam bijvoorbeeld zien dat om adequate sedatie te bereiken een 
groot deel van de patiënten (met name de geagiteerde patiënten) een hogere dosis zou 
moeten krijgen. Echter voordat dit soort aanbevelingen in de richtlijnen kunnen worden 
opgenomen zullen de modellen eerst extern gevalideerd dienen te worden en is tevens een 
prospectieve studie naar het effect van het nieuwe doseeralgoritme nodig.
Desondanks, is dit werk een eerste stap in deze richting en bovendien heeft het laten 
zien dat het mogelijk is om klinische studies bij palliatieve patiënten uit te voeren met een 
minimale belasting voor de patiënten. Ik hoop dan ook dat dit werk ervoor zal zorgen dat 
er meer onderzoek in terminale patiënten zal worden uitgevoerd, aangezien er nog veel 
onderzoeksvragen liggen. Zo zou het bijvoorbeeld interessant zijn om te kijken naar andere 
voorspellende covariaten dan nu in deze onderzoeken zijn meegenomen. De klinisch che-
mische paramaters die wij in ons onderzoek gebruikt hebben, geven namelijk wel inzicht in 
de onderliggende processen maar worden in de klinische praktijk niet standaard gemeten, 
en zijn daardoor lastiger te implementeren in nieuwe richtlijnen. Bovendien liet ons onder-
zoek naar morfine zien dat er naast deze klinisch chemische waardes wellicht nog andere 
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factoren zijn die de farmacokinetiek beïnvloeden. Het zou dan ook erg interessant zijn om 
te kijken of factoren die wel routine matig worden beoordeeld, en niet afhankelijk zijn van 
bloedafnames, ook een relatie hebben met de farmacokinetiek. Vochtinname en urinepro-
ductie zouden bijvoorbeeld een maat kunnen zijn voor de eliminatie van geneesmiddelen 
met een renale klaring. En ondanks dat de exacte levensverwachting lastig te voorspellen is, 
is er wel een redelijk goed gedefinieerd moment in het palliatieve traject waar de stervens-
fase start. Op dit moment wordt in de praktijk het zorgpad stervensfase gestart. Het zou dan 
ook interessant zijn om te onderzoeken of dit moment gebruikt kan worden als punt om de 
medicatie aan te passen (en bijvoorbeeld de morfine dosis te verlagen). Dergelijk onderzoek 
naar andere typen covariaten maken het ook haalbaarder om uiteindelijk doseeralgoritmes 
te implementeren in de klinische praktijk. Er zal altijd onverklaarbare variabiliteit blijven 
bestaan in de heterogene palliatieve populatie, maar door het integreren van farmacokine-
tische kennis met de praktijk ervaring van de behandelaars moet het mogelijk zijn om de 
zorg voor deze patiënten te verbeteren. 
Andere interessante mogelijkheden voor verder onderzoek komen voort uit de tekort-
komingen van de huidige studies. In de genoemde studies ontbrak het bijvoorbeeld aan 
voldoende farmacogentische data om de invloed hiervan te testen. Omdat we weten dat 
genetische polymorfismen van invloed kunnen zijn op de metabole capaciteit van CYP3A 
(wat verantwoordelijk is voor de omzetting van midazolam) en CYP2D6 (wat een rol speelt 
bij het metabolisme van haloperidol) zou meer onderzoek naar effect hiervan nuttig zijn. 
Vooral omdat, in tegenstelling tot alle pathofysiologische veranderingen, de farmacoge-
netica niet veranderen over de tijd. Hiervoor zou dus een eenmalige test volstaan en dit 
zou ook al voorafgaand aan het starten van een therapie kunnen gebeuren. Een andere 
tekortkoming in onze studies was dat voor veel patiënten gegevens over hun gewicht 
ontbraken, en als het al was vastgelegd was dit slechts enkel genoteerd bij opname. Voor 
toekomstig onderzoek is het sterk aan te bevelen de gewichten van patiënten regelmatiger 
te noteren, aangezien gewicht vaak van invloed is op de kinetiek van geneesmiddelen en 
het bekend is dat patiënten veel gewicht kunnen verliezen in de laatste levensfase. Een van 
de redenen dat gegevens over het gewicht vaak ontbraken was dat men het te belastend 
vond voor de patiënten om hen regelmatig te wegen. Een mogelijke oplossing voor toe-
komstig onderzoek zou dan ook zijn om patiënten niet te wegen maar de verpleging een 
inschatting van het gewicht te laten maken. Om na te gaan hoe accuraat dit te schatten is 
zou eerst een pilot studie uitgevoerd kunnen worden. 
Bij de uitgevoerde studies was het door het spaarzaam verzamelen van bloed monsters, 
soms nodig aannames te doen op basis van bekende literatuur. Zo ontbrak het in alle drie 
de farmacokinetische studies aan bloedafnames kort na toediening van het geneesmiddel. 
Hierdoor was niet mogelijk een absorptie constante te bepalen. Een studie die focust op de 
opnamesnelheid interessant zijn omdat het inzicht kan geven in de snelheid waarmee de 
maximale concentratie wordt bereikt. Voor de palliatieve populatie zal dit klinisch relevant 
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zijn omdat het in veel gevallen belangrijk is zo snel mogelijk effect te bereiken en omdat 
er redenen zijn om aan te nemen dat de absorptie bij deze patiënten anders is dan bij 
andere populaties, bijvoorbeeld door een verminderd maaglediging bij orale toedieningen 
en minder onderhuids vetweefsel bij subcutane toepassingen. Ook in het farmacodynamiek 
onderzoek naar het effect van midazolam zou het interessant zijn om meer te focussen 
op de snelheid in het optreden van het effect. Om dit optimaal te kunnen beschrijven zal 
een studie met een continue sedatie meting nodig zijn. Daarnaast is het met een dergelijk 
onderzoek wellicht mogelijk om tevens een effect van het ziekteproces op de mate van 
sedatie te beschrijven. Een dergelijk effect (weergegeven door hypoalbuminemie of retro-
spectief berekend aan de hand van het tijdstip van overlijden) liet in onze farmacodynamiek 
studie namelijk wel een trend zien maar er was te weinig data om dit statistisch significant 
aan te tonen. 
Een andere belangrijke aanbeveling is het uitvoeren van een farmacodynamische studie 
naar haloperidol bij de behandeling van terminaal delier. Zoals eerder gezegd is er nog on-
voldoende bewijs naar de effectiviteit van haloperidol bij deze toepassing. Het verdient dan 
ook de aanbeveling om de resultaten uit onze farmacokinetiek studie te combineren met 
een farmacodynamische parameter om hier meer inzicht in te krijgen. Ook een klinische trial 
naar de effectiviteit van haloperidol en andere antipsychotica (zoals clozapine, olanzapine, 
risperidon of quetiapine) bij (terminaal) delier zou zeker van klinische waarde zijn. Dit kan 
namelijk niet alleen van waarde zijn voor de palliatieve populatie maar ook voor ouderen 
en kritische zieke patiënten in het ziekenhuis. Tot slot liet onze studie naar midazolam zien 
dat inflammatie mogelijk resulteert in een verminderde metabole capaciteit van het CYP3A 
enzym. Dit is een belangrijke bevinding aangezien de helft van alle geneesmiddelen door 
dit enzym wordt omgezet. Meer onderzoek naar het effect van inflammatie op de farma-
cokinetiek in zijn algemeenheid, en op het CYP3A metabolisme specifiek, is dan ook nodig. 
Voor alle toekomstige onderzoeken kunnen is financiële ondersteuning essentieel, en 
in het begin van dit project is gebleken dat het financieren van onderzoek in de palliatieve 
setting lastig is. Dit kan een aantal redenen hebben. Zo is er weinig incentive vanuit de 
farmaceutische industrie om onderzoek in deze kwetsbare populatie uit te voeren, ook 
omdat de middelen die gebruikt worden al lange tijd op de markt zijn. Daarnaast bleek ook 
financiering met private gelden lastig omdat men bedenkingen had bij de haalbaarheid en 
ethische aspecten. Onze onderzoeken hebben laten zien dat het wel degelijk haalbaar is om 
met populatie farmacologie onderzoek uit te voeren met een minimale belasting voor de 
patiënten. Bovendien hebben we gemerkt dat, ondanks dat het een kwetsbare populatie 
is, er wel degelijk bereidheid is deel te nemen aan wetenschappelijk onderzoek en dat een 
groot deel van de populatie goed in staat is om hier een weloverwogen beslissing in te 
nemen. De medisch ethische toetsingscommissies hebben uiteraard een belangrijke taak 
in het beschermen van (kwetsbare) patiëntengroepen tegen onnodig invasief onderzoek. 
Echter is het tevens net zo belangrijk om de autonomie van de patiënten hierin te respec-
teren indien zij in staat zijn zelf een weloverwogen keuze te maken. Sommige patiënten 
zien bijvoorbeeld deelname aan een wetenschappelijk onderzoek als een betekenisvolle 
bijdrage in hun laatste levensdagen. Ik hoop dan ook dat onze studies niet alleen meer 
kennis hebben opgeleverd, maar dat ze ook kunnen bijdragen aan het vergroten van de 
interesse in wetenschappelijk onderzoek in de palliatieve zorg. 
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2014
2014-2015
2014
2015
2016
0.2
1.4
0.2
0.3
0.3
Presentations
- PAGE meeting, Chersonisos, Greece, poster presentation
- FIGON dutch medicine days, Ede, poster presentation
- IATDMCT meeting, Rotterdam, oral presentation 
- PAGE meeting, Lisbon, Portugal, poster presentation
- Voorjaarsdag NVKFB 
- Ziekenhuisfarmaciedagen, Bunnik, oral presentation
2015
2014
2015
2016
2017
2017
1
1
1
1
1
1
186
Appendices
(Inter)national conferences
- Lareb Bijwerkingen dag, Leiden
- Ziekenhuisfarmaciedagen, Rotterdam 
- Symposium of alternative sampling strategies in toxicology 
and TDM, Gent, Belgium
- Lage landen symposium intoxicaties, Gent, Belgium 
2014
2014
2014
2014
2015
1
1
1
1
1
Other
- NONMEM workgroup AMC 
- NVKFB scientific meeting
- PhD day
- Journal club, monthly (oral presentations)
- NONMEM research meetings, weekly (oral presentations)
- Clinical pharmacology meetings weekly (oral presentations)
2013-2017
2014-2015
2014
2013-2017
2014-2017
2013-2017
0.5
0.4
0.5
1
2
2
2. Teaching
Year Workload 
(Hours/
ECTS)
Lecturing
- Lecture on basic pharmacokinetics, Winter course Master 
Infection and Immunity, Erasmus MC Rotterdam
- Lecture on medication interactions and pharmacokinetics in 
palliative care, Zorg academie Erasmus MC Rotterdam  
- Lecture on TDM and toxicology (3rd year medical students)
- Lecture on polypharmacy (3rd year medical students)
- Lecture on pharmacokinetics and dynamic in the elderly
- Prescribing course for medical students 
2013, 2015
2013, 2015
2013-2017
2014-2017
2016
2015-2016
0.5
0.5
0.5
0.5
0.2
0.5
Supervising Master’s theses
- S. Barutcu 6 month research theses 2017 2
Other
- Basis Kwalificatie Onderwijs (deel registratie) 2016-2017 1
